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Tyrode solution containing Br-OA (160 µmol L-1) during the treatment period (n = 2). 
Patch pipettes had a final resistance of 2-4 MΩ when filled with internal solution.  
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Figure 25: Concentration–response curves for carbachol in mesenteric segments (A) and 
aortic rings (B) isolated from Wistar rats pre-contracted with sub-maximal concentration 
of KCl (50 mM). Curves were obtained in arteries with denuded and intact endothelium. 
The values shown are means ± SEM (n = 7).     p ˂ 0.001 vs denuded. 
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Figure 26: Concentration–response curves for OA, Me-OA, and Br-OA in endothelium-
intact mesenteric arteries [A and B] or aortic rings [C and D] isolated from Wistar rats, 
pre-contracted with sub-maximal concentration of PHE (5 μΜ) [A and C] and KCl (50 








Figure 27: Concentration–response curves for OA in endothelium-intact mesenteric 
arteries [A and B] or aortic rings [C and D] isolated from Wistar and DSS rats, pre-
contracted with sub-maximal concentration of PHE (5 μΜ) [A and C] and KCl (50 mM) 
[B and D]. The values shown are means ± SEM (n = 7).      p ˂ 0.001 vs control). 
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Figure 28: Concentration–response curves for Br-OA in mesenteric arteries (A) and aortic 
rings (B) isolated from Wistar rats pre-contracted with PHE (5 μΜ). Curves were obtained 
in endothelium-denuded and intact arteries. Some endothelium-intact vessels were 
incubated in the presence of INDO (10 μM) only or in combination with L-NoArg (100 




Figure 29: Concentration–response curves for Br-OA in denuded mesenteric arteries (A) 
and aortic rings (B) isolated from Wistar rats pre-contracted with PHE (5 μΜ). Curves in 
denuded arteries incubated in the presence of Gli (5 mM) or in combination with AP (1 
mM) prior to the addition of the drug. Values shown are means ± SEM (n = 7).     p ˂ 
0.001 vs control. 
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Figure 30: Concentration–response curves for Br-OA in intact mesenteric arteries (A) and 
aortic rings (B) isolated from Wistar rats pre-contracted with PHE (5 μΜ). Curves in intact 
arteries incubated in the presence of INDO (10 µM) and Gli (5 mM) only or in 
combination with AP (1 mM) prior to the addition of the drug. Values shown are means ± 
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Despite the various conventional treatments that are available to treat hypertension, this disease 
continues to be globally responsible for approximately 9.4 million deaths each year. The high 
mortality can partly be attributed to side effects of available drugs or to the inaccessibility of 
current synthetic drugs to communities from poor socioeconomic background because of their 
relative high cost. This problem has resulted in a growing interest in the use of medicinal plant 
products because they are considered to be cheap, believed to possess few side effects and are 
easily accessible to the general population in developing countries. Although traditional herbal 
remedies are widely used in Africa for the management of various disorders including 
cardiovascular diseases, very little reliable data is available on their therapeutic and 
pharmacological effects. In search for plants with therapeutic properties for the treatment of 
hypertension and complications, our laboratory has scientifically evaluated several plant species. 
In particular, we have isolated Syzygium spp-derived triterpenes and focused on the therapeutic 
effects of oleanolic acid (OA) and maslinic acid (MA). In the present study, we investigated the 
effects of Syzygium aromaticum-derived OA and related synthetic derivatives on arterial pressure 
and evaluated the underlying mechanisms in Wistar, spontaneously hypertensive rats (SHR) and 
Dahl salt-sensitive (DSS) animals.  
 
Materials and methods  
 
OA was extracted from dried flower buds of Syzygium aromaticum using a previously validated 
protocol in our laboratory. Oleanolic acid methyl ester (Me-OA) and a brominated derivative of 
OA (Br-OA) were synthesised according to methods described by Fu and Gribble. The structures 
of extracted OA and synthesised derivatives were confirmed using 1H and 13C nuclear magnetic 
resonance (NMR) spectroscopy and were comparable to previously reported data. Acute renal 
clearance studies investigated the influence of OA and derivatives on mean arterial pressure 
(MAP) and Na+ handling in the proximal tubule of anaesthetised Wistar rats using lithium 
clearance. Animals were given water with lithium (12 mmol L-1) for 48 hours following which 
they were anaesthetised and cannulated using a previously validated standard protocol that has 
been reported from our laboratories. After a 3.5 h equilibration, animals were challenged with 
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hypotonic saline for 4 h of 1 h control, 1.5 h treatment and 1.5 h recovery periods. OA, Me-OA 
and Br-OA were added to the infusate during the treatment period followed by measurements of 
arterial pressure, fluid and electrolyte handling.  
 
Sub-chronic study experiments were restricted to OA because of the low amounts of synthetic 
derivatives obtained during the synthetic studies to prepare the derivatives. Various doses of OA 
(30, 60, 120 mg kg-1, p.o.) were administered to separate groups of male Wistar, SHR and DSS 
rats twice (8 h apart) every third day for nine weeks. Rats given dimethyl sulphoxide (DMSO)-
saline (3 mL kg-1, p.o.) acted as untreated controls. Mean arterial pressure (MAP) was monitored 
every third consecutive day using non-invasive tail cuff method with photoelectric sensors. 
Measurements of body weight, food and water intake, Na+, K+, Cl-, urea and creatinine were taken 
24 h after dosing. At the end of this 9 week study, the cardiac, renal and hepatic tissues harvested 
from hypertensive animals were evaluated for oxidative status by measuring malonyldialdehyde 
(MDA, lipid peroxidation marker) and antioxidant enzymes; superoxide dismutase (SOD) and 
glutathione peroxidase (GPx). In addition, we evaluated the effects of OA and derivatives on 
aldosterone and arginine vasopressin (AVP) secretion on plasma samples from both sub-chronic 
and acute experimental settings. 
 
Additional Ex vivo studies to unravel the mechanisms of action of OA and derivatives were carried 
out in isolated ventricular cardiomyocytes and arteries. Measurements of cell shortening and Ca2+ 
currents were done in cells isolated from Wistar and DSS animals using edge detection and whole 
cell patch clamp techniques, respectively. Isometric tension measurements were done in 
endothelium-intact and denuded aortic rings and mesenteric arteries of Wistar and DSS rats. The 
influence of indomethacin (INDO), N-nitro-L-arginine methyl ester (L-NAME), glibenclamide 




The purity of the plant-derived OA was approximately 98% and the percentage yield varied from 
0.79% to 1.72% of the dry plant material. The percentage yield of the synthetic derivatives, Me-
OA and Br-OA was 65% and 30%, respectively, from the starting materials. Our results show that 
OA decreased MAP in both acute and sub-chronic experimental settings, and that the MAP 
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lowering effect was more marked in hypertensive animals compared to normotensive rats. 
Similarly, the two OA derivatives, used in acute settings, also decreased MAP. OA increased 
urinary Na+ excretion rate under acute and sub-chronic conditions. A similar but quantitatively 
more marked increase was obtained with Br-OA derivative under acute conditions. Untreated 
hypertensive animals had elevated levels of plasma aldosterone and AVP in comparison to Wistar 
rats. OA treatment significantly reduced aldosterone secretion in these animals but had no 
influence on plasma concentrations of AVP. Compared with respective control rats, OA-treated 
animals exhibited significantly lower MDA levels and increased activity of the antioxidant 
enzymes, SOD and GPx in hepatic, cardiac and renal tissues. OA and derivatives had a positive 
inotropic effect on isolated ventricular cardiomyocytes in Wistar rats and had no influence on the 
contraction of cells from hypertensive animals. OA and derivatives caused relaxation in aortic 
rings and mesenteric arteries of both Wistar and DSS animals. This effect was partly inhibited by 
INDO and K+ channel blockers when used independently. Addition of L-NAME did not further 
inhibit the cyclooxygenase (COX)-resistant relaxation. The combination of INDO, Gli and AP 
completely abolished OA or derivatives-evoked relaxation in endothelium-intact arteries 




The present study investigated the effects of OA and related synthetic derivatives (Me-OA and Br-
OA) on blood pressure and thereafter examined the possible underlying mechanisms. The absolute 
stereo-structure of S. aromaticum-derived OA and synthetic derivatives elucidated from the 
spectra using 1H- and 13C-NMR was comparable to previously reported data. Our results confirm 
the previously reported antihypertensive properties of OA in experimental models of hypertension. 
However, the present study demonstrates a more marked action in SHR and DSS by comparison 
with non-hypertensive animals, suggesting a specifically enhanced action in disease conditions. 
We noticed that urinary Na+ excretion in control, untreated animals tended to spontaneously 
increase with time during the following 9 weeks post weanling. In both hypertensive models, no 
such increase with time was obtained, instead, urinary Na+ excretion tended to decrease with time 
after weanling in the DSS model supporting Na+ retention previously reported in these animals. 
To further support this theory we found increased aldosterone levels in the plasma of non-treated 
hypertensive rats. Our data show that OA decreased aldosterone secretion and increased urine Na+ 
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excretion, relatively larger increases were obtained in the hypertensive models.  This suggests that 
treatment with the drugs was accompanied by alleviation of Na+ retention in these animals. This 
increase in urinary Na+ output is, at least in part, mediated via inhibition of proximal tubular Na+ 
reabsorptions as indicated by increased Li+ clearance. Indeed, we found a positive correlation 
between the increase in urinary Na+ excretion rate and the decrease in MAP. However, despite the 
potent natriuretic effects of these triterpenes mediated by decreased aldosterone levels, the urine 
flow rate was not changed as supported by unchanged levels of AVP.  
 
Our experiments indicated that OA induces vasorelaxation of aortic rings and small mesenteric 
arteries in both normotensive and hypertensive animals. The maximum relaxation evoked by the 
derivatives, particularly Br-OA, was significantly larger in the mesenteric vessels although these 
differences were not observed in the aorta. Glibenclamide and 4-aminopyridine used allowed a 
complete blockade of the relaxation to OA, Br-OA and Me-OA suggesting that ATP-dependent 
and voltage-activated K+ channels opening mediate the endothelium-independent relaxation. Our 
experiments using isolated cardiomyocytes showed that OA and derivatives do not decrease but 
rather tend to increase myocyte shortening and had no influence on Ca2+ currents in Wistar rats. 
Increase cardiomyocyte contractility implies an increase in the force of cardiac tissue contraction 
and increase cardiac output which may be ideal for a drug which causes natriuresis. The results 
showed that OA-treated DSS animals had normal levels of MDA, SOD and GPx in comparison to 
untreated hypertensive rats. Therefore, we suggest that OA-evoked decreased reactive oxygen 
species (ROS) and increased antioxidant enzymes may have enhanced the production of 
prostanoids, thereby improving vasodilation. Hence, we speculate that antioxidant properties of 




The results of this study introduce the first evidence that OA and its oleanane derivatives induce 
similar effects. These involve 1) increased urinary Na+ output mediated by inhibition of proximal 
and distal tubular Na+ reabsorption as indicated by increased Li+ clearance and decreased 
aldosterone levels, respectively. 2) Modulation of oxidative status in cardiac, renal and hepatic 
tissues in hypertensive animals. As well as 3) decreased vascular resistance via endothelium-
dependent COX/prostanoids pathway and endothelium-independent opening of ATP-dependent 
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and voltage-activated K+ channels. The results of this study are novel and clinically relevant 
because OA and related triterpene derivatives exert multiple blood pressure lowering mechanisms 
while increasing the force of cardiac contraction hence balancing the fluid volume in the 
circulatory system so as to avoid a state of hypotension. 
 
Limitations and direction for future studies 
 
Due to low amounts obtained for the synthetic derivatives, we were unable to study their sub-
chronic effects in conscious animals, therefore this should be explored in future. OA effects on 
renal function seem to mimic oxytocin-like activities i.e. increase Na+ output without changing the 
urine flow rate, hence future studies should explore whether this hormone can have synergistic 
effects with OA and derivatives. This study did not evaluate the effects of these triterpenes on 




Examiner 1   
1. Specify name of Ca2+ channel. 
 Voltage-operated calcium channel pg 20. 
 
2. Include section on the control of vascular tone. 
 This section has been included and comprises of various factors which initiate events 
that lead to contraction of smooth muscle cells based on receiving a relevant stimulus 
hence controlling the vascular tone. The mechanisms underlying vascular smooth 
muscle contraction have been discussed with particular mention of Ca2+ release being 
the mediator of contraction and the importance of channels involved including K+ 
channels. 1.4.1  and 1.4.1.1 pg 27-29. 
 
3. Add also, amend ROS scavengers, mention the role of uncoupled eNOS in oxidative stress. 
 Added also, deleted the sentence on ‘Aprindine……..’; then mentioned currently used 
ROS scavengers (N-acetyl-cysteine (NAC), vitamins C and E) on pg 30. Mentioned 
the role of uncoupled eNOS on pg 31 section 1.4.3. 
 
4. Mention classical techniques for monitoring oxidative stress. 
 This has been added on section 1.4.4.1 pg 33. 
 
5. Amend section on therapeutic medications. 
 Vasodilatory effects of β-blockers mediate their function either by α-blocking action or 
activation of NOS thereby improving endothelial function in patients with hypertension 
pg 36. 
 ACE inhibitors mediate their anti-hypertensive properties via inhibition of Ang II-
dependent vasoconstriction and production of aldosterone pg 36. 
 Statement about cocaine has been shifted to the last paragraph pg 38. 
 
6. Opposing synthetic and natural drugs on the basis of the propency to induce side effects is 
incorrect. 
 I do not understand the meaning of propency. 
 
7. Page 37 is missing. 
 Pg 37 is not missing on the electronic copy. 
 
8. Change Ang 11 to Ang II. 
 This has been done on pg 7, 17, 27-29, 36. 
 
Methods 
1. Add 2.8.2.3 ‘in a wire myograph (DMT, Aarhus, Denmark)’; 2.8.2.3 were; and 2.8.2.3 
software from DMT. 





1. Rearrange structure. 
 Results now divided into 3 chapters (pgs 68, 74, 99) with the results for phytochemical 
studies having their own chapter. In vitro has been replaced with ex vivo (pgs 38, 47, 
54, 63, 68, 97, 99). 
 
2. Could the effects of derivatives be due to OA contamination? 
 No. The proton and carbon peaks obtained from NMR and IR spectra analysis for 
synthetic OA derivatives (Me- and Br-OA) were comparable to previously reported 
data and did not have any additional peaks which don’t belong to the derivative’s 
structure indicating that there was no contamination of the derivative products by any 
traces of OA pg 117/118. 
 
3. Amend NO-dependent mechanisms of vasodilatory effects since this was not the finding 
of our study. 
 The results of our study suggest that OA and derivatives mediate their vasodilatory 
effects via additional mechanisms involving prostanoid pathway and action on K+ 
channels pg 112, 121. 
 
Examiner 2 
1. Acknowledge the role of the central nervous system in blood pressure regulation as 
abnormalities may also be implicated in hypertension. 
 Dysfunction of the central nervous system has been acknowledged as one of the 
possible causes of abnormal blood pressure as this system plays a crucial role in the 
regulation of blood pressure pg 1. 
 
2. Table 1 does not refer to types of hypertension. 
 As indicated in table 1 has been deleted pg 3. 
 
3. Neural effects for blood pressure long-term regulation. 
 I have included a section on the role of the CNS in the long-term regulation of blood 
pressure pg 6-7. 
 
4. Pacemaker activity begins at the SAN not AVN. 
 Atrioventricular deleted pg 17. 
 
5. Statement ‘Reports suggest….’ is not clear. 
 Sentence re-phrased pg 18 1st statement. 
 
6. Mention tropomyosin. 




7. Energy is only for Na+/Ca2+ exchanger. 
 This has been specified on pg 18 3rd paragraph. 
 
8. Literature on abnormalities of ryanodine receptor. 
 This section has been added on pg 18 1st paragraph. 
 
9. Supra-threshold refers to any size above threshold, replace with that phrase. 
 Replaced with voltage above threshold pg 23. 
 
10. Acknowledge other important references for electrophysiology techniques. 
 Hodgkin & Huxley; Neher & Sakmann have been acknowledge for their work in the 
discovery of electrophysiology techniques pg 24. 
 
11. What is a triterpene. 
 this had been defined on pg 42. 
 
12. Did you extract yourself? 
  Yes. 
 
13. Real record of parameters measured pg 64. 
This is not possible since it can only be done with the Clampfit computer programme which 
is in the university computers in KU Leuven and I am now in SA (Real recording is shown 
on the results section (pg 100-102). 
  
14. Discussion on results section? 
There cannot be a discussion in chapter 3 as I needed to separate between results and 
discussion and make sure not to discuss results on the results section but only to describe 
what they show. 
 
15. Tyrode solution composition. 
 Tyrode solution containing (in mM: 135 NaCl, 5.4 KCl, 0.9 MgCl2, 10 hepes, 10 
glucose, pH adjusted to 7.45 with NaOH) was already mentioned on the methods 
section for cardiac studies pg 63. 
 Perfusion of cells replaced with superfusion pg 99, and on legends for Figs.18-24 (100-
106). 
 
16. Continuous trace of cardiomyocyte contraction. 
 Not possible because the software record traces on separate files as shown (pg 100-
102). 
 
17. Could the persistent increase during the wash period indicate that increase during treatment 
period is a coincidence (pg 100)? 
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 We think the increase is due to irreversible OA effects after 5 mins of washing the cells. 
We believe that a longer was period would have brought back the contraction to be the 
same as control period as there was already a slight decrease after 5 mins, however, for 
consistency we had to wash for 5 mins only as the drug was applied for that period. In 
addition, we got the same trend from 6 animals, we tested at least 5 cells for each animal 
and therefore this exclude the ‘coincidental effect’,  
 
18. Was n of 2 used for Ca2+ current measurements? If so this should be stated explicitly. 
 We had mentioned on the description of results that these were preliminary studies, 
however, we have added that ‘Due to time constraints, we could only perform the 
experiment on 2 animals, however, at least 3 cells were recorded for each of those two 
animals and for each drug pg 104. 
 
19. Units for vascular results? 
 They are expressed as Log [drug], doses adopted from Rodriguez-Rodriguez et al. 
(2008) Figs 25-30, pg 108-116. 
 
Examiner 3 
1. Partly inhibition of vasodilatory effects by NOS should be omitted as it doesn’t correspond 
with the results of this study. 
 This statement has been deleted pg xxx abstract, pg 113.  
 
2.  Amend conclusions based on new contribution of the study in the field. 
 This has now been clearly stated pg xxxi abstract, pg127.  
 
3. Table 1 should be omitted. 
 This has already been deleted pg 3, comment from examiner 2. 
 
4. Include statistics of hypertension in South Africa. 
 This section has been added on 1.1.2 pg 4. 
  
5. Increase not decrease. 
 Amended on pg 5. 
 
6. Include other mechanisms in which aldosterone increase Na+ absorption. 
 Amended: ‘The mechanism through which aldosterone mediates Na+ reabsorption is 
by modulating the expression and activation of Na+ channels in the plasma membrane 
as well as insertion of Na+/K+-pumps in the basolateral membrane’ pg 12. 
 
7. Add a reference for cardiomyopathies. 




8. Remove cardiac glycoside, as it refers to digitalis drugs. 
 Cardiac glycoside deleted 1.5.2.1 pg 37. 
 
9. Add a reference for discovery of reserpine. 
 Added on pg 37 (Gilani, 2005) 1st paragraph. 
 
10. Herbal remedies are not always safe unless proven. 
 ‘safety’ deleted pg 39. 
 
11. Include literature on effects of oxytocin under hormonal influence in the introduction 
section. 
 This section has been added 1.2.3 pg 13. 
 
12. Add a review on cardiovascular, renal, antioxidant and vasodilatory effects of OA on 
section 1.6.1.2. 
 This section has been added and used as the basis of this study pg 44-45. 
 
13. Some drugs and chemicals are missing on section 2.0. 
 The list of the missing drugs has been added on pg 47/48. 
 
14. Where was the plant material obtained from? 
 2.1.1 pg 49 added. ‘The dried flower buds of Syzygium aromaticum [(Linnaeus) Merrill 
and Perry] (Myrtaceae) were purchased from the spice market in Durban, South 
Africa’. 
 
15. Were dried flower buds milled? 
 Yes, amended on pg 49. 
 
16. Add Elisa kits and cell isolation enzymes under drugs and chemicals 2.0 
 Added on pg 48. 
 
17. General chemicals like NaCl need not be listed on 2.0 
 Removed but mentioned that it was also of analytical grade like other chemicals pg 48. 
 
18. Mention spectroscopic technique used for confirmation of OA structure. 
 1H, 13C NMR and infrared spectra recorded on a Bruker DRX-400 and Bruker Alpha 
FT-IR spectrometer pg 49/50. 
 
19. Give credit to Fu & Gribble for the use of their method for derivatives synthesis. 
 Statement added on 2.1.3 ‘We are grateful to Fu and Gribble (2013) for having used 




20.  Do not use brine or normal saline terms or give concentrations for bromination and sub-
chronic studies. 
 Changed to NaCl pg 52 and 56. 
 
21. Were the triterpenes soluble in polar solution without DMSO? 
 No, they were dissolved in DMSO 1st before being added into the polar solutions, this 
has been amended 2.5.1 pg 54; 2.8.1.2 pg 64. 
 
22. Method for determination of urine and blood concentrations of electrolytes pg 54. 
 This is discussed in the next section 2.5.1.1, for more clarity this has been mentioned 
in the text pg 54. 
 
23. Where were the dosage derived from for acute and sub-chronic studies. 
 The dosage for OA used in the acute studies was based on previous studies (Mapanga 
et al., 2009) and the same dosage for the derivatives was used for fair comparison of 
the effects pg 54. 
 The same study by Mapanga et al., (2009) used 60 mg/kg for sub-chronic studies hence 
our study decided to add a lower and a higher dose to determine the possibility of dose-
dependent effects (Madlala et al., 2012). Added on pg 56. 
 
24. Give the name of enzyme conjugate. 
 Aldosterone-alkaline phosphatase conjugate 2.6.1.1 pg 57. 
 
25. Which company provided the ELISA kit. 
 Added: ELISA Kit (DRG International Inc, New Jersey, USA) 2.6.1.1 pg 57. 
 
26. Aldosterone ELISA does not contain a vasopressin antibody. 
 Replaced with polyclonal rabbit antibody 2.6.1.1 pg 57. 
 
27. Volume of assay buffer was 150 µL and not 150 mL. 
 Units changed to µL 2.6.1.2 pg 57. 
 
28. Standards were not added to the Bo wells. 
 Amended on pg 58. 
 
29. Assay was performed in duplicate or triplicate? 
 This was originally mentioned. ‘Each determination was performed in duplicates for 
both standards and the test samples.’ 2.6.2.2 pg 58. 
 This information has now been added for the determination of MDA, SOD and GPx 
2.7.1 pg 60. 
 
30. Rename kit components. 
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 Amended: ‘The kit components included a 96 well plate coated with goat anti-rabbit 
antibodies, vasopressin-alkaline phosphatase conjugate, rabbit anti-vasopressin 
antibody, assay buffer, wash buffer concentrate, vasopressin standards, p-nitrophenyl 
phosphatesubstrate (pNpp) and a stop solution’ 2.6.2.1 pg 58. 
 
31. Edit the name of antibody. 
 Rabbit anti-vasopressin antibody pg 58. 
 
32. Replace antigen with non-covalent forces. 
 Amended pg 58. 
 
33. Vasopressin does not bind to conjugate but to the rabbit anti-vasopressin antibody 
 Amended pg 58 
 
34. The wash does not remove enzyme-labelled antibody. 
 The wash removes enzyme-labelled vasopressin pg 58. 
 
35. The plate was coated with what? 
 Already amended for comment 30 above (with goat anti-rabbit antibodies) pg 58. 
 
36. What was used to blank the plate? And how was non-specific binding (NSB) determined? 
 Assay diluent was used as a blank. NBS was determined by adding a NSB solution in 
some wells and adding all other ingredients pg 58. 
 
37. What is the composition of the isolation buffer? 
 0.1 M Tris-HCl buffer, pH 7.4 pg 59. 
 
38. How was the line of the standard curve fitted? 
 The BSA standard curve was plotted as a linear fit function of protein concentration pg 
60. 
 
39. Include units for Ca2+ concentration. 
 1.8 Mm pg 63. 
 
40. Was the pH adjusted? 
 Yes pH was adjusted to 7.45 with NaOH (was originally mentioned on pg 63). 
 
41. How was the aorta and mesenteric arteries cut into rings? 
 Each aorting or mesenteric segment was cut with a sterile dissection scissor into rings 
of approximately 1.5 - 2 mm width pg 65. 
 
42. What is meant by rubbing the lumen of the artery with hair? 
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 The piece of a large diameter straight black hair was inserted inside the vessel and the 
endothelium was removed by gentle moves back and forth inside the vessel (Gauthier 
et al., 2008) pg 66. 
 
43. PSS cannot contain both 50 and 94 mM KCl. 
 Amended, high KCl solution used to induce vessel contraction was 94 mM pg 66. 
 
44. Was PSS-DMSO used as a solvent for various drugs used to test vasodilatory effects? 
 Yes, this has now been mentioned on pg 66. 
 
45. Was acetylcholine or carbachol used to test vasodilatory action of drugs? 
 Charbachol, amended on pg 66. 
 
46. What was used to block NOS? 
 L-NAME pg 66. 
 
47. Include stat analysis for acute correlation between urinary Na+ and MAP. 
 p < 0.05 pg 76. 
 
48. Make asterisks visible on figures to indicate stat significance. 
 Made asterisks bigger on figure 9 pg 77. 
 
49. Vertical bars indicating SEM are not visible, decrease side of line and symbols. 
 Amended for Figs 9, 10, 12, 15 pg 77ff. 
 
50. Was total K+ excretion significant on table 3? 
 Yes for Br-OA, asterisk placed pg 79. 
 
51. Omit statement on referring to FECl and FEK data since it is not shown pg 81. 
* Phrase deleted  
 
52. Give a reason for no dose-dependent MAP effects. 
* we suspect that we recruited maximal effects with the doses used and that more 
specificity could be demonstrated if sub-maximally effective doses were administered 
hence it would be recommended to look at lower OA doses for future studies pg 87. 
 
53. Include the legend for Fig 15. 
* Legend is present on the electronic copy pg 91. 
 
54. Do the bars in Fig 16 represent means of the 3 OA doses? 




55. Place the asterisks on the treated DSS rats for plasma Na+ significance not on the value for 
the control group. 
* Asterisks placed on OA 30, 60, 120 mg/kg Table 7 pg 94. 
 
56. Acute effects on aldosterone and AVP should be moved to section on acute results. 
* Hormone measurements are deliberately placed on their own to avoid having many 
small tables. In addition, we discriminated between acute and subchronic effects although 
placed in one table pg 96. 
 
57. What is meant by …. As parameters measured above in this study? 
* Sentence re-phrased ‘There was no dose dependent effects observed with the three doses 
of OA tested in this study’ pg 97. 
 
58. Refer to Figs 13 and 16A when talking about OA and derivative effects on ventricular 
cardiomyocytes. 
 This has been added on 5.1 pg 99. 
 
59. Legend refers to asterisk indicating significance on Figs 18-20 but there is none on the fig 
itself. 
 Asterisks added on Figs 18-20 pg 100-102. 
 
60. Shift protocol from results on how functional endothelium was tested into the method 
section. 
 Statement moved to pg 2.8.2.3 pg 66. 
 
61. Add ‘ than OA and Me-OA’. 
 Phrase added 5.2.1 pg 109. 
 
62. Replace DMSO with control Figs 25-30. 
 Replaced on Figs and legends pg 108-116. 
 
63. Remove (M) on legends for Figs 26, 29, 30. 
 M removed on these Figs pg 110, 115, 116. 
 
64. Show results of the effects of OA and Me-OA on vessel contraction. 
 Fig 26 pg 110 is showing the difference in vasodilatory effects both in the aorta and 
mesenteric arteries between OA and the two derivatives tested in this study. 
 
65. Clearly state that Br-OA vasodilatory effects were blunted by indomethacin pre-treatment. 
 This fact has been explicitly stated on pg 112, paragraph 2, sentence 2. 
 
66. Rephrase legend for Fig 28 ‘endothelium-intact vessels were incubated in the presence of 
INDO only or in combination with L-NoArg’.  
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 Legend amended pg 113. 
 
67. Refer only to Br-OA and not OA and derivatives because only results for Br-OA are shown. 
 Reference to OA and derivatives deleted 5.2.3 pg 114. 
68. Delete the statement ‘larger endothelium-dependent relaxation observed with Br-OA as no 
comparison is shown for OA and Me-OA. 
 Statement removed pg 114. 
 
69. Rephrase legend Fig 29 to ‘denuded arteries incubated in the presence of Gli (5 mM) or in 
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INTRODUCTION / LITERATURE REVIEW 
1.0 Basis of the study 
Despite conventional treatments available for elevated blood pressure in the market, hypertension 
continues to be associated with the deaths of approximately 9.4 million people each year globally. 
The high mortality can partly be ascribed to side effects and inaccessibility of current synthetic 
drugs especially to the communities from poor socioeconomic background because of high cost. 
This problem has resulted in a growing interest of many communities to use medicinal plant 
products because they are cheaper. Although the use of medicinal plant extracts by different 
cultures around the world, including rural Africa, dates back to the origin of the human being, only 
recently have scientific studies started to validate their therapeutic and pharmacological properties. 
In search for plants with potential beneficial effects in alleviating cardiovascular disorders, we 
have also scientifically evaluated several plant species. In particular, we have isolated triterpenes 
from Syzygium spp and focused on the therapeutic effects of oleanolic acid (OA) and maslinic acid 
(MA). Literature has reported diverse pharmacological properties of OA and this therapeutic 
importance has led to the use of this triterpene as a starting material for the synthesis of new 
oleanane derivatives. In this study, we synthesised oleanane derivatives and investigated their 
therapeutic activities on experimental models of hypertension. We also investigated the effects of 
OA and related synthetic derivatives, a methyl ester of OA (Me-OA) and a brominated derivative 
of OA (Br-OA) on arterial blood pressure in Wistar, and experimental models of hypertension; 
Dahl-salt sensitive (DSS) and spontaneously hypertensive rats (SHR). The potential mechanisms 
responsible for an abnormal blood pressure include a combination of abnormal renal electrolyte 
handling, myocardial, endothelial and central nervous system dysfunction. Accordingly, we 
investigated whether these oleananes influence kidney, cardiac and vascular functions of 
hypertensive animals. Studies report that hypertension is associated with oxidative stress which 
plays a major role in endothelial dysfunction. In this regard, we also evaluated the effects of OA 
on oxidative status of cardiac, renal and hepatic tissues by monitoring levels of malonyldialdehyde 
(MDA), a commonly known marker of oxidative stress, and the levels of antioxidant defence 





1.1   Introduction / Literature review 
 
1.1.1   Blood Pressure 
 
Blood pressure (arterial) can be defined as the pressure exerted by circulating blood on the walls 
of blood vessels. During each heartbeat, blood pressure varies between a maximum level (called 
systolic pressure, and occurring during cardiac contraction) and minimum level (called diastolic 
pressure, associated with cardiac relaxation. The mean arterial pressure is an average of the 
pressure over the whole cardiac cycle (Janssen, De Celle, Debets, Brouns, Callahan and Smith, 
2004). Determinants of the mean arterial pressure are the cardiac output (CO) and the total 
peripheral resistance (TPR) (Hsiu, Chao, Hsu, Jan, Wang and Wang, 2008), and an abnormal 
change in blood pressure is often an indication of a problem affecting the cardiovascular system. 
Hence, blood pressure monitoring is critical for assessment of any pathology related to CO and 
blood vessel resistance (Calhoun, Jones, Textor, Goff, Murphy, Toto, White, Cushman, White and 
Sica, 2008).  These parameters are influenced by physical factors such as dietary salt intake, 
exercise, disease, alcohol, stress and obesity (Writing Group of the Premier Collaborative Research 
Group, 2003). This thesis investigated how therapeutic interventions modulate the effects of diet 
and genetic factors on the development of high blood pressure in experimental animals.  
 
Other physical factors such as blood viscosity also affect blood pressure by their effect on the 
resistance to flow (Walsh, Culleton, Tonelli and Manns, 2005). Under normal conditions, changes 
in blood pressure have an effect of the activity of the  autonomic nervous system, which then 
triggers corrective mechanisms that will bring blood pressure back to normal levels (Guyenet, 
2006). Despite the involvement of nervous and other different organs systems in the regulation of 
blood pressure, chronic disease conditions can result in dysfunctional regulatory mechanisms 
which can cause blood pressure to become too low or high. This study was interested in 
pathologically high blood pressure referred to as hypertension which is defined as systolic and 







1.1.2     Hypertension 
 
Hypertension, commonly known as high blood pressure, is a chronic medical condition in which 
the blood pressure in the arteries is elevated. The most common form of hypertension is classified 
as primary (essential) hypertension which contributes about 90-95% of hypertension cases with 
unknown underlying medical cause (Rosario and Wesson, 2006). The remaining cases (5-10% of 
hypertension cases) constitute secondary hypertension and are due to underlying diseases that 
affect the kidneys, arteries, heart and endocrine system (Kearney, Whelton, Reynolds, Muntner, 
Whelton and He, 2005). Gestational hypertension is also a case of secondary hypertension and 
occurs in approximately 8-10% of pregnancies. Most women with high blood pressure in 
pregnancy are at risk of developing pre-eclampsia which occasionally progresses to life-
threatening eclampsia (Dildy and Belfort, 2010). Eclampsia is a hypertensive emergency and has 
several serious complications including vision loss, cerebral oedema, seizures or convulsions, 
renal failure and pulmonary oedema (Duley, 2009).  In the present study we used the accepted 
experimental models of hypertension, Dahl-salt sensitive (DSS) and spontaneously hypertensive 
(SHR) rats to evaluate the effects of plant-derived products as potential alternative treatment for 
hypertension. 
 
Over 1 billion people are living with high blood pressure and this number is continuing to grow 
despite the use of conventional therapeutic drugs to control this condition (WHO, 2013). The 
global prevalence of hypertension in 2008, in adults aged 25 and above was around 40% (WHO, 
2013). Arterial hypertension is a major risk factor for renal failure and cardiovascular disease 
(CVD) such as heart attacks, stroke, left ventricular hypertrophy and heart failure. An estimated 
17.3 million people died from CVDs in 2008 of which over 80% of this mortality occurred in low- 
and middle-income countries where health systems are weak (Meyer, Yoon, Kaufmann and Office 
for State, 2013). The number of annual CVD mortalities is estimated to reach 23 million by 2030, 






Studies reported a significant burden from hypertension, referred to as the silent epidemic in South 
Africa, due to under-diagnosis or inadequately treatment which results in extensive target-organ 
damage and premature death (Hasumi and Jacobsen, 2012). In population-based surveys, high 
rates of hypertension were found among older adults in South Africa, 44.0-52.0% among men and 
51.6-60.4% among women in 1998 (Steyn, Gaziano, Bradshaw, Laubscher and Fourie, 2001). 
These have probably increased due to a rise in the predisposing factors but recent data on the 
national prevalence of hypertension are, unfortunately, lacking. Data from the South African 
Dialyses and Transplantation Registry have shown that hypertension was responsible for 35% of 
end-stage renal failure in blacks and that malignant hypertension was diagnosed in 57% of the 
black patients with essential hypertension (Veriava, Du Toit, Lawley, Milne and Reinach, 1990). 
Elevated blood pressure triggers regulatory mechanisms which are responsible for maintaining 
normal blood pressure levels.  
 
1.1.3      Regulation of blood pressure 
 
The endogenous regulation of arterial pressure is not completely understood. However, the 
mechanisms of arterial pressure regulation outlined in the following sections have been well-
characterised. Based on the time scale of their effects, one can distinguish two types of mechanisms 
that mediate regulation of blood pressure. These are short- and long-term regulatory mechanisms. 
 
1.1.3.1  Short-term regulation 
 
Short-term mechanisms are largely neural and regulate blood pressure by influencing blood vessel 
diameter, heart rate (HR) and contractility (Janssen, Leenders and Smits, 2000). When arterial 
blood pressure changes, the baroreceptors in the high pressure receptor zones detect these changes 
and send impulses to the medulla of the brain stem, particularly the rostral ventro-lateral medulla 
(RVLM) (Kishi, Hirooka, Kimura, Ito, Shimokawa and Takeshita, 2004). The most important 
arterial baroreceptors are located in the left and right carotid sinuses and in the aortic arch. A 
decrease in mean arterial pressure decreases the stretch of baroreceptors, which then transmit less 
afferent inputs to the medulla. As afferent signals normally inhibit centres in the medulla, the 




activity of parasympathetic efferences. The combination of increased sympathetic activity and 
decreased parasympathetic activity adjusts the mean arterial pressure by increasing both the force 
and rate of the heart contractions, hence increasing the CO, and by causing peripheral 
vasoconstriction. In contrast, an increase in mean arterial pressure increases the stretch of 
baroreceptors, which then transmit more afferent signals to the medulla, and results in a decreased 
sympathetic efferences and increased parasympathetic efferences. The combination of a decreased 
sympathetic tone and an increased parasympathetic activity will adjust the mean arterial pressure 
by decreasing both the force and rate of the heart contractions, hence decreasing the CO (Freeman, 
Dewey, Hadley, Myers and Froelicher, 2006). In addition, the decreased sympathetic activity 
causes relaxation of vascular smooth muscles and increases the arterial diameter hence decreasing 
total peripheral resistance (Munir, Jiang, Guilcher, Brett, Redwood, Marber and Chowienczyk, 
2008).  
 
Whereas the above effects are neutrally mediated, they are also enhanced by changes of the 
hormonal release of adrenalin and noradrenalin by the adrenal gland (Morrison and Cao, 2000). In 
addition, other changes that are associated with those of blood pressure may themselves constitute 
additional trigger mechanisms for responses that have an effect on blood pressure. Decreased 
blood volume (which can be the cause of the decrease in blood pressure) constitutes itself a trigger 
mechanism for responses that involve increased thirst (leading the individual to drink) and 
increased arginine vasopressin (AVP) secretion (causing increased water reabsorption in the 
kidneys). Increased blood osmolarity also activates the thirst centre in the hypothalamus (Heusser, 
Tank, Engeli, Diedrich, Menne, Eckert, Peters, Sweep, Haller and Pichlmaier, 2010). Conditions 
that cause dehydration such as diarrhoea result in increased osmolarity which is sensed by the 
hypothalamus which in turn stimulates the release of antidiuretic hormone (ADH) by the posterior 
pituitary gland. ADH mediates water retention through V2-type receptors by causing insertion of 
water channels (aquaporin-2) in the apical membrane of the principle cells via activation of 






Therapeutic drugs such as alpha-adrenergic receptor blockers and beta-adrenergic receptor 
blockers (β-blockers) exert part of their effect by interfering with the neural regulation of the 
cardiovascular system. Alpha-blockers are used to reduce vascular restistance, whereas β-blockers 
are used to reduce force and rate of heart contraction. Plant extracts such as reserpine also interfere 
with the neural regulation. Extracts of Mentha villosa, Orthosiphon aristatus, Petasites formosanus 
and a bioactive compound, verapamil isolated from Sideritis raeseri have been shown to possess 
blood pressure lowering effects mediated by reduction of the force and the rate of contraction in 
the heart as well as vasorelaxant effects on smooth muscles (Matsubara, Bohgaki, Watarai, Suzuki, 
Ohashi and Shibuya, 1999; Wang, Shum, Lin, Liao, Wu, Ren and Chen, 2001; Guedes, Silva, 
Barbosa-Filho and Medeiros, 2004; McNeill and Jurgens, 2006). The effects of the latter extracts 
are likely mediated by a direct action on cardiac and vascular cells. This study investigated whether 
plant-derived triterpenes influence the force of contraction of cardiomyocytes and vascular smooth 
muscle cells to probably modulate the blood pressure. 
 
1.1.3.2  Long-term regulation 
Long-term regulation of blood pressure is mainly achieved by altering the blood volume. Incidents 
such as haemorrhage, or donating blood lower blood pressure and therefore trigger processes that 
restore blood volume or pressure back to normal levels. Long-term regulatory processes stimulate 
the preservation of body fluids by neural and renal mechanisms which normalise blood volume or 
pressure via the sympathetic or parasympathetic systems and the renin-angiotensin aldosterone 
system (RAAS), respectively (Bie, 2009). Neural regulation of arterial blood pressure is 
maintained by baroreceptors located at the carotid sinus and aortic arch that transmit their signals 
to integrative medullary areas (Chapleau, Li, Meyrelles, Ma and Abboud, 2001; Fisher and Paton, 
2012). Thus, the balanced activity of the efferent autonomic nervous system and arterial 
baroreceptors is essential for the control of the cardiovascular system to achieve optimal blood 
flow to the organs of the body. Autonomic neural regulation of the circulation that provides optimal 
perfusion of every organ in accordance to its metabolic needs. The baroreceptor reflexes activated 
during a rise in pressure and the chemoreceptor reflexes activated with hypoxia and acidosis are 




and Chapleau, 2002). Abnormalities in this coordinated neural effects of blood pressure control 
may result in abnormalities which could cause cardiovascular diseases including hypertension. 
Renal mechanisms that mediate arterial pressure regulation involves RAAS which is activated 
when the juxtaglomerular cells in the kidney sense the decline in blood pressure and release renin 
into the blood stream. The renin activates the inactive angiotensinogen, a plasma protein released 
by the liver, into angiotensin 1. Angiotensin 1 is converted to angiotensin II (Ang II) by an 
angiotensin-converting enzyme (ACE) in the lung capillaries (Weir and Dzau, 1999). Ang II is a 
vasoconstrictor and therefore contributes to the changes in vascular peripheral resistance. Ang II 
reaches the adrenal gland via the blood stream and stimulates the adrenal cortex cells to release 
aldosterone.  
 
Aldosterone stimulates sodium retention and potassium excretion by the distal tubules of the 
kidney. Since sodium is the main ion that determines the extracellular fluid (including vascular 
fluid) volume, aldosterone increases indirectly arterial pressure (Meneton, Loffing and Warnock, 
2004). When the blood pressure is increased such as in hypertension, the opposite is true for the 
events mentioned above. Therapeutic drugs such as ACE inhibitors as well as diuretics like 
thiazides are used to lower the blood pressure in hypertension (Wing, Reid, Ryan, Beilin, Brown, 
Jennings, Johnston, McNeil, Macdonald and Marley, 2003). Plant extracts of Rosmarinus 
officinalis, Centaurium erythraea, Carum carvi, Tanacetum vulgar and Tropaeolum majus have 
been shown to block RAAS and possess diuretic properties (Haloui, Louedec, Michel and Lyoussi, 
2000; Lahlou, Tahraoui, Israili and Lyoussi, 2007; Gasparotto Junior, Boffo, Lourenço, Stefanello, 
Kassuya and Marques, 2009). To elucidate the mechanisms by which plant-derived potential 
therapeutic products tested in this study influence the blood pressure, we investigated the effects 
of these drugs on fluid and electrolyte handling by the kidney in hypertensive animals. 
 
1.1.4   Techniques used for blood pressure measurement  
 
The auscultatory technique and mercury sphygmomanometer used to be the method of choice for 
blood pressure measurement. However, due to toxicity of mercury, new devices known as hybrid 




gauge similar to oscillometric devices (Pickering, 2003). The major difference with oscillometric 
technique is that the oscillations of pressure in a sphygmomanometer cuff are recorded during 
gradual deflation, the point of maximal oscillation represents the mean intra-arterial pressure 
(Ogedegbe and Pickering, 2010). In addition to these two methods is the ultrasound technique 
which uses a transmitter and receiver positioned over the brachial artery under a 
sphygmomanometer cuff. This method also perceives the onset of blood flow at systolic pressure, 
which has been found to be of particular significance for measuring pressure in infants and children 
(Clothier, Rigby and Sinha, 2012). This technique is beneficial for patients with very faint 
Korotkoff sounds since placing a Doppler probe over the brachial artery may help to detect the 
systolic pressure. This experimental study, however, was conducted on animals and various 




1.1.4.1  Invasive and non-invasive techniques  
 
Direct blood pressure measurement using invasive surgical procedures is the gold standard in terms 
of accuracy in comparison to the non-invasive blood pressure technologies. Radio telemetry is a 
highly invasive surgical procedure which involves implanting radio transmitters in the rodent’s 
body (D'eon, Serrouya, Smith and Kochanny, 2002). The non-invasive blood pressure 
methodology consists of placing a cuff on the animal’s tail to block the blood flow. The three types 
of non-invasive blood pressure sensor technologies include photoplethysmography (PPG), 
piezoplethysmography and volume pressure recording (VPR).  
 
PPG is based on light and detects the first presence and absence of the pulses which corresponds 
to deflation and inflation of the occlusion cuff, respectively. The sensor is responsible for 
Illumination of the tail with the light and for measuring tiny changes in light intensity normally 
caused by variations in perfusion volume of the tail (Maeda, Sekine and Tamura, 2011). 
Piezoplethysmography records the presence of a pulse in the tail which corresponds to systolic 
blood pressure and HR. This technology is based on piezoelectric ceramic crystals which are 




volume by means of differential pressure apparatus. VPR measures systolic, diastolic, mean blood 
pressure, heart pulse rate, tail blood volume and tail blood flow (Daugherty, Rateri, Lu and 
Balakrishnan, 2009). This technique is reliable due to absence of light illumination which is 
normally associated with ambient light artifacts. This study used both PPG and VPR non-invasive 
tail cuff measurement techniques to monitor blood pressure in experimental hypertensive animals.  
 
We investigated the effects of the triterpenes on kidney function, isolated cardiac cells and vascular 
smooth muscles to determine the mechanisms of their hypotensive effects. The next paragraphs 
will outline the roles of kidney, cardiac and vascular function in the regulation of blood pressure 
and how their normal function is influenced by hypertension. In addition, the section discusses 
how therapeutic drugs and plant-derived herbal extracts alleviate abnormalities caused by 
hypertension as well conventional methods that are used to assess the functional status of these 
body systems.  
 
1.2    Kidney function 
 
Kidneys play a vital role in maintaining the normal volume and composition of body fluids (Rosner 
and Bolton, 2006; Zhu and Wang, 2008; Edwards, 2010; DeFronzo, Davidson and Prato, 2011). 
They achieve this by working together with other body organs like the lungs and the liver to ensure 
that homeostasis is maintained. The kidneys maintain this homeostasis through filtration, 
reabsorption and secretion. Tubular reabsorption of electrolytes and water is regulated by 
hormones and physical factors such as renal arterial pressure and glomerular filtration rate (GFR) 
(Rosner and Bolton, 2006; Wagner, Kovacikova, Stehberger, Winter, Benabbas and Mohebbi, 
2006; Edwards, 2010; DeFronzo, Davidson and Prato, 2011). However, in adverse conditions like 
hypertension, regulation of tubular reabsorption of electrolytes is disrupted due to structural and 
functional changes of the kidney and result in the decline of renal function. This study examined 







1.2.1   Importance of Na+ handling  
 
Na+ is the major cation that controls osmolality in the extracellular fluid (ECF) volume (DeFronzo, 
Cooke, Andres, Faloona and Davis, 1975) and hence Na+ reabsorption is vital for maintenance of 
homeostasis in the ECF (Edwards, 2010; DeFronzo, Davidson and Prato, 2011). Na+ present in the 
ECF is filtered and reabsorbed in the largest amount in the kidneys.  Reabsorption of water and 
many other solutes is linked to Na+ reabsorption as some substances depend on co-transport with 
Na+ for their uptake (Hackenthal, Paul, Ganten and Taugner, 1990; Klar, Vitzthum and Kurtz, 
2004). However, the normal blood volume brought about by Na+ reabsorption is disturbed in 
hypertension since this condition is associated with Na+ and water retention. Na+ reabsorption 
consumes a tremendous amount of adenine triphosphate (ATP) and oxygen and this is why the 
kidney receives approximately 25% of CO (Lewy, Quintanilla, Levin and Kessler, 1973; 
Ljungman, Laragh and Cody, 1990; Hallows, Mount, Pastor-Soler and Power, 2010). Two thirds 
of the filtered Na+ is handled in the proximal tubule through transport processes explained below. 
Proximal tubular Na+ handling can be quantitatively estimated through lithium (Li+) clearance and 
hence this study employed this technique to establish OA and derivatives’ effects on Na+ handling 
in the proximal tubule. 
 
1.2.2   Transport processes in the renal tubule  
 
The most important process in the proximal tubule is the reabsorption of two thirds of the filtered 
Na+ by an active process using transport proteins like the apical Na+/H+-exchanger type 3 (NHE3) 
and the basolateral Na+/K+-ATPase  (Auriemma, Galdiero, De Martino, De Leo, Grasso, Vitale, 
Cozzolino, Lombardi, Colao and Pivonello, 2010). In the loop of Henle, the countercurrent 
multiplication system preserves inner medullary interstitial solute gradient (Yuan and 
Pannabecker, 2010). The transport proteins that play a role in this process include the Na+/K+/Cl- 
cotransporter type 2 or bumetanide-sensitive cotransporter type 1 (NKCC2/BSC1) and the NHE3 
(Pannabecker and Dantzler, 2006; Pannabecker and Dantzler, 2007). In the early part of distal 
tubule, a thiazide-sensitive Na+/Cl-cotransporter (NCC) plays a major role, whereas in more distal 




all segment the transport of Na+ from the tubular cells to the peritubular interstitium is mainly via 
the Na+/K+-pump (Na+/K+-ATPase).  
 
Hypertension is associated with increased Na+ reabsorption probably due to increase function of 
the NHE3 in the proximal tubule and this is accompanied by water retention. The function of Na+ 
transporters like NKCC2/BSC1, NHE3 and NCC can be inhibited by drugs such as furosemide, 
bumetanide, thiazides, hydrochlorothiazide and bendroflumethiazide; potassium sparing, 
amiloride and carbonic anhydrase inhibitors, acetazolamide (Martinez-Maldonado and Cordova, 
1990; Kim, 2004; Pannabecker and Dantzler, 2007). This inhibition can be beneficial in 
hypertension by causing natriuresis and diuresis which may decrease blood volume (Martinez-
Maldonado and Cordova, 1990; Kim, 2004). Some plant extracts such as those from Foeniculum 
vulgare L. (fennel, Apiaceae) have been shown to increase water and sodium excretion (Bardai, 
Lyoussi, Wibo and Morel, 2001). Furthermore, aqueous extracts from the roots of Carissa edulis 
(forssk) vahl (Apocynaceae), Ananas comosus (Linn.) Merr. and Carica papaya Linn. (Pawpaw, 
Melon tree) have been shown to possess diuretic properties (Sripanidkulchai, Wongpanich, 
Laupattarakasem, Suwansaksri and Jirakulsomchok, 2001; Nedia, Mekonnena and Urgab, 2004). 
Transport processes occurring in the late distal tubules and collecting ducts are mostly influenced 
by hormones.  
 
 
1.2.3   Hormonal influence 
 
Late distal tubules and collecting ducts have principal and α/β-intercalated cells which play a role 
in acid-base homeostasis (Prasad, Narra, Shah, Humphrey, Jagirdar, Catena, Dalrymple and 
Siegel, 2007). Principal cells play a role in the reabsorption of Na+ which is associated with 
secretion of K+.  Na+ reabsorption is increased by aldosterone whose effects are mediated through 
Na+ pumps and transporters (Abdallah, Schrier, Edelstein, Jennings, Wyse and Ellison, 2001; 
Arroyo, Ronzaud, Lagnaz, Staub and Gamba, 2011). Principal regulators of aldosterone 
biosynthesis are the RAAS, extracellular potassium concentration and adrenocorticotrophic 




Connell, MacKenzie, Freel, Fraser and Davies, 2008; Arroyo, Ronzaud, Lagnaz, Staub and 
Gamba, 2011).  
The major action of aldosterone on epithelial cells is to cause the reabsorption of Na+ thereby also 
influencing the transport of water across the cell apical membrane (Hackenthal, Paul, Ganten and 
Taugner, 1990; Klar, Vitzthum and Kurtz, 2004; Arroyo, Ronzaud, Lagnaz, Staub and Gamba, 
2011). Aldosterone-induced reabsorption of Na+ in the distal tubule is mediated via Na+/K+-
ATPase and amiloride-sensitive epithelial sodium channel (ENaC) (McCormick, Bhalla, Pao and 
Pearce, 2005). Reports indicate that high-salt diet elevate ENaC expression in the kidney of salt-
sensitive hypertensive rats thereby causing the disturbance of Na+ balance (Aoi, Niisato, Miyazaki 
and Marunaka, 2004). The flavonoid, quercetin, which is abundant in plants has been shown to 
possess antihypertensive action in high-salt-induced hypertension by diminishing the elevated 
expression of ENaC messenger ribonucleic acid (mRNA) in the kidney (Aoi, Niisato, Miyazaki 
and Marunaka, 2004). The mechanism through which aldosterone mediates Na+ reabsorption is by 
modulating the expression and activation of Na+ channels in the plasma membrane as well as 
insertion of Na+/K+-pumps in the basolateral membrane (Geering, Beguin, Garty, Karlish, Fuzesi, 
Horisberger and Crambert, 2003; Klar, Vitzthum and Kurtz, 2004). 
 
The global effect of increased Na+ reabsorption on water retention depends to some extent on the 
water permeability of the collecting duct.  The ADH, also known as AVP, increase water 
permeability in the luminal membrane (Ecelbarger, Kim, Wade and Knepper, 2001; Floyd, Mason, 
Proudman, German, Marples and Mobasheri, 2007). The primary AVP receptor that controls water 
reabsorption is the G protein-coupled V2 receptor which, when activated, results in a cascade of 
events that leads to trafficking of aquaporin-2 (AQP2) water channels to the apical membrane 
(Perucca, Bichet, Bardoux, Bouby and Bankir, 2008; Bugaj, Pochynyuk and Stockand, 2009). In 
the absence of AVP, the principal cells are virtually impermeable to water.  In addition to V2 
receptor, AVP has been shown to exert a natriuretic effect via V1 receptor in experimental animals 





Oxytocin (OT) is another hormone involved in regulation of fluid balance, blood pressure and 
cardiac function (McCann, Antunes-Rodrigues, Jankowski and Gutkowska, 2002; Michelini, 
Marcelo, Amico and Morris, 2003). This non-peptide hormone is produced in neurons originating 
from the paraventricular nucleus (PVN) and projecting to many brain areas with receptors present 
in the vasculature, heart, and kidney (Petersson, Alster, Lundeberg and Uvnäs-Moberg, 1996; 
Rigatto, Puryear, Bernatova and Morris, 2003). Studies report that OT enhances natriuresis and 
does not influence urine flow rate but exert antidiuretic effects via V2 AVP receptor at high doses 
(Conrad, Gellai, North and Valtin, 1986; Chou, DiGiovanni, Luther, Lolait and Knepper, 1995). 
Natriuretic action of OT is caused by NO mediated generation of cyclic guanosine monophosphate 
(cGMP) and release of atrial natriuretic peptide (ANP) which further increase cGMP levels 
responsible for decreased Na+ reabsorption via blockade of Na+ channels (Haanwinckel, Elias, 
Favaretto, Gutkowska, McCann and Antunes-Rodrigues, 1995; Soares, Coimbra, Martins, Pereira, 
Carnio, Branco, Albuquerque-Araujo, de Nucci, Favaretto, Gutkowska, McCann and Antunes-
Rodrigues, 1999). 
 
1.2.4   Methods used to assess kidney function 
1.2.4.1  Plasma and urine biomarkers 
 
Kidney biomarkers are used to assess exposure to illness and to detect biological abnormalities, 
but are more often used to diagnose and measure a pathological condition (Madero, 2006; Endre 
and Westhuyzen, 2008; Tesch, 2010; Fassett, Venuthurupalli, Gobe, Coombes, Cooper and Hoy, 
2011). There are a number of plasma and urine biomarkers that can be used to assess the functional 
status of the kidney and these biomarkers have to fulfill a certain number of criteria in order to be 
considered reliable. Blood urea nitrogen (BUN) and creatinine clearance are well established 
biomarkers of renal function that can be measured cheaply and easily using an enzyme/oxidation 
reaction assay and high performance liquid chromatography (HPLC), respectively (Mouton and 






Creatinine clearance has been used by several authors to assess renal tubular function as a measure 
of GFR (Bursztyn, Ben-Ishay, Mekler and Raz, 1995; Travlos, Morris, Elwell, Duke, Rosenblum 
and Thompson, 1996; Girchev, Markova, Mikhov and Natcheff, 1998; Bertuzzi, Bensi, Mayer, 
Niebylski, Armario and Gauna, 2003; Gondwe, Kamadyaapa, Tufts, Chuturgoon and Musabayane, 
2008; Mapanga, Tufts, Shode and Musabayane, 2009; Mkhwanazi, Serumula, Myburg, Van 
Heerden and Musabayane, 2014). GFR can also be estimated using exogenous filtration markers 
like inulin, iothalamate, ethylenediaminetetra-acetic acid (EDTA), diethylene triamine penta-
acetic acid and iohexol (Dharnidharka, Kwon and Stevens, 2001; Rosner and Bolton, 2006; 
Stevens, Coresh, Greene and Levey, 2006). One of the effects of hypertension is increased plasma 
flow into the kidney which may affect the GFR. Therefore, this study used creatinine clearance to 
assess the sub-chronic effects of OA on GFR.  
 
A recently emerged, reliable alternative biomarker of renal function is cystatin-C which is a 
cysteine protease inhibitor that is normally catabolized by kidney tubules without re-entering the 
blood stream and can be measured by an enzyme-linked immunosorbent assay (ELISA) (Endre 
and Westhuyzen, 2008; Tesch, 2010). Urine angiotensinogen, microalbuminuria, transforming 
growth factor-β1 (TGF-β1) and connective tissue growth factor are also potential biomarkers of 
kidney diseases and can be measured by ELISA (Tesch, 2010; Fassett, Venuthurupalli, Gobe, 
Coombes, Cooper and Hoy, 2011). Analysis of the urine sediment by quantitative polymerase 
chain reaction (PCR) or ELISA can determine mRNA or protein levels of podocyte-specific 
molecules like nephrin, podocin and podocalyxin as markers of podocyte injury (Wang, Lai, Lai, 
Chow, Li and Szeto, 2007; Wang, Lai, Tam, Li, Lai, Chow, Li and Szeto, 2007b). In addition to 
creatinine clearance, the kidney function biomarker of interest in this study was Li+ clearance 
which is used to quantify the amount of Na+ output from the proximal tubule.  
 
1.2.4.2  Lithium clearance 
 
Renal clearance of Li+ has been used widely in animal studies and clinical investigations as a means 
of assessing proximal tubular function in the mammalian kidney (Koomans, Boer and Dorhout-




Shirley, Walter, Boer and Koomans, 1995; Whiting, 1999; Madlala, Masola, Singh and 
Musabayane, 2012; Mkhwanazi, Serumula, Myburg, Van Heerden and Musabayane, 2014). Li+ 
clearance measurements are based on the observation that Li+ undergoes iso-osmotic reabsorption 
in the proximal renal tubule to the same extent as Na+ and water, hence is regarded as the best 
available marker for proximal tubular reabsorption of Na+ (Thomsen, 1984). Consequently, Li+ 
clearance techniques can be used in both experimental and clinical studies to assess glomerulo-
tubular function and handling of Na+ by the proximal tubule in both health and disease states 
(Whiting, 1999). 
 
However, studies have shown that Li+ reabsorption also takes place in the distal nephron in Na+/K+ 
deprived rats (Thomsen and Shalmi, 1997; Shalmi, Jonassen, Thomsen, Kibble, Bie and 
Christensen, 1998; Emamifar, Shalmi, Thomsen and Christensen, 2000). On the other hand, 
clearance and micropuncture studies in rats indicate that using low concentrations of Li+ prevents 
this previously reported distal reabsorption of this marker (Koomans, Boer and Dorhout-Mees, 
1989; Shirley, Walter and Sampson, 1992). Hence this study employed Li+ clearance to investigate 
the effects of OA on proximal tubular Na+ handling since salt-induced hypertension results from 
the changes in this part of the nephron where most of Na+ reabsorption takes place. 
 
1.3   Cardiac function 
 
The primary function of the heart is to pump the blood in order to generate and sustain an arterial 
blood pressure necessary to provide adequate perfusion of organs. The heart achieves this by 
contracting the muscular walls around a closed chamber to generate sufficient pressure to propel 
blood from the ventricle, through the aortic valve and into the aorta.  Each time the heart beats, a 
volume of blood, stroke volume (SV), is ejected. The SV multiplied by the number of beats per 
minute (HR), equals the CO. In general, an increase in arterial blood pressure can be caused by 
either an increase in systemic vascular resistance (SVR) or an increase in CO (Debrah, Conrad, 
Jeyabalan, Danielson and Shroff, 2005). The SVR is determined by the vascular tone (i.e. state of 
constriction) of systemic resistance vessels, whereas the CO is determined by HR and SV (Lamia, 




SVR and CO during a single cycle of cardiac activity is necessary for understanding how arterial 
blood pressure can become elevated.  
 
1.3.1   Cardiac cycle 
 
Diastole represents the period of time when the ventricles are relaxed (not contracting). 
Throughout most of this period, blood is passively flowing from the left and right atrium into the 
left and right ventricle, respectively. The blood flows through atrioventricular valves (mitral and 
tricuspid) that separate the atria from the ventricles. The right atrium receives venous blood from 
the body through the superior vena cava (SVC) and inferior vena cava (IVC). The left atrium 
receives oxygenated blood from lungs through four pulmonary veins that enter the left atrium.  
 
Contraction of both atria at the end of diastole forces an additional amount of blood into the 
ventricles. Systole represents the time during which the left and right ventricles contract and eject 
blood into the aorta and pulmonary artery, respectively. During systole, the aortic and pulmonic 
valves open to permit ejection into the aorta and pulmonary artery. The atrioventricular valves are 
closed during systole, therefore no blood is entering the ventricles; however, blood continues to 
enter the atria though the vena cava and pulmonary veins (Hundley, Kitzman, Morgan, Hamilton, 
Darty, Stewart, Herrington, Link and Little, 2001). Factors that influence the mechanisms that 
regulate both SVR and CO during cardiac activity may result in elevated arterial blood pressure. 
Disease conditions such as sustained hypertension result in decreased blood ejection from  the 
heart (because of increased afterload) and may cause hypertrophic enlargement of the ventricles 
and complications such as dilated cardiomyopathy (Wang, Lee, Fabsitz, Devereux, Best, Welty 
and Howard, 2006).  
 
Cardiomyopathy is characterised by reduced cardiac contractility which often progresses to heart 
failure and sudden death (Fang, Prins and Marwick, 2004; Piccini, Klein, Gheorghiade and Bonow, 
2004; Diamant, Lamb, Smit, De Roos and Heine, 2005; Abhayaratna, Seward, Appleton, Douglas, 
Oh, Tajik and Tsang, 2006; Lacombe, Viatchenko-Karpinski, Terentyev, Sridhar, Emani, 




muscle which occurs when the heart’s muscle wall stretches or thickens and as a result fails to 
efficiently function as a pump. Cardiomyopathies can be the result of coronary artery disease, but 
can also be caused by untreated hypertension, viral infections, drinking too much alcohol, certain 
other toxins; including certain chemotherapy agents, and other diseases that may deposit abnormal 
proteins or iron in the heart muscle (Maron, Wolfson, Epstein and Roberts, 1986; Foley, Parfrey, 
Harnett, Kent, Murray and Barre, 1996).  
 
Hypertension has been reported to be associated with left ventricular hypertrophy (LVH) which is 
a fundamental manifestation of preclinical cardiovascular disease that strongly predicts myocardial 
infarction, stroke and cardiovascular death in hypertensive patients (Devereux and Alderman, 
1993). Reports suggest that interruption of RAAS activity with ACE inhibitors or Ang II receptor 
antagonists such as losartan and atenolol may regress hypertensive LVH most effectively 
(Devereux, Dahlöf, Gerdts, Boman, Nieminen, Papademetriou, Rokkedal, Harris, Edelman and 
Wachtell, 2004). Green tea extract was shown to block the development of cardiac hypertrophy 
via attenuation of hypertension in experimental renal failure (Priyadarshi, Valentine, Han, 
Fedorova, Bagrov, Liu, Periyasamy, Kennedy, Malhotra and Xie, 2003). In addition, a plant extract 
isolated from Allium sativum (garlic) has been shown to be effective in reducing both systolic and 
diastolic blood pressure (Ashraf, Khan, Ashraf and Qureshi, 2013) in experimental models of salt-
induced hypertension.  
 
1.3.2   Cardiac excitation-contraction coupling 
 
An action potential is induced by pacemaker cells in the sinoatrial node and conducted from non-
contractile cardiac myocytes to contractile cells through gap junctions. The action potential travels 
along T-tubules and triggers calcium release from terminal cisternae via L-type calcium channels 
causing a net flux of calcium ions into the cardiac myocyte (Green, 2004). The increase in 
intracellular calcium ions is detected by ryanodine receptors (RyR) in the membrane of the 
sarcoplasmic reticulum (SR) which transport calcium out into the cytosol in a positive feedback 
physiological response. Calcium is the central factor in myocardial contraction and is stored within 
calsequestrin, a Ca
2+ 




Fields, Dunker and Kang, 2004). Reports suggest that calsequestrin Ca2+ store is the main source 
of Ca
2+
 ions that are released during  excitation-contraction (Bers, 2002). Studies have shown that 
cardiac diseases are associated with chronic stimulation of the β-adrenergic signaling pathway 
leads to hyperphosphorylation of RyR which leads to impaired contractility and increases the 
probability of cardiac arrhythmias (Marks, 2001; Wehrens and Marks, 2002). Compounds such as 
dantrolene, 1,4-benzothiazepines and flecainide modulate RyR via improved channel gating, ion 
channel translocation, RyR subunit composition or posttranslational modifications (Wehrens, 
Lehnart, Reiken, Deng, Vest, Cervantes, Coromilas, Landry and Marks, 2004; Kobayashi, 
Bannister, Gangopadhyay, Hamada, Parness and Ikemoto, 2005; Hilliard, Steele, Laver, Yang, Le 
Marchand, Chopra, Piston, Huke and Knollmann, 2010). 
 
Contraction of the cardiac muscle is dependent on this calcium-induced calcium release 
phenomenon. Cytoplasmic calcium binds to troponin C, calcium-activated troponin undergoes a 
conformational change which moves the troponin complex away from the actin binding site 
allowing the myosin head to bind to the actin filament (Clapham, 2007). Using ATP hydrolysis, 
the myosin head pulls the actin filament to the centre of the sarcomere (contraction). Troponin 
complex that plays a major role in excitation-contraction coupling is made up of troponin C, I, and 
T. Troponin I is tightly bound to actin and blocks its interaction with myosin when Ca2+ levels are 
low during diastole (Clapham, 2007). For relaxation, intracellular calcium is taken up by the 
sarco/endoplasmic reticulum ATPase pump into the sarcoplasm, or ejected from the cell by the 
sodium-calcium exchanger or the plasma membrane calcium ATPase.  
 
The energy for ion transport via Na+/Ca2+-exchanger (NCX) is indirectly derived from ATP 


















 and is the major Ca
2+ 
extrusion mechanism of the cardiac myocyte and may 
contribute significantly to myocardial relaxation. When intracellular calcium concentration drops, 




inhibiting myosin-actin interaction and the muscle fiber relaxes.  Altered function of troponin I 
due to either ischaemia, long term hypertension or depletion of cardiac troponin I can produce 
diastolic dysfunction and myocardial hypertrophy (Devereux, Dahlöf, Gerdts, Boman, Nieminen, 
Papademetriou, Rokkedal, Harris, Edelman and Wachtell, 2004).  
 
Diastolic dysfunction is evident when the time period during which the myocardium loses the 
ability to generate force and shorten or returns to an unstressed length is prolonged, slowed, or 
incomplete (Zile and Brutsaert, 2002). This results from changes in calcium homeostasis caused 
by (1) abnormalities in the sarcolemmal transporters responsible for short- and long-term extrusion 
of calcium from the cytosol, such as the sodium calcium exchanger and the calcium pump; (2) 
abnormal SR calcium re-uptake caused by a decrease in SR Ca2+-ATPase; and (3) changes in the 
phosphorylation state of the proteins that modify SR Ca2+-ATPase function, such as 
phospholamban, calmodulin, and calsequestrin (Zile and Brutsaert, 2002b). Changes in any of 
these processes can result in increased cytosolic diastolic calcium concentration, prolongation in 
the calcium transient, delayed and slowed diastolic decline in cytosolic calcium concentration (Zile 
and Brutsaert, 2002b). Reports suggest that diastolic dysfunction and myocardial hypertrophy are 
vital signs for development of systemic hypertension (Aeschbacher, Hutter, Fuhrer, Weidmann, 
Delacrétaz and Allemann, 2001). We investigated the effects of medicinal plant bioactive 
compound and its derivatives on the cell contraction (measured as cell shortening) and Ca2+ 
currents in isolated cardiomyocyte of hypertensive animals. 
 
Reports suggest that SR Ca2+-ATPase pump (SERCA) and sarcolemma NCX  remove 70% and 
28% of the cytosolic Ca2+, respectively (Bers, 2000). However, the relative contributions of Ca2+ 
transporters are altered in heart failure preceded by hypertension, with a shift toward NCX and 
away from SERCA (Hasenfuss, 1998). This shift is detrimental due to reduction of Ca2+ stored in 
the SR, hence decreasing the amount of Ca2+ available for release during systole. In addition, the 
NCX system is energetically draining due to transportation of only one Ca2+ for each ATP 
consumed as opposed to the SERCA system which transports two Ca2+ per ATP (Villars, Hamlin, 
Shaw and Kanusky, 2004). Therapeutic upregulation of SERCA2 expression using replication 




analogues, β-adrenergic receptor antagonists, and novel metabolically active compounds are 
currently under investigation for the treatment of uncompensated cardiac hypertrophy and heart 
failure (Zarain-Herzberg, 2006). Interestingly, plant-derived extracts such as astragaloside IV, a 
saponin isolated from Astragalus membranaceus have been reported to improve the expression of 
SERCA in isolated cardiomyocytes (Xu, Chen, Ji, Li, Bian, Yang, Xu, Bian and Zhang, 2008).  
 
1.3.3   General structure of calcium channels 
 
Voltage-operated calcium channel is composed of five different polypeptide subunits with 
different molecular masses (Takahashi, Seager, Jones, Reber and Catterall, 1987). The α1 subunit 
(175 kD) forms the ion channel and contains Ca2+ antagonist binding sites and is considered to be 
the principal structural component of the Ca2+ channel (Tanabe, Takeshima, Mikami, Flockerzi, 
Takahashi, Kangawa, Kojima, Matsuo, Hirose and Numa, 1987; Cribbs, 2006). Alpha2 subunit 
(143 kD) is associated with α1 but does not contain any high-affinity binding site; and the 
remaining three low-molecular weight subunits include β (54 kD), γ (30 kD) and δ (27 kD) (Ruth, 
Rohrkasten, Biel, Bosse, Regulla, Meyer, Flockerzi and Hofmann, 1989; Jay, Ellis, McCue, 
Williams, Vedvick, Harpold and Campbell, 1990). The α1 and β subunits contain phosphorylation 
sites for cAMP-dependent protein kinase. The α2, γ, and δ subunits are heavily glycosylated, 
indicating that they are located extracellularly (Takahashi, Seager, Jones, Reber and Catterall, 
1987).  
 
The Ca2+ channels possess four homologous domains each having six trans-membrane regions 
(Catterall, 1988). These domains are predicted to span the cell membrane and to contribute to the 
outer portion of the channel pore. However, the short amino- and long carboxy-terminal segments 
of the α1 subunit are positioned intracellularly (Yamakage and Namiki, 2002). Various types of 
Ca2+ channels are shown in Table 1 below. Ca2+ influx through ion channels and Ca2+ released 
from intracellular stores have been proposed as the major contributors of cardiac and smooth 
muscle contraction (Moosmang, Schulla, Welling, Feil, Feil, Wegener, Hofmann and Klugbauer, 




therefore are the targets of many important therapeutic agents, including anti-arrhythmic, Ca2+ 
channel antagonists and catecholamines. Calcium antagonists have been used extensively to treat 
hypertension for more than 15 years and are among the compounds listed as first-line treatment 
for the management of mild hypertension (Hansson, Hedner, Lund-Johansen, Kjeldsen, Lindholm, 
Syvertsen, Lanke, de Faire, Dahlöf and Karlberg, 2000). Medicinal plant extracts of Marrubium 
vulgare L. (horehound, Lamiaceae) and Croton schiedeanus Schlecht (Euphorbiaceae) possess 
hypotensive effects mediated via blockade Ca2+ channels which inhibit K+ induced contraction of 
smooth muscles (Bardai, Lyoussi, Wibo and Morel, 2001). This study assessed the effects of plant-
derived compounds on L-type Ca2+ currents in isolated rat cardiomyocytes using a whole-cell 




























Channel type Tissue distribution Antagonists/Blockers Reference 
L-type (Long 
lasting)         
brain, neuronal, endocrine, kidney 
cells, cardiac, smooth and skeletal 





(Chang and Hosey, 1988; 
Yamakage and Namiki, 2002; 
Cantí, Davies and Dolphin, 2003) 
N-type 
(Neural/Non-L)       
brain, neuronal cells ω-conotoxin, agatoxin (Witcher, De Waard, Sakamoto, 
Franzini-Armstrong, Pragnell, 
Kahl and Campbell, 1993; Liu, 
De Waard, Scott, Gurnett, 
Lennon and Campbell, 1996) 
P/Q-type 
(Purkinje) 
brain, neuronal cells, heart funnel spider venom toxin  
(Randall and Tsien, 1995) 
R-type 
(Residual) 
brain, neuronal cells agatoxin  
(Clozel, Ertel and Ertel, 1999) 
T-type 
(Transient) 





1.3.4   Methods used to assess cardiac functional status 
Two-dimensional (2D) echocardiography allows an evaluation of the valvular structure as well as 
the impact of the volume overload on the cardiac chambers by measuring aortic velocities, CO, 
left ventricular systolic and diastolic functions (Zoghbi, Enriquez-Sarano, Foster, Grayburn, Kraft, 
Levine, Nihoyannopoulos, Otto, Quinones, Rakowski, Stewart, Waggoner and Weissman, 2003). 
Disease conditions in which coronary flow reserve is decreased are potential sources of intolerance 
of increased systolic cardiac load (Hartley, Reddy, Madala, Michael, Entman and Taffet, 2008) 
and can be determined by measuring coronary flow using a 20 MHz Doppler ultrasound probe.  
 
With the increasing use of small animals for research, molecular imaging must have sufficiently 
high spatial resolution to allow anatomic localisation of small coronary arteries (De Kemp, 
Epstein, Catana, Tsui and Ritman, 2010). Imaging methods based on electromagnetic radiation, 
such as positron emission tomography (PET), single-photon emission computed tomography 
(SPECT) and magnetic resonance imaging (MRI) are increasingly applicable due to recent 
advances in novel scanner hardware, image reconstruction software and availability of novel 
molecules which have enhanced sensitivity in these methodologies (Gilson, Yang, French and 
Epstein, 2004; Kreissl, Wu, Stout, Ladno, Schindler, Zhang, Prior, Prins, Chatziioannou and 
Huang, 2006; Beekman and van der Have, 2007; Catana, Procissi, Wu, Judenhofer, Qi, Pichler, 
Jacobs and Cherry, 2008; Stegger, Heijman, Schäfers, Nicolay, Schäfers and Strijkers, 2009; De 
Kemp, Epstein, Catana, Tsui and Ritman, 2010).  
 
Measurement of cell shortening can be performed by video edge detection technique which 
monitors the edges of the cell as it contracts. The parameters that can be measured with this 
technique include the amplitude of the shortening, the time to peak shortening and the relaxation 
time constant obtained by fitting an exponential on the contraction curve (Steadman, Moore, 
Spitzer and Bridge, 1988). To capture the contraction process of the isolated cardiac myocytes, 
cells must be placed in a chamber mounted on the stage of an inverted microscope. Rod-shaped 
myocytes with clear edges have to be selected for recording of mechanical properties. The cells 




of the stimulus. The stimulation is performed using a pair of platinum wires placed on opposite 
sides of the chamber connected to an electrical stimulator. The polarity of the stimulatory 
electrodes is reversed automatically to prevent electrode polarisation (Lim, Apstein, Colucci and 
Liao, 2000). Myocyte motion is then digitally recorded with a camera mounted on the microscope. 
For this study we employed this technique to investigate the effects of OA or derivatives on the 
cell contraction (shortening) in isolated cardiomyocytes. 
 
We acknowledge collaborations of Hodgkin and Huxley for laying the foundation for 
understanding electrophysiology in terms of how voltage-gated ion channels give rise to 
propagating action potentials and for studying and analysing ion channel kinetics (Hodgkin, 
Huxley and Katz, 1952). Their work was extended by Neher and Sakmann who discovered the 
function of single ion channels in cells; and MacKinnon who studied structural and mechanistic 
studies of ion channels (Neher, Sakmann and Steinbach, 1978; Jiang, Lee, Chen, Ruta, Cadene, 
Chait and MacKinnon, 2003). Electrophysiology techniques are used to record changes in voltage 
and electric current of single ion channel proteins in isolated cells (Zimmermann, 
Schneiderbanger, Schubert, Didie, Münzel, Heubach, Kostin, Neuhuber and Eschenhagen, 2002). 
The preparations normally used for electrophysiology experiments include living organisms, 
excised tissue, dissociated cells from excised tissue, artificially grown cells or tissues (Vunjak-
Novakovic, Tandon, Godier, Maidhof, Marsano, Martens and Radisic, 2009).  
 
Conventional electrophysiology techniques are based on insertion of electrodes into membranes 
of various preparations of biological tissues. These electrodes are usually empty capillary glass 
tubes with a sharp tiny tip that has a resistance of few mega ohms (Clayton, Bernus, Cherry, 
Dierckx, Fenton, Mirabella, Panfilov, Sachse, Seemann and Zhang, 2011). The electrodes are filled 
with similar ionic composition to the intracellular fluid of the cell. The electrolyte is connected 
electrically to the amplifier and signal processing circuit by a chloride-based silver wire is inserted 
into the electrode. The sharp tip of the electrode is inserted on the cell membrane and to allow 
intracellular recording the membrane potential of a particular channel. The voltage of a reference 




in contact with the extracellular fluid around the cell (Keenan and Folch, 2008). The smaller the 
electrode tip, the higher the electrical resistance, so an electrode is a compromise between size and 
resistance (Piacentino, Weber, Chen, Weisser-Thomas, Margulies, Bers and Houser, 2003). 
 
1.3.4.1  Voltage and current clamp 
 
The voltage clamp technique is useful for determining the cell potential at a certain value to allow 
measurement of how much ionic current crosses a cell membrane at any given voltage (Kiss, 
Bennett, Uebele, Koblan, Kane, Neagle and Schroeder, 2003). This is necessary because most 
voltage-gated ion channels open when the membrane voltage is within a certain range. The digital 
subtraction of transient capacitive currents that permit the recording electrode and cell membrane 
are charged to alter the cell potential by voltage clamp measurements of current (Williams and 
Mitchell, 2008). The current clamp technique records the membrane potential by injecting current 
into a cell via the recording electrode (Hodgkin, Huxley and Katz, 1952; Prinz, Abbott and Marder, 
2004). This technique is used to study the response of the cell to the entry of an electric current. 
For example, this is beneficial for understanding the response of neurotransmitters to opening 
membrane ion channels. In the voltage clamp mode, the membrane potential is held at a particular 
level determined, whereas in current clamp mode the membrane potential is free to change, and 
the amplifier records any voltage the cell produces due to stimulation (Gustafson, Gireesh-
Dharmaraj, Czubayko, Blackwell and Plenz, 2006; Perkins, 2006).  
 
1.3.4.2  Patch-clamp 
 
Conventional intracellular recording explained above involves impaling a cell with a fine 
electrode; patch-clamp recording uses a micropipette with a relatively large tip microelectrode 
diameter (Stuart and Brownstone, 2011). The microelectrode is placed next to a cell, and gentle 
suction is applied through the microelectrode to draw a piece of the cell membrane (the 'patch') 
into the microelectrode tip; the glass tip forms a high resistance 'seal' with the cell membrane 
(Rugiero, Gola, Kunze, Reynaud, Furness and Clerc, 2002). This configuration is the cell-attached 
mode which is used for studying the activity of the ion channels that are present in the patch of 




of membrane in the electrode tip to be displaced, leaving the electrode sealed to the rest of the cell. 
This whole-cell mode allows a very stable intracellular recording (Neher, Sakmann and Steinbach, 
1978). This study used the whole-cell patch clamp technique to assess the effects of OA or 
derivatives on L-type Ca2+ currents in isolated cardiomyocytes. 
 
 
1.4   Vascular function 
 
The vascular system also called the circulatory system, is made up of the vessels that carry blood 
and lymph through the body. The arteries and veins carry blood throughout the body delivering 
oxygen and nutrients to the body tissues and taking away tissue waste matter. The lymph vessels 
carry lymphatic fluid and help to protect and maintain the fluid environment of the body by 
filtering and draining lymph away from each region of the body (Swartz, 2001; Oliver and Detmar, 
2002). In addition to circulating blood and lymph throughout the body, the vascular system 
functions as an important component of other body systems such as respiratory, digestive, kidney 
and urinary systems.  
 
Vascular disease is a term that encompasses several pathological states of the arterial wall that may 
lead to obstructed blood flow and thereby give rise to acute cardiovascular events (Makin, Blann, 
Chung, Silverman and Lip, 2004). Such pathological states include arterial remodeling, 
atherosclerosis, thrombosis and restenosis. Hypertension is a cardiovascular risk factor which 
regularly precedes the onset of vascular disease (Drummond, Selemidis, Griendling and Sobey, 
2011). Hypertension is characterised by loss of elasticity of arteries in the vascular system which 
cause enhanced blood pressure leading to coronary and renal vascular disease, heart attack or 
stroke and angina (Bleyer, Shemanski, Burke, Hansen and Appel, 2000; Mukai, Shimokawa, 








1.4.1  Regulation of vascular tone 
Vascular tone control is essential for fluid regulation in cases of shock, ischemia-reperfusion, 
inflammation, vessel injury or repair, wound healing, temperature regulation, digestion, 
metabolism (Zhou, Sutliff, Paul, Lorenz, Hoying, Haudenschild, Yin, Coffin, Kong and Kranias, 
1998) and most importantly for this study, blood pressure regulation. Vascular tone is influenced 
by substances that either cause dilation or contraction of the arteries or arterioles. These substances 
can be separated into extrinsic factors that originate from outside of the organ or tissue in which 
the blood vessel is located, and intrinsic factors that originate from the vessel itself or the 
surrounding tissue.  
 
Extrinsic factors regulate arterial blood pressure by altering total peripheral resistance, whereas 
intrinsic mechanisms are important for local blood flow regulation within an organ (Lautt, 2007). 
Examples of extrinsic factors include sympathetic nerves and circulating Ang II which increase 
vascular tone; also there are some circulating factors such as atrial natriuretic peptide which 
decrease vascular tone (Myatt, 1992).  Intrinsic factors include endothelial-derived substances such 
as nitric oxide (NO) and endothelin which either decrease or increase tone, respectively. Local 
hormones or chemical substances such as arachidonic acid metabolites, histamine, bradykinin, 
noradrenaline, vasopressin, serotonin and thrombin amongst many, can either increase or decrease 
tone (Haefliger, Flammer, Bény and Lüscher, 2001; Sellers and Stallone, 2008; Rubanyi, 2012).  
 
Endothelial cells can induce contractions of the underlying vascular smooth muscle by generating 
vasoconstrictor prostanoids (endothelium-dependent contracting factor; EDCF). The main 
prostanoids involved in endothelium-dependent contractions appear to be endoperoxides and 
prostacyclin, which activate thromboxane-prostanoid (TP) receptors of the vascular smooth 
muscle cells. Studies indicate that endothelium-dependent contractions are exacerbated by ageing, 
obesity, hypertension and diabetes, and therefore these contractions are likely to contribute to the 
endothelial dysfunction observed in older people and in essential hypertensive patients (Vanhoutte 
and Tang, 2008; Vanhoutte, 2009). The production of the EDCF involves an increase in endothelial 
intracellular calcium concentration, production of reactive oxygen species (ROS), activation of 




cause stimulation of their thromboxane A2-endoperoxide TP receptors (Félétou and Vanhoutte, 
2006; Félétou, Huang and Vanhoutte, 2011).  
 
COX catalytic activity leads to the formation of prostaglandin G2 (PGG2) which is the critical 
modulator of vascular tone and platelet activity under both physiological and pathophysiological 
conditions (Félétou, Huang and Vanhoutte, 2011). Ca2+ channel antagonists such as 
dihydropyridine, phenylalkylamines and benzothiazepines are widely used as anti-hypertensive 
treatment due to their vasodilatory properties (Webb, 2003). The antagonists bind to distinct 
receptors on the channel protein and inhibit Ca2+ entry in smooth muscle (Webb, 2003). In addition, 
medicinal plant products of Sarcococca saligna, Prosopis juliflora and withanolides from 
Withania somnifera, Sesamum indicum, Lavandula stoechas, ginger and Carum copticum were 
found to possess a unique combination of activities (ACE inhibitory and calcium antagonist)  
(Khalid, Ghayur, Feroz, Gilani and Choudhary, 2004; Choudhary, Nawaz, Azim, Ghayur, Lodhi, 
Jalil, Khalid, Ahmed, Rode and Gilani, 2005; Ghayur and Gilani, 2005; Gilani, 2005; Gilani, 
Ghayur, Khalid, Zaheer, Choudhary and Rahman, 2005; Choudhary, Nawaz, Lodhi, Ghayur, Jalil, 
Riaz, Yousuf, Malik and Gilani, 2005b). The mechanisms by which the above factors either 
constrict or relax blood vessels involve a variety of signal transduction mechanisms that involves 
Ca2+ release in the smooth muscle as described in the next paragraph. 
 
1.4.1.1  Mechanisms of smooth muscle contraction 
The ras homolog gene family member A (RhoA) pathway modulates the phosphorylation state of 
the regulatory chain of myosin II, mainly through inhibition of myosin phosphatase, and 
contributes to agonist-induced Ca2+ sensitization in smooth muscle contraction via the activity of 
its main effector Rho kinase (Swärd, Mita, Wilson, Deng, Susnjar and Walsh, 2003; Calo, 2006). 
The ultimate effect is to increase smooth muscle cell contraction. Exact mechanisms whereby Ang 
II stimulates Ca2+ influx are unclear but may involve voltage-dependent calcium channels, which 
are directly or indirectly activated by Ang II, Ca2+-permeable, nonspecific dihydropyridine-
insensitive cation channels, receptor-gated Ca2+ channels, Ca2+-activated Ca2+ release channels, 




Schiffrin, 2000). Binding of agonists such as noradrenalin, Ang II and endothelin to serpentine 
receptors which are coupled to a heterotrimeric G protein, stimulate phospholipase C activity 
(Swärd, Mita, Wilson, Deng, Susnjar and Walsh, 2003; Calo, 2006). This enzyme is specific for 
the membrane lipid phosphatidylinositol 4,5-bisphosphate to catalyze the formation of two potent 
second messengers: inositol trisphosphate (IP3) and diacylglycerol (DG). The binding of IP3 to 
receptors on the SR results in the release of Ca2+ into the cytosol. DG and Ca2+ activate protein 
kinase C (PKC), which phosphorylates specific target proteins.  
 
The rate of Ca2+ entry into the cytosol and release from sarcoplasm reticulum is modulated by the 
resting membrane potential. Membrane potential may be regulated by at least two types of K+ 
channels. These include inwardly rectifying K+ channels activated upon hyperpolarisation or shear 
stress and a Ca2+-activated K+ channel activated upon depolarisation, the latter may function to 
repolarize the agonist-stimulated endothelial cell (Adams and Hill, 2004). Receptor-operated and 
voltage-operated Ca2+ channels located in the plasma membrane are important in Ca2+ influx and 
smooth muscle contraction. The blood pressure regulatory factor, NO, which inhibit Ca2+ influx 
and cause smooth muscle relaxation is impaired in hypertension. 
 
1.4.2   Nitric oxide 
 
Endothelium-dependent relaxation of vascular smooth muscle to acetylcholine (ACh) is mediated 
by an endogenous mediator, NO which was initially referred to as endothelium-derived relaxing 
factor (Vanhoutte, Shimokawa, Tang and Feletou, 2009). Endothelium-derived NO is a potent 
vasodilator synthesised from the amino acid L-arginine by the endothelial isoform of NO synthase 
(NOS) (Palmer, Ashton and Moncada, 1988). Three isoforms of NOS have been identified; 
endothelial (eNOS), neuronal (nNOS) and inducible isoforms (iNOS) (Palmer, Ashton and 
Moncada, 1988). All three NOS isoforms play distinct roles in the regulation of vascular tone. 
Endothelial NOS and nNOS are normal constituents of healthy cells and iNOS is expressed mainly 





Biological functions of NO also include suppression of platelet aggregation, leukocyte migration 
and cellular adhesion to the endothelium, and attenuation of vascular smooth muscle cell 
proliferation and migration (Moncada, Palmer and Higgs, 1991; Alderton, Cooper and Knowles, 
2001; Vallance and Chan, 2001). Therefore, reduced NO bioavailability leads to leukocyte 
adhesion and infiltration of monocytes, macrophages and lipoproteins into the artery wall which 
is the first stage in the formation of foam cells during atherosclerosis (Jessup, Mohr, Gieseg, Dean 
and Stocker, 1992; Mombouli and Vanhoutte, 1999; Usui, Egashira, Kitamoto, Koyanagi, Katoh, 
Kataoka, Shimokawa and Takeshita, 1999). 
 
There is evidence that basal NO synthesis is reduced in untreated hypertension as indicated by 
reduced vasoconstrictor response to NOS inhibitor Nγ-monomethyl-L-arginine (L-NMMA) 
(Calver, Collier, Moncada and Vallance, 1992; Mizuno, Jacob and Mason, 2010). Drugs such as 
N-acetyl-cysteine (NAC), vitamins C and E are used to scavenge ROS and thereby may increase 
NO. In addition, there are various plant-derived compounds that have been shown to increase NO 
bioavailability via different mechanisms. Among these compounds are chlorogenic acid from 
Solanum indicum, betulinic acid from seeds of Zizyphus jujuba and crude herbal extracts from 
Phyllanthus acidus, Olea europaea, Fritillaria ussuriensis and Cudrania tricuspidata (Suzuki, 
Yamazaki and Yazaki, 2001; Komaki, Yamaguchi, Maru, Kinoshita, Kakehi, Ohta and Tsukada, 
2003; Somova, Nadar, Rammanan and Shode, 2003; Kang, Sohn, Lee, Lee, Han, Kim and Lee, 
2004; Bahgat, Abdel-Aziz, Raafat, Mahdy, El-Khatib, Ismail and Khayyal, 2008; Connell, 
MacKenzie, Freel, Fraser and Davies, 2008; Perrinjaquet-Moccetti, Busjahn, Schmidlin, Schmidt, 
Bradl and Aydogan, 2008; El and Karakaya, 2009; Leeya, Mulvany, Queiroz, Marston, 
Hostettmann and Jansakul, 2010). We investigated the effects of OA and related triterpene 
derivatives on vascular smooth muscle contraction and relaxation profiles in the presence of NOS 










1.4.3 Oxidative stress 
 
Oxidative stress is associated with all known cardiovascular risk factors including hypertension. 
In oxidative stress, the production of ROS superoxide anion (O2
•−) exceeds the available 
antioxidant defence systems which cause a rapid oxidative inactivation of vascular NO signaling 
and bioavailability (Chew and Watts, 2004). The majority of ROS generation in the vasculature is 
derived from eNOS uncoupling. Uncoupling of eNOS in the pathogenesis of endothelial 
dysfunction is thought to be associated with the decrease of essential eNOS cofactor, 
tetrahydrobiopterin (BH4), bioavailability (Alp and Channon, 2004). This cofactor facilitates 
NADPH-derived electron transfer from the eNOS reductase to the oxygenase domain to convert 
L-arginine to NO and L-citrulline (Kietadisorn, Juni and Moens, 2012). When BH4 levels are 
inadequate, eNOS becomes unstable and uncoupled, leading to subsequently less NO production 
and more O2
•− generation. The interaction between NO and superoxide leads to the formation of 
another toxic free radical called peroxynitrite, a potent oxidant, which further oxidises BH4 
(Crabtree, Tatham, Al-Wakeel, Warrick, Hale, Cai, Channon and Alp, 2009; Crabtree, Hale and 
Channon, 2011). 
 
Another source of ROS generation in the vasculature is mediated by NADPH oxidases (NOX) and 
therefore inhibitors of these enzymes such as apocynin and diphenyleneiodonium (DPI) are 
pharmacologically used to combat oxidative stress and the associated vascular pathologies in 
cardiovascular diseases (Selemidis, Sobey, Wingler, Schmidt and Drummond, 2008; Drummond, 
Selemidis, Griendling and Sobey, 2011). Various plant extracts have been shown to possess 
antioxidant properties that can alleviate symptoms of vascular disease by scavenging the ROS 
radicals. These include Salvia species, Lavandula angustifolia (all Lamiaceae family), Calendula 
officinalis, Matricaria recutita, Echinacea purpurea, Rhaponticum carthamoides (Asteraceae 
family), Juglans regia, (Juglandaceae), Melilotus officinalis (Fabaceae), Geranium macrorrhizum 
(Geraniaceae) and Potentilla fruticosa (Rosaceae) (Tang and Yuan, 1997; Bolshakova, 
Lozovskaya and Sapezhinskii, 1998; Ohsugi, Fan, Has, Xiong, Tezuka, Komatsu, Namba, Saitoh, 
Tazawa and Kadota, 1999; Lei, Mehta, Berenbaum, Zangerl and Engeseth, 2000; Zupko, 




evaluated the effects of a plant-derived OA and derivatives on pro and antioxidative enzymes in 
the heart, kidney and the liver tissues of hypertensive animals. Persistent oxidative stress results 
in dysfunctional eNOS such that the NO production ceases, and increase  O2
•− which prevents 




1.4.4   Conventional methods used to assess oxidative stress 
 
Monitoring oxidative stress is achieved by assaying products of oxidative damage or by 
investigating the potential of an organism, tissue or body fluids to withstand further oxidation 
(Palmieri and Sblendorio, 2007). Unfortunately, there is little consensus concerning the selection 
of parameters of oxidative stress or antioxidant state to be determined in defined diseases. This is 
not only due to the uncertainty on whether or not a certain parameter is playing a causative role 
but also because the methods of determination described in the literature represent very different 
levels of analytical practicability, costs and quality (Dalle-Donne, Rossi, Colombo, Giustarini and 
Milzani, 2006). Analytical techniques including HPLC, gas chromatography-mass spectrometry 
(GC-MS), fluorometric and colourometric assays, ELISA and gel electrophoresis have become 
more common standards. 
 
1.4.4.1  Free radical measurements 
 
Electron Spin Resonance (ESR) spectrometry can usually be applied to analysis of samples in vivo 
only through the technique of spin trapping. This involves the addition of a compound known as 
spin-trap, which reacts rapidly with the free radicals to form radical-adducts. These radical-adducts 
are very stable and long-lived than the original species and can therefore build up to steady state 
concentrations in the detectable range (Davies and Hawkins, 2004; Augusto and Vaz, 2007; Lee, 
Margaritis, Channon and Antoniades, 2012; Lee, Han, Kim, Baek and Baik, 2013). Electron 
paramagnetic resonance (EPR) technique is based on detection of a persistent nitroxide generated 
under physiological or pseudo-physiological conditions by oxidation of a highly lipophylic 




nitroxide is reduced to the diamagnetic hydroxylamine, which can be evaluated by EPR, is related 
to the reducing capacity of the organism and hence to its oxidative status (Hirayama, Nagase, 
Ueda, Oteki, Takada, Obara, Inoue, Yoh, Hirayama and Koyama, 2005). Furthermore, nitroxide 
crosses cell membranes and distributes in a biological environment without the need to alter or 
destroy compartments. Therefore, this method is suitable for quantitative measurements of ROS 
and can be applied to human tissues in real clinical settings (Palmieri and Sblendorio, 2007).  
 
Dihydroethidium (DHE) or hydroethidine is a cell-permeable compound that, upon entering the 
cells, interacts with O2
•− to form oxyethidium (Zhao, Kalivendi, Zhang, Joseph, Nithipatikom, 
Vásquez-Vivar and Kalyanaraman, 2003), which in turn interacts with nucleic acids to emit a 
bright red colour detectable qualitatively by fluorescent microscope (Tarpey, Wink and Grisham, 
2004). DHE assay may be adapted for HPLC for specific and quantitative detection of O2
•− from 
biological samples (Fink, Laude, McCann, Doughan, Harrison and Dikalov, 2004). Cytochrome 
C Reduction Assay was considered the “gold standard” for detection of O2
•− prior to the discovery 
of ESR (Tarpey, Wink and Grisham, 2004). The use of lucigenin at low concentrations (<5 µM) 
has been shown to detect O2
•− without background noise and this assay remains a valid method for 
O2
•− production, when appropriate experimental procedures are used (Münzel, Afanas’ev, 
Kleschyov and Harrison, 2002). Hydrogen peroxide levels in vascular cells and tissues can be 
monitored by dichlorofluorescein fluorescent, amplex red assay and o-phenylenediamine 




1.4.4.2  Lipid peroxidation 
 
Lipid peroxidation is a complex process whereby polyunsaturated fatty acids (PUFAs) in the 
phospholipids of cellular membranes undergo reaction with oxygen to yield lipid hydroperoxides 
(LOOH) (Halliwell and Chirico, 1993). The thiobarbituric acid (TBA) assay is the most common 
and easiest method used to assess lipid peroxidation and free radical activity in biological samples. 
The assay is based on the reaction of two molecules of TBA with one of malondialdehyde (MDA), 




product of arachidonate metabolism (Bouzid, Hammouda, Matran, Robin and Fabre, 2014). The 
excess MDA produced as a result of tissue injury can combine with free amino groups of proteins. 
There are a lot of variations but mainly the sample is heated with TBA under acidic conditions and 
the amount of pink-coloured MDA-TBA adduct produced is measured using a spectrophotometer 
(Bloomer and Goldfarb, 2004). 
 
1.4.4.3  Measurement of antioxidants 
 
Different animal studies have shown that antioxidants delay or protect against the oxidative 
damage produced by free radical reactions (Selemidis, Sobey, Wingler, Schmidt and Drummond, 
2008; Drummond, Selemidis, Griendling and Sobey, 2011). Radical-scavenging antioxidants are 
consumed during this process and antioxidant status is sometimes used indirectly to assess free 
radical activity. The commonly used total peroxyl radical-trapping antioxidant parameter (TRAP) 
assay is an empirical measurement of antioxidant activity in plasma (Ghiselli, Serafini, Maiani, 
Azzini and Ferro-Luzzi, 1995). Assessment of the relative contribution of individual antioxidants 
(ascorbate, urate, α-tocopherol, protein sulphydryls) to the total antioxidant capacity requires 
separate specific assays (Palmieri and Sblendorio, 2007). Antioxidant amounts are parameters 
indicative of the predisposition of the individual to oxidative stress. 
 
Superoxide dismutase (SOD) assay uses xanthine and xanthine oxidase to generate superoxide 
radicals that react with 2-(4-iodophenyl-)-3-(4-nitrophenyl)-5-phenyltetrazoluim chloride to form 
a red formazan dye (Bouzid, Hammouda, Matran, Robin and Fabre, 2014). The SOD activity is 
then quantified by measuring the degree of inhibition of this reaction. Glutathione peroxidase 
(GPx) assay employs the principle that oxidised glutathione (GSSG), produced upon reduction of 
an organic hydroperoxide by GPx, is recycled to its reduced state by glutathione reductase (GR) 
and nicotinamide adenine dinucleotide phosphate (NADPH) (Ho, Karimi Galougahi, Liu, Bhindi 
and Figtree, 2013). The oxidation of NADPH to NADP+ is accompanied by a decrease in 
absorbance at 340 nm. The rate of decrease is directly proportional to the GPx activity in the 




oxidative status of hepatic, cardiac and renal tissues of hypertensive animals by measuring levels 
of MDA, SOD and GPx. 
 
1.5    Management of hypertension        
1.5.1   Lifestyle modifications 
 
Preventive lifestyle change such as dietary changes, physical exercise and weight loss have all 
been shown to significantly reduce blood pressure in people with hypertension (Siebenhofer, 
Jeitler, Berghold, Waltering, Hemkens, Semlitsch, Pachler, Strametz and Horvath, 2011). Even 
when blood pressure is high enough to justify immediate use of medications, lifestyle changes are 
still recommended in conjunction with medication (Gilliam, 2012). Studies indicate that a long 
term low sodium diet is effective in reducing blood pressure, both in people with hypertension and 
in people with normal blood pressure (He, Marciniak, Visagie, Markandu, Anand, Dalton and 
MacGregor, 2009; He, Li and MacGregor, 2013).  
 
The South African Hypertension Guidelines recommend a maximum salt intake of 6 g day-1 which 
is the upper boundary of the 4-6 g day-1 recommended by the WHO (WHO, 2003). Consequently, 
SA diet is high in salt, with bread contributing to 25-40% of Na+ intake (Charlton, Steyn, Levitt, 
Zulu, Jonathan, Veldman and Nel, 2005). Average daily intake, measured by 24-hour urinary Na+ 
excretion, is 7.8 g in black persons, 8.5 g in mixed-race persons, and 9.5 g in white persons in SA 
(Charlton, Steyn, Levitt, Zulu, Jonathan, Veldman and Nel, 2005). If Na+ content of bread, soup 
mix, seasoning and margarine could be reduced, the average salt intake would decrease by 0.85 g 
person-1 day-1 and this would result in 7 400 fewer CVD deaths and 4 300 less non-fatal strokes 
per year compared with 2008 (Bertram, Steyn, Wentze-Viljoen, Tollman and Hofman, 2012). In 
addition, a diet rich in nuts, whole grains, fish, poultry, fruits and vegetables lowers blood pressure 
(Hu, 2003). Several exercise regimes such as isometric resistance and aerobic exercises may be 






1.5.2   Therapeutic medication  
 
Several classes of medications, collectively referred to as antihypertensive drugs, are currently 
available for management of hypertension. Reduction of the blood pressure by 5 mmHg can 
decrease the risk of stroke by 34%, ischaemic heart disease by 21% and reduce the likelihood of 
dementia, heart failure, and mortality from cardiovascular disease (Law, Wald and Morris, 2005). 
The current drugs used for treatment of cardiovascular disorders include β-blockers, alpha-
adrenoceptor blockers, Ca2+ channel blockers (CCB), ACE inhibitors, Ang II type 1 angiotensin 
receptor blockers (ARB) and diuretics. β-blockers such as atenolol, metoprolol, nebivolol and 
carvedilol also provide antioxidant activity and have direct vasodilatory properties either through 
α blocking action or activation of NOS thereby improving endothelial function in patients with 
hypertension (Tzemos, Lim and MacDonald, 2001; Mason, Kubant, Jacob, Walter, Boychuk and 
Malinski, 2006; Weiss, 2006; Bank, Kelly, Thelen, Kaiser and Gonzalez-Campoy, 2007).  
Alpha-adrenoceptor blockers such as prazosin, terazosin and doxazosin lower peripheral vascular 
resistance by relaxing smooth muscles (Khwanchuea, Jansakul, Mulvany, Queiroz and 
Hostettmann, 2007; Mackraj, Ramesar, Singh, Govender, Baijnath, Singh and Gathiram, 2008; 
Leeya, Mulvany, Queiroz, Marston, Hostettmann and Jansakul, 2010; Soncini, Santiago, Orlandi, 
Moraes, Peloso, dos Santos, Alves-da-Silva, Paffaro, Bento and Giusti-Paiva, 2011; Tom, 
Demougeot, Mtopi, Dimo, Djomeni, Bilanda, Girard and Berthelot, 2011). Ca2+ channel blockers 
like nifedipine, amlodipine, lercanidipine and isradipine cause peripheral vasodilation (Perticone, 
Ceravolo, Maio, Ventura, Iacopino, Cuda, Mastroroberto, Chello and Mattioli, 1999; Taddei, 
Virdis, Ghiadoni, Sudano and Salvetti, 2002). ACE inhibitors like captopril, cilazapril, lisinopril, 
perindopril and ramipril restore endothelium-dependent vasodilatory response to ACh. These 
drugs mediate their anti-hypertensive properties via inhibition of AngII-dependent 
vasoconstriction and production of aldosterone (Atlas, 2007). 
ARB antagonists such as irbesartan, candesartan, telmisartan have effects similar to those of ACE 
inhibitors (Ghiadoni, Virdis, Magagna, Taddei and Salvetti, 2000; Schiffrin, Park, Intengan and 
Touyz, 2000; Bellien, Iacob, Eltchaninoff, Bourkaib, Thuillez and Joannides, 2007; Benndorf, 




ethacrynic acid, torsemide, spironolactone and amiloride suppress tubular reabsorption of sodium, 
thus increasing the excretion of sodium and water thereby decrease blood volume (Greenberg, 
2000; Abdallah, Schrier, Edelstein, Jennings, Wyse and Ellison, 2001; Padilla, Armas-Hernández, 
Hernández, Israili and Valasco, 2007). The majority of people require more than one drug to 
control hypertension. Those with a systolic blood pressure greater than 160 mmHg or a diastolic 
blood pressure greater than 100 mmHg should use a thiazide and an ACE inhibitor, ARB or CCB 
(Go, Bauman, King, Fonarow, Lawrence, Williams and Sanchez, 2014). 
 
1.5.2.1  Plant-derived drugs  
Digitalis drugs derived from the foxglove (Digitalis purpurea) are perhaps the classic example of 
compounds from plant sources that have contributed successfully is cardiovascular research 
(Hauptman and Kelly, 1999; Gilani, 2005). They represent a widely used group of clinically 
effective compounds which produce positive inotropic effect on the failing heart as well as having 
value in the treatment of atrial fibrillation (Gilani, 2005). A second discovery of natural products 
with cardiovascular activity led to the isolation of reserpine over five decades ago (Gilani, 2005). 
Reserpine and rescinnamine are obtained from the roots of the Indian plant Rauwolfia serpentine. 
Studies indicate that lower doses of reserpine combined with low doses of thiazide diuretic and 
hydralazine provide highly effective blood pressure lowering regimen. This combination has renal 
protective effect and is relatively free from conventional side-effects (Pavan, Ghini, Castro and 
Lopes De Faria, 2003; Milne and Pinkney-Atkinson, 2004).  
 
Furthermore, rhomitoxin isolated from Rhododendron molle G. Don, protoveratrines from 
Veratrum album, deserpidine from Rauvolfia canescens are also drugs that have also been shown 
to alleviate cardiovascular disorders (Fabricant and Farnsworth, 2001; Salgueiro, Martins and 
Correia, 2010). Aspirin, an acetyl salt of salicylic acid (an active principle from willow bark) is 
considered one of the most effective analgesic, antipyretic and anti-inflammatory agents 
commonly used in modern medicine (Fabricant and Farnsworth, 2001). With the passage of time, 
multiple therapeutic uses of aspirin have emerged, with most prevalent use as the antiplatelet or 




suffered from one heart attack (Saeed, Atiq, Verani and Gilani, 2002). Few compounds derived 
from plants such as muscarine and nicotine (pioneer selective agonists for muscarinic and nicotinic 
receptors, respectively), cocaine (catecholamine uptake inhibitor) yohimbine (selective α2 blocker) 
and himbacine, a prototype of cardio-selective antimuscarinic agents (Gilani, 1998) have 
detrimental instead of therapeutic effects.  
 
Ongoing research seeks to validate more plant extracts with potent beneficial effects for use in the 
management of hypertension. Plant-derived remedies that have been reported to possess 
hypotensive effects include extracts of Marrubium vulgare L. (horehound, Lamiaceae) and 
Foeniculum vulgare L. (fennel, Apiaceae) (Bardai, Lyoussi, Wibo and Morel, 2001; El Bardai, 
Morel, Wibo, Fabre, Llabres, Lyoussi and Quetin-Leclercq, 2003). Furthermore, herbal remedies 
from Moringa oleifera, Terminalia superba (Combretaceae), Averrhoa carambola L. 
(Oxalidaceae), Phyllanthus acidus (L.), Tulbhagia violacea (Alliacea), Herniariaglabra, 
Verbesina caracasana and Randia siamensis have been shown to have anti-hypertensive effects 
mediated via unknown mechanisms (Faizi, Siddiqui, Saleem, Aftab, Shaheen and Gilani, 1998; 
Rhiouani, Settaf, Lyoussi, Cherrah, Lacaille-Dubois and Hassar, 1999; Botta, 2003). However, ex 
vivo studies on isolated atrial muscle preparations have suggested that natural products from Allium 
savitum (Linn.), Securidaca longipendunculata (Fresen.) and Achillea millefolium mediate their 
anti-hypertensive properties via reduction of noradrenaline-induced inotropic and chronotropic 
responses (Ojewole, 2000; Ojewole and Adewunmi, 2001; Niazmand, Esparham, Rezaee and 
Harandizadeh, 2011).   
Interestingly, the presence of a unique combination of activities (ACE inhibitory and calcium 
antagonist) was found in extracts of Sarcococca saligna (Khalid, Ghayur, Feroz, Gilani and 
Choudhary, 2004; Gilani, Ghayur, Khalid, Zaheer, Choudhary and Rahman, 2005). Similarly, 
juliflorine from Prosopis juliflora and withanolides from Withania somnifera were also found to 
possess this unique combination of activities (Choudhary, Nawaz, Azim, Ghayur, Lodhi, Jalil, 
Khalid, Ahmed, Rode and Gilani, 2005; Choudhary, Nawaz, Lodhi, Ghayur, Jalil, Riaz, Yousuf, 




stoechas, ginger and Carum copticum which have been used traditionally for lowering of blood 
pressure were found to mediate this effect through a combination of Ca2+ channel blockers and 
ACh-like activities (Gilani, 2001; Ghayur and Gilani, 2005).  
Although conventional drugs for treatment of cardiovascular disorders are effective, they have 
limitations as their use is associated with various side effects. These side effects include asthma 
symptoms, cold hands and feet, depression, erection problems, insomnia and sleep problems. ACE 
inhibitors may cause a persistent dry, hacking cough, skin rash and a loss of taste (Yeolekar and 
Kelkar, 2005). Diuretics side effects include excessive urination, weakness, leg cramps and fatigue 
(Maquirriain and Merello, 2007). In addition to these side effects, these medications are expensive 
and not easily accessible, especially to the communities from poor socio-economic background. 
Therefore, there has been an increased interest in the use of medicinal plant products for treatment 
of cardiovascular disorders because they are cheap and readily available.  
 
 
1.6   Traditional (indigenous/folk) medicine 
 
Reports indicate that 80% of the world’s population uses herbal medicine for primary health care 
especially in developing countries. Approximately 12-15 million South Africans still use 
traditional remedies from as many as 700 indigenous plant species (Meyer and Afolayan, 1995; 
Grierson and Afolayan, 1999). Plant products also play an important role in health care systems of 
the remaining 20% of the population, mainly residing in developed countries. Analysis of the data 
on prescriptions dispensed from community pharmacies from 1959 to 1980, indicated that 25% of 
these prescriptions contained plant extracts or active principles derived from higher plants 
(Farnsworth and Soejarto, 1985). 
 
Herbal drugs are at the basis of traditional medicines. Traditional plants have been used for 
hundreds of years because of their affordability, efficacy, accessibility and assumed lesser side 
effects (Kamboj, 2000; Ozsoy-Sacan, Karabulut-Bulan, Bolkent, Yanardag and Ozgey, 2004; Gao, 
Li, Li, Liu, Fan, Liu, Zhao, Li and Han, 2009). Increased side effects of synthetic products, lack 




drugs for new emerging diseases are some of the reasons for renewed public interest in alternative 
medicines (Patwardhan, Warude, Pushpangadan and Bhatt, 2005). Reports indicate that medicinal 
plants possess bioactive compounds which are responsible for many therapeutic effects (Shinawie, 
Singh and Padmavathi, 2000) and there are a number of conventional drugs that originate from 
plants such as aspirin (from willow bark), digoxin (from foxglove), quinine (from cinchona bark), 
and morphine (from the opium poppy) (Shinawie, 2002). Table 2 below summarises medicinal 
plant extracts that have been shown to possess beneficial anti-hypertensive properties in human 










































Eucommia ulmoides Leaves, bark aqueous  Vasorelaxation (Kwan, Chen, Deyama and 
Nishibe, 2003; Luo, Wu, 
Zhou, Yan, Yang and 
Ouyang, 2010). 
Hibiscus sabdariffa dried calyces aqueous  ACE inhibition (Ojeda, Jiménez-Ferrer, 
Zamilpa, Herrera-Arellano, 
Tortoriello and Alvarez, 
2010). 
Vaccinium myrtillus bilberry anthocyanins ACE inhibitory (Persson, Persson and 
Andersson, 2009). 
Vitis thunbergii root, leaves (+)-vitisin A anti-ACE and vasodilation (Lin, Lu, Wang, Chen, Wen 
and Hou, 2012). 
Theobroma cacao fruits polyphenols, flavanol Increase NO bioavailability (Corti, Flammer, Hollenberg 
and Lüscher, 2009). 
Nigella sativa seeds aqueous  Reduce total and low-density-
lipoprotein (LDL)-cholesterol 
(Dehkordi and Kamkhah, 
2008). 
Urtica dioica aerial parts aqueous  diuresis and natriuresis (Tahri, Yamani, Legssyer, 
Aziz, Mekhfi, Bnouham and 
Ziyyat, 2000). 
Phyllanthus debilis dried leaves methanol and phenolic 
compounds 
Antioxidant activity which 
improve NO production 




stem-bark aqueous, methanol, 
ethanol 
diuresis and natriuresis (Agunu, Abdurahman, 
Andrew and Muhammed, 
2005). 
Ekebergia capensis leaves ethanol NO-dependent vasorelaxant 
activity 
(Kamadyaapa, Gondwe, 





1.6.1   Syzygium aromaticum 
 
The plant bioactive compound of interest in this study is a pentacyclic triterpenoid isolated from 
Syzygium aromaticum (Hochst.) [Myrtaceae].  S. aromaticum belongs to Myrtaceae family and is 
referred to as a clove tree (Figure 1). S. aromaticum is an evergreen tree that grows to a height of 
15 to 30 metres tall and is native in North Moluccas (Indonesia), but is also grown in India, 
Jamaica, Brazil, and other tropical areas (Agbaje, Adeneye and Daramola, 2009). This plant has 
opposite, ovate leaves which are more than 12.7 centimetres long. When fully grown, the flowers 
are red and white, bell-shaped and grow in terminal clusters. The brown, dried, unopened flower 
buds are called cloves. The dried flower bud is familiarly used in the kitchen and the fruit is a one- 
or two-seeded berry (Agbaje, Adeneye and Daramola, 2009).  
 
The leaves are glabrous, with numerous oil glands on lower surface. S. aromaticum contains 
bioactive chemical compounds such as glycosides, tannins, polyphenols, triterpenes and saponins. 
Triterpene is a precursor of steroids in plants consisting of six isoprene units with a molecular 
formula C30H48. Triterpenes can be classified into lupane, oleanane or ursane groups (Laszczyk, 
2009). Of particular interest in this study is an oleanane triterpene, OA. Syzygium spp-derived OA 
has been shown to possess hypoglycaemic, hypotensive, reno- and cardioprotective effects in 
experimental animals (Musabayane, Mahlalela, Shode and Ojewole, 2005; Mapanga, Tufts, Shode 









Figure 1: Syzygium aromaticum (Hochst.) [Myrtaceae] flower buds are harvested when they are 
bright green, 1 - 2 cm in length and when the flower is still unopened. Marketed clove is dark 
brown in colour and sold as whole or ground clove and OA is isolated from these dried flower 
buds (Attokaran, 2011). 
 
1.6.1.1  Triterpene OA and synthetic oleanane derivatives 
 
OA is the major constituent of many African plant species used in traditional medicine but is 
mostly abundant in plants that belong to Oleaceae family such as Olea europaea (Pollier and 
Goossens, 2012). This compound which exists in plants in the form of a free acid has been isolated 
from more than 1620 plant species  (Fai and Tao, 2009; Fukushima, Seki, Ohyama, Ono, 
Umemoto, Mizutani, Saito and Muranaka, 2011). Plants synthesize OA from the sterol precursor, 




importance due to diverse pharmacological properties and lower systemic toxicities which have 
led to the use of this triterpene as a starter molecule for the synthesis of new derivatives (Liu, 2005; 
Braga, Ayres-Saraiva, Gattass and Capella, 2007; Patil, Jadhav, Singh, Mundada and Patil, 2010; 
Sporn, Liby, Yore, Fu, Lopchuk and Gribble, 2011). OA derivatives are generated by chemical 
modifications of this triterpene in the active sites of the structure, the C-3 hydroxy, the C-12-C-13 
double bond, and the C-28 carboxylic acid (Honda, Finlay, Gribble, Suh and Sporn, 1997; Honda, 
Rounds, Gribble, Suh, Wang and Sporn, 1998; Honda, Rounds, Bore, Favaloro Jr, Gribble, Suh, 
Wang and Sporn, 1999; Honda, Rounds, Bore, Finlay, Favaloro, Suh, Wang, Sporn and Gribble, 
2000; Honda, Honda, Favaloro Jr., Gribble, Suh, Place, Rendi and Sporn, 2002; Sporn, Liby, Yore, 
Fu, Lopchuk and Gribble, 2011). 
 
The most potent OA derivatives that have been synthesised are 2- cyano-3,12-dioxooleana-
1,9(11)-dien-28-oic acid (CDDO) and C-28 methyl ester, CDDO-Me. In comparison to OA, these 
new synthetic compounds have improved biological activities attributed to the presence of enone 
functions in their A- and C-rings and nitrile group in C-2 in the A-ring (Couch, Browning, Honda, 
Gribble, Wright, Sporn and Anderson, 2005; Dinkova-Kostova, Liby, Stephenson, Holtzclaw, 
Gao, Suh, Williams, Risingsong, Honda, Gribble, Sporn and Talalay, 2005; Yates, Tauchi, 
Katsuoka, Flanders, Liby, Honda, Gribble, Johnson, Johnson, Burton, Guilarte, Yamamoto, Sporn 
and Kensler, 2007). Examples of improved biological activities of OA derivatives include anti-
inflammatory and antioxidant properties mediated by inhibition of iNOS and Keap1 protein, 
respectively (Reisman, Buckley, Tanaka and Klaassen, 2009; Shin, Wakabayashi, Yates, 
Wakabayashi, Dolan, Aja, Liby, Sporn, Yamamoto and Kensler, 2009).  
 
1.6.1.2  Basis of this study 
This section will briefly state the various pharmacological effects of OA which are of interest in 
this study. These include cardiovascular, vasodilatory, renal and antioxidant effects. OA has been 
shown to have hypotensive effects in healthy Sprague Dawley rats and streptozotocin (STZ)-
induced diabetic rats. This effect was associated with beneficial effects on some processes 




Musabayane, 2009; Madlala, Masola, Singh and Musabayane, 2012). Particularly, OA corrected 
the previously reported Na+ retention and reduction in GFR in STZ-induced diabetic and DSS rats 
(Somova, Nadar, Rammanan and Shode, 2003; Mapanga, Tufts, Shode and Musabayane, 2009). 
Somova observed a diuretic effect of OA, whereas Mapanga and Madlala reported no change in 
urine flow rate. This study used experimental models of hypertension to investigate the 
mechanisms of antihypertensive effects of OA, we hypothesize that natriuretic effects of OA 
reported by these authors may alleviate blood pressure progression in SHR and DSS rats.   
 
In a study by Somova, OA alleviated high blood pressure levels, increased heart rate and 
modulated blood antioxidant status based on GPx and SOD activities in DSS rats (Somova, Shode, 
Ramnanan and Nadar, 2003). Therefore, we also explored antioxidant properties of this triterpene 
as the possible mechanism for antihypertensive effects, however, we assessed the antioxidant 
status in the liver, kidney and heart tissues. In addition, we evaluated the effects of this triterpene 
on isolated cardiomyocyte contractility and L-type Ca2+ channels.  
 
Rodriguez-Rodriguez reported another OA effects which may influence blood pressure levels, i.e 
olive oil OA-evoked decreased smooth muscle cell relaxation mediated by endothelium-dependent 
release of NO and not COX-mediated pathways (Rodríguez-Rodríguez, Herrera, Perona and Ruiz-
Gutiérrez, 2004). However, another study suggested that OA modulate Cox-2-dependent release 
of prostacylin (PGI2) mediated by phosphorylation of p38 mitogen-activated protein kinases 
(MAPK), a key transcription factor involved in Cox-2 transcriptional upregulation (Martínez-
González, Rodríguez-Rodríguez, González-Díez, Rodríguez, Herrera, Ruiz-Gutierrez and 
Badimon, 2008). These conflicting finding influence our interest in studying OA effects on both 
NO-dependent and independent pathways. In addition, our study tested whether two new synthetic 
derivatives of OA display similar cardiovascular, renal, antioxidant and vasorelaxant effects to 








1.7   Aims of the study  
 
The general aim of this study was to investigate the mechanisms of cardiovascular effects of OA 
and related triterpene derivatives in hypertensive animals by assessing the effects of OA and 






























MATERIALS AND METHODS 
This chapter describes experimental protocols used to investigate the following studies:  
A)  phytochemical studies 
1. extraction of OA, 
2. synthesis of oleanane derivatives. 
 
B)  whole animal experiments, acute and sub-chronic effects of OA/oleanane derivatives on: 
1. blood pressure measurements, 
2. fluid and electrolyte handling, 
3. renal clearance assessment. 
 
C)  ex vivo  effects of OA and oleanane derivatives 
1. oxidative stress evaluation, 
2. cardiomyocyte shortening, 
3. Ca2+ current measurements, 




2.0 Drugs and chemicals 
 
Drugs and chemicals used in this study are listed below and were sourced as indicated:  
dimethyl sulphoxide (DMSO), inactin (5-ethyl-5-(l'-methylpropyl)-2-thiobarbiturate), sodium 
bicarbonate (NaHCO3), sodium hydroxide (NaOH), sodium thiosulphate (Na₂S₂O₃), diethyl ether 
(Et2O); tetrahydrofuran (THF), acetic acid (AcOH), bromine (Br2), hydrogen bromide (HBr), 
potassium hydroxide (KOH), potassium bromate (KBrO3),  methylammonium chloride (CH3CIN), 
sulphuric acid (H2SO4), urea, 2-iodobenzoic acid, Li
+ chloride (LiCl) and m-chloroperoxybenzoic 




carbachol, phenylephrine (PHE), L-nitro-arginine (L-NoArg), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) and protease (Sigma-Aldrich, St. Louis, Missouri, USA); 
 
silica gel, anhydrous sodium sulphate (Na2SO4), ethyl acetate (EA), dichloromethane (DCM), 
methanol (CH3OH), chloroform (CHCl3) and Folin-Ciocalteu reagent (Merck, Modderfontein, 
South Africa);  
 
isofor (Safeline Pharmaceuticals (PTY) LTD, Weltevreden Park, Rooderpoort, South Africa); 
 
creatinine (BDH Biochemicals LTD, Poole, England); 
 
bovine serum albumin (BSA) (Thermo Scientific, Randburg, Johannesburg);  
 
collagenase A  (Roche Diagnostics, Mannheim, Germany);  
 
pentobarbital (Nembutal, Abbott Laboratories, North Chicago, USA);  
 
SOD and GPx Assay Kits (BioVision Research Products, Mountain View, California, USA);  
 
arg8-vasopressin ELISA Kit (Abcam, Cambridge, Massachusetts, USA);  
 
aldosterone ELISA Kit (DRG International Inc, New Jersey, USA). 
 











2.1   Phytochemical studies  
 
2.1.1   Extraction of oleanolic acid (compound 1) 
 
The dried flower buds of Syzygium aromaticum [(Linnaeus) Merrill and Perry] (Myrtaceae) were 
purchased from the spice market in Durban, South Africa and were authenticated by Professor H. 
Baijnath, the former Chief Taxonomist/Curator of the University of KwaZulu-Natal’s Department 
of Botany. The extraction of OA was performed in the School of Chemistry and Physics at the 
University of KwaZulu-Natal, Pietermaritzburg campus using a previously validated standard 
protocol that has been reported by our laboratories (Mapanga, Tufts, Shode and Musabayane, 
2009; Musabayane, Tufts and Mapanga, 2010; Madlala, Masola, Singh and Musabayane, 2012). 
Briefly, air-dried flower buds of S. aromaticum (500 g) were milled using an industrial blender 
and exhaustively extracted sequentially with dichloromethane (DCM) and ethyl acetate (EA) 
(twice with 1 L for 24 h for each solvent) at room temperature. The plant material was removed 
by filtration and the resultant filtrates were concentrated in vacuo at 60 ± 1 °C using a Büchi rotary 
evaporator (Buchi Labortechnik AG, Flawil, Switzerland) to obtain DCM soluble (63 g) and ethyl 
acetate soluble (EAS, 85 g) crude extracts. Crude EAS were subjected to further purification since 
previous studies indicated that they contain mixtures of OA/ursolic acid (UA) and methyl 
maslinate/methyl corosolate (Somova, Nadar, Rammanan and Shode, 2003; Musabayane, 
Mahlalela, Shode and Ojewole, 2005). Column chromatography with silica gel was used for 
fractionation of a portion of EAS (10 g) using a step-wise gradient of hexanes-EA, increasing the 
ratio from 9:1 to 7:3.  
 
Fractions collected were monitored and analysed by thin layer chromatography (TLC) on pre-
coated aluminium plates which were developed with EA/hexanes (8:2) in a TLC tank. Compounds 
were detected under UV (254 nm) followed by staining the plates with p-anisaldehyde. Analysed 
data collected from the fractions was compared with authentic OA values. Eluates with similar 
TLC profiles to OA were combined and subjected to further chromatographic purification. The 
yield of OA was 2.5 – 3.0 g per 10 g (30%) EAS extraction with m.p. 298 – 300 °C (Lit value: 295 
– 298 °C) (Habila, Shode, Ndukwe, Amupitan and Nok, 2012). Pure OA was obtained by 




resonance (NMR) and infrared spectra (IR) recorded on a Bruker DRX-400 and Bruker Alpha FT-
IR spectrometer (Figure 2). OA had the same physical properties as the OA purchased from Sigma-
Aldrich (St. Louis, Missouri, USA) and hence isolated OA was used as a parent compound for the 







Figure 2: The structure of S. aromaticum-derived OA showing the carbon-carbon olefinic double 
bond which is characteristic of the triterpenoids. 
 
2.1.2   Reagents for synthesis of oleanane derivatives 
 
2.1.2.1  Nitrosomethylurea (Diazomethane precursor)  
 
Methylammonium chloride (50.64 g, 0.75 mol) was added into a 500 mL beaker followed by 
addition of deionised water (200 mL) and urea (150 g, 2.5 mol). The solution was refluxed gently 
for 2.75 h and vigorously for further 15 minutes. After cooling the solution to room temperature, 
55 g (0.75 mol) of sodium nitrite was dissolved in this mixture and temperature was further 
dropped to 0 °C. In a 1 L beaker with 300 g of ice, 0.5 M sulphuric acid (27.2 mL) was added. The 
beaker was placed in ice to maintain the temperature at 0 °C. The cold methylurea-nitrite solution 
was then poured into a dropping funnel and added slowly into the ice-sulphuric acid mixture while 
stirring. Nitrosomethylurea ascended to the surface of the reaction mixture as a foamy precipitate 
which was filtered and washed with water under suction. The material obtained was then dried in 





2.1.2.2              Iodoxybenzoic acid (IBX) for oxidation 
 
To a vigorously stirring solution of 2-iodobenzoic acid (1.129 g, 0.0345 mmol) and sulphuric acid 
(20 mL, 2 M) at 50 °C, was added potassium bromate (1 g, 4.55 mmol). The temperature was then 
increased to 65 °C and the reaction mixture was stirred for further 6 h (Dess and Martin, 1991). 
The material (IBX powder; 1.01 g, 89%) obtained was filtered and dried in a vacuum oven and 
stored at room temperature. 
 
2.1.3   Synthesis of oleanane derivatives  
 
We are grateful to Fu and Gribble (2013) for having used their method below for the preparation 
of oleanane derivatives. 
 
2.1.3.1  Methylation (compound 2) 
 
Diethyl ether (40 mL, 0.54 mmol) was added into 100 mL conical flask and placed in an ice bath. 
A 40 % (m/v) aqueous solution of KOH (7.5 mL, 0.21 mol) was added while stirring. This was 
followed by addition of 2 g (0.02 mol) of nitrosomethylurea in small portions while temperature 
was maintained at 0 °C. When nitrosomethylurea was completely dissolved, the yellow ethereal 
layer was transferred into a conical flask with KOH pellets to remove residual water. OA (Figure 
3, compound 1) (500 mg, 1.09 mmol) was dissolved in 5 mL tetrahydrofuran (THF) and the 
solution was cooled to 0 °C in ice. The yellow ethereal layer of diazomethane was poured into the 
THF solution of OA and the mixture was stirred for 4 h. The mixture was left in the fume hood 
overnight and compound 2 (Me-OA, Figure 3) was obtained as a whitish powder (325 mg, 65%) 
with m.p.  124 – 126 °C.  
 
 
2.1.3.2  Bromination (compound 3) 
 
Compound 2 (1.20 g, 2.55 mmol) was oxidised with IBX (2.86 g, 10.2 mmol) in dimethyl 
sulphoxide (35 mL). This was followed by epoxidation of the oxidised product using m-




drop wise to a stirred solution of epoxidised compound (200 mg) in acetic acid (10 mL) at room 
temperature. The reaction mixture was then heated to 35 °C followed by drop wise addition of 
bromine (0.12 mL, 1.04 mmol). The resulting reaction mixture was kept stirring for another 24 h. 
Upon completion of the reaction, the acid was removed in vacuo. The resulting residue was 
quenched with 20% aqueous Na2S2O3 (20 mL) and extracted with dichloromethane (3 x 30 mL). 
The combined organic extracts were washed with saturated NaHCO3 (2 x 20 mL), NaCl (2 x 20 
mL), dried over anhydrous Na2SO4 and concentrated in vacuo. An analytically pure sample was 
obtained by column chromatography (hexanes-EA, 4:1 to 2:1) to give compound 3 (Br-OA, Figure 
3) (150 mg, 37%) as a yellowish solid with m.p. 137 – 140 °C. All structures of synthetic products 
were confirmed by 1H, 13C NMR and infrared spectra recorded on a Bruker DRX-400 and Bruker 
Alpha FT-IR spectrometer, respectively, and therefore were used for animal studies. 
 
 
 Figure 3: Reaction scheme for the synthesis of OA derivatives as previously described (Fu and 










2.2   Whole animal experiments 
 
2.2.1.   Animals 
 
Male Wistar rats (250 - 300 g) and weaning SHR and DSS rats (100 - 150 g) bred and housed in 
the Biomedical Resource Unit (BRU) of the University of KwaZulu - Natal were used for arterial 
pressure and renal function studies. SHR and DSS rats were selected for this study because these 
rat models develop hypertension as they age due to genetics or high salt diet, respectively. The 
animals were maintained under standard laboratory conditions of constant temperature (22 ± 2 °C, 
CO2 < 5000 p.p.m), relative humidity (55 ± 5%), illumination (12 h light/dark cycles) and noise 
levels (< 65 decibels). The animals had free access to water and standard rat chow (Meadow Feeds, 
Pietermaritzburg, South Africa).  
 
For cardiac and vascular studies, male Wistar and DSS rats (250 - 300 g) purchased from Charles 
River Laboratories, Inc. (Wilmington, MA, USA) and housed in the Animalia of the Catholic 
University of Leuven were used. The DSS rats were fed high salt Na+ diet (8%) (Bio Services, 
Berlin, Germany) from the age of 4 to 10 weeks. The animals were maintained under standard 
laboratory conditions as above and had free access to water and rat chow (Bio Services, Berlin, 
Germany). 
 
2.3   Ethical approval 
 
All experimental protocols were reviewed and approved by the animal ethics committee of the 
University of KwaZulu-Natal (077/12/Animal; 028/13/Animal) and of the Catholic University of 
Leuven (4500768204); see Appendices I, II and III. 
 
2.4   Experimental design 
 
Normotensive Wistar, DSS and SHR rats were divided into separate groups to study the following: 
1) acute (4 h) effects of OA and oleanane derivatives MAP and renal function of Wistar rats under 
anaesthesia. 2) Sub-chronic (9 weeks) effects of OA on MAP and kidney function in conscious 




and oleanane derivatives on cardiomyocyte contractility and Ca2+ currents as well as effects on 
contraction / relaxation profiles of isolated thoracic aortic and mesenteric rings. 
 
2.5   Renal and arterial pressure studies  
 
2.5.1   Acute studies 
 
The rats were prepared for acute mean arterial blood pressure and renal function measurements 
using a protocol previously reported from our laboratories (Musabayane, Gondwe, Kamadyaapa, 
Chuturgoon and Ojewole, 2007). Briefly, the rats were anaesthetised by intra-peritoneal injection 
of 0.11 g kg-1 inactin [5-ethyl-5- (10-methylpropyl)-2 thiobarbiturate] (Sigma Aldrich, St. Louis, 
MO, USA) and tracheotomy was performed. A catheter was implanted in the left carotid artery for 
withdrawal of blood samples and continuous recording of arterial blood pressure at 30 min 
intervals via a pressure transducer (Statham MLT 0380, Ad Instruments, Bella Vista, NSW, 
Australia), compatible with PowerLab System ML410/W (Bella Vista, NSW, Australia).  
 
Another catheter was inserted in the right jugular vein for continuous intravenous infusion 
(Harvard Syringe Infusion Pump 22, Harvard Apparatus, Holliston, MA, USA) of saline (0.077 M 
NaCl) with 1 % DMSO containing creatinine (0.15 mg mL-1) at 9 mL h-1 to allow calculation of 
creatinine clearance as a measure of GFR. A minimal abdominal incision was made and a urinary 
bladder catheter was inserted for the collection of urine samples. After a 3.5 h equilibration period, 
blood pressure recordings and urine samples were taken every 30 min and blood samples (200 µL) 
were drawn hourly for measurements of electrolytes (methodology described in section 2.5.1.1 
below) over a 4 h experiment divided into 1 h control, 1.5 h treatment and 1.5 h recovery periods. 
In those animals in which the effects of OA or derivatives were examined, the infusate was 
changed during the 1.5 h treatment period to the one identical in ionic composition, but containing 
OA, Me-OA and Br-OA (90 µg h-1). The dosage for OA was based on previous studies (Mapanga, 
Tufts, Shode and Musabayane, 2009) and the same dosage for the derivatives was used for fair 





The effects of OA, Me-OA and Br-OA on proximal tubular Na+ handling was assessed in 
anaesthetised Wistar rats through measurement of Li+ clearance (CLi) (Thomsen, 1990). Male 
Wistar rats were fed standard rodent chow supplemented with Li+ chloride (12 mmol kg-1 dry 
weight) for 48-hours (h) prior to experimentation in order to raise plasma Li+ to measurable 
concentrations without affecting renal Na+ or water excretion. 
  
2.5.1.1  Urinalysis 
 
Urine volume was determined gravimetrically using a balance (Mettler balance PC 180-
instruments, Protea Laboratory Services, Johannesburg, South Africa). Quantitative measurements 
of total urinary outputs and plasma concentrations of Na+, K+, Cl-, urea and creatinine were 
performed using Beckman Coulter (Synchron LX20 Clinical Systems, Fullerton, California, USA) 
with reagent kits from Beckman Coulter (Synchron LX20 Clinical Systems, Dublin, Ireland).  Li+ 
was determined by flame emission spectroscopy at 670.8 nm (Optima 2100 DV, Perkin Elmer, 
Shelton, CT) using a modified procedure that has been previously described (Madlala, Masola, 
Singh and Musabayane, 2012). Fractional excretion rates of Na+ (FENa) and Li
+ (FELi) were 
determined simultaneously. 
 
Li+ clearance (CLi) was used as a marker for the output of Na
+ from the proximal tubules (Thomsen, 
1990). Renal clearances (C) and fractional excretions (FE) were calculated with the standard 
formulae C = U x V/P and FE = C/GFR, where U is the urinary concentration, V is the urine flow 
rate and P is the plasma concentration. GFR, as assessed by creatinine clearance was calculated at 
1 h intervals in anaesthetised rats and in the 9th week in conscious animals using the standard 
formulae from measurements of the plasma and urinary concentrations of creatinine and urine flow 
rate. 
 
2.5.2   Sub-chronic studies  
 
Separate groups (n = 6 in each) of male Wistar, SHR and DSS rats housed individually in Makrolon 
polycarbonate metabolic cages (Techniplast, Labotec, South Africa) were treated with various 




The dose of 60 mg kg-1 was determined from previous studies, for the purpose of evaluating 
whether OA effects are dose dependent, we investigated the lower and higher doses also based on 
previous studies (Mapanga, Tufts, Shode and Musabayane, 2009; Madlala, Masola, Singh and 
Musabayane, 2012). These experiments were restricted to OA because of the poor yield of 
synthetic derivatives obtained during the phytochemical studies. OA was freshly dissolved in 
dimethyl sulphoxide (DMSO, 2 mL) and 9% saline (19 mL) (Musabayane, Mahlalela, Shode and 
Ojewole, 2005) before use in each case. Rats given DMSO/saline (3 mL kg-1, p.o.) acted as 
untreated controls. The rats were given both food and water ad libitum.  
 
Urine volume and urinary concentrations of creatinine, urea, Na+, K+ and Cl- were determined daily 
(Beckman Coulter, Synchron LX20 Clinical Systems, Fullerton, Carlifornia, USA), similar 
methodology for acute measurements as described in 2.5.1.1 above. Mean arterial blood pressure 
(MAP) was monitored every third consecutive day using non-invasive tail cuff method with 
photoelectric sensors (IITC Model 31 Computerised Blood Pressure Monitor, Life Sciences, 
Woodland Hills, California, USA) as previously described (Gondwe, Kamadyaapa, Tufts, 
Chuturgoon and Musabayane, 2008; Kamadyaapa, Gondwe, Moodley, Ojewole and Musabayane, 
2009). The equipment was calibrated each day prior to measurements. The animals were kept 
warm at ± 30 °C in an enclosed chamber (IITC Model 303sc Animal Test Chamber, IITC Life 
Sciences, Woodland Hills, California, USA) for 30 minutes before blood pressure recording. All 
measurements were conducted at 09h00. Blood samples were collected by cardiac puncture into 
individual pre-cooled heparinized containers at the end of the 9 week experimental period for 
biochemical and hormone analysis. GFR, as assessed by creatinine clearance (CCr) was calculated 
using the standard formulae from measurements of the plasma and urinary concentrations of 








2.6   Analysis of plasma aldosterone and AVP secretion 
 
2.6.1   Aldosterone assay 
 
2.6.1.1  Principle 
 
Plasma aldosterone concentrations were measured from plasma samples of Wistar and 
hypertensive groups of non-treated and treated animals using an ELISA Kit (DRG International 
Inc, New Jersey, USA). The kit components included a 96 microtiter well plate, standards, 
controls, enzyme conjugate (aldosterone-alkaline phosphatase), substrate, stop and wash solutions. 
Standards and samples are added to wells coated with polyclonal rabbit antibody. Aldosterone in 
the sample competes with an aldosterone-horseradish peroxidase conjugate for binding to the 
coated antibody which is directed towards an antigenic site of the aldosterone molecule. After 
incubation at room temperature, addition of the substrate solution allows the intensity of colour 




2.6.1.2   Procedure 
 
Standards (0, 20, 80, 200, 500, 1000 pg mL-1), controls and samples (50 μL of each) were dispensed 
together into appropriate wells. An enzyme conjugate (150 μL) was added into each well followed 
by thorough mixing for 10 seconds. The mixture was left at room temperature for 1 hour. The 
contents of the wells were vigorously shaken out. The wells were rinsed with 300 μL diluted wash 
solution per well (5 times). Residual droplets were removed by sharply striking the plate on 
absorbent paper. Substrate solution (200 μL) was added into each well and the plate was left at 
room temperature for 1 hour. The enzymatic reaction was stopped by adding 100 μL of stop 
solution to each well. The absorbance (OD) was determined at 405 ± 10 nm using a Spectrostar 
nano microtiter plate reader (BMG Labtech GmbH, Ortenberg, Germany). A standard curve was 
constructed from the absorbance values of the known concentrations of the standards using the 
spline regression curve in Graph Pad Instat software (version 5.00). The respective aldosterone 





2.6.2   Arginine vasopressin (AVP) assay 
 
2.6.2.1  Principle  
 
Plasma AVP concentrations were measured from blood samples collected from non-treated and 
treated groups of hypertensive rats using an Arg8-Vasopressin ELISA Kit (Abcam, Cambridge, 
Massachusetts, USA) after 9 weeks of OA treatment. The kit components included a 96 well plate 
coated with goat anti-rabbit antibodies, vasopressin-alkaline phosphatase conjugate, rabbit anti-
vasopressin antibody, assay buffer, wash buffer concentrate, vasopressin standards, p-nitrophenyl 
phosphatesubstrate (pNpp) and a stop solution. The Arg8-Vasopressin ELISA Kit is a competitive 
immunoassay for the quantitative determination of vasopressin in samples. The assay uses a rabbit 
anti-vasopressin antibody to bind covalently in a competitive manner with non-covalent forces in 
unknown samples. During the incubation period AVP in the sample reacts with rabbit anti-
vasopressin antibodies bound to the microtitration well. The washing step removes enzyme-
labelled vasopressin, leaving the bound conjugate which reacts with pNpp. This reaction is stopped 
by adding acid 2 N hydrochloric acid (HCl) to give a colourimetric endpoint that is read 
spectrophotometrically on a microplate reader (BMG Labtech GmbH, Ortenberg, Germany) at 405 
nm. 
 
2.6.2.2  Procedure  
 
A volume of 100 µL of vasopressin standards (4, 10, 23, 59, 148, 369 and 923 pmol L-1) was added 
into anti-vasopressin wells. Samples and non-specific binding solution (100 µL) were then added 
to the remaining wells followed by 50 µL vasopressin conjugate into all standard and sample wells. 
Assay diluent was used as the blank. Each determination was performed in duplicate for both 
standards and the test samples. The plates were incubated at 4 ºC for 24 hours. Following 
incubation, the reaction mixture was discarded. 400 µL of wash buffer was added to all wells and 
aspirated, the process was repeated 3 times. After the final wash, the plates were inverted firmly 
against absorbent paper to remove all the liquid. Two hundred (200) µL of substrate pNpp were 
added to all wells and incubated at 37 ºC for 1 h. The reaction was stopped by adding 50 μL of 
stop solution to all wells and mixing on the shaker for 5 minutes. The absorbance was read at 405 




standard curve was constructed from the absorbance values of the known concentrations of the 
standards using the spline regression curve in Graph Pad Instat software (version 5.00). The 
respective AVP concentrations of the unknown samples were then extrapolated from the standard 
curve. The lower and upper limits of detection were 4 pmol L-1 - 923 pmol L-1, respectively. The 
intra-assay analytical coefficient of variation ranged from 5.9 to 10.6% and the inter-assay 
coefficient variation from 6.0 to 8.5%. 
 
2.7   Tissue sample harvesting  
 
At the end of a 9-week experimental period, all animals were sacrificed by exposing them to isofor 
(100 mg kg-1, for 3 min) using a gas anaesthetic chamber. Livers, hearts and kidneys were removed, 
snap frozen in liquid nitrogen and stored in a BioUltra freezer (Snijers Scientific, Tilburg, 
Netherlands) at -70 °C for subsequent biochemical analysis. All organs were analyzed for protein 
content in addition to other biochemical parameters. The protein content was quantified using the 
Lowry method (Lowry, Rosebrough, Farr and Randall, 1951). The Lowry method is best used with 
protein concentrations of 0.01–1.0 mg mL-1 and therefore all the samples were standardized to one 
concentration (1.0 mg mL-1). The Lowry method is based on the principle that total protein 
concentration is demonstrated by a colour change of the sample solution in proportion to protein 
concentration detected using colourimetric techniques. The method combines the reactions of 
copper ions with the peptide bonds under alkaline conditions with the oxidation of aromatic protein 
residues such as tryptophan and tyrosine. The reaction involves the reduction of the Folin–
Ciocalteu reagent. The concentration of the reduced Folin- Ciocalteu reagent is measured by 
absorbance at 750 nm, hence the total concentration of protein in the sample can be deduced from 
the concentration of tryptophan and tyrosine residues that reduce the Folin–Ciocalteu reagent 
(Everette, Bryant, Green, Abbey, Wangila and Walker, 2010). 
 
We also used the Lowry method to quantify protein content in all tissues that were analyzed for 
oxidative stress markers using 2 mg mL-1 BSA as standard (0-1 mg mL-1). Kidney, heart and liver 
samples (0.5 g) were homogenized in 0.1 M Tris-HCl buffer, pH 7.4 (1 mL).  The homogenate 




mL). The alkaline reagent consisted of 100 volumes of 4% sodium carbonate, 1 volume of 4% 
copper sulphate and 4% of sodium potassium tartrate. The mixture was incubated for 15 min at 
40 ̊ C and Folin Ciocalteu reagent (0.5 mL, diluted with 0.5 mL deionised water) was added. The 
samples were left at room temperature for 30 min and then absorbances were read at 600 nm. A 
BSA standard curve was plotted as a linear fit function of protein concentration. The protein 
concentration of each sample was calculated by relating its absorbance to the standard curve. 
 
2.7.1   Oxidative stress evaluation 
 
To establish the effects of OA on oxidative stress in the liver, heart and kidney of SHR and DSS 
rats, we monitored levels of MDA, a commonly known marker of oxidative stress and of 
antioxidant defence enzymes SOD and GPx of Wistar and OA-treated hypertensive rats and 
compared with respective untreated rats and normotensive Wistar animals. For these 
measurements, the samples were analysed in duplicates. 
 
2.7.1.1  Malonyldialdehyde (MDA) 
 
MDA levels in the tissue homogenates of the heart, kidney and liver from Wistar, DSS  and SHR 
rats were estimated using thiobarbituric acid (TBA) by a previously described method (Kasapoglu 
and Özben, 2001; Mkhwanazi, Serumula, Myburg, Van Heerden and Musabayane, 2014). Tissues 
(50 mg) were homogenised in 500 µL of 0.2% phosphoric acid. The acid reacts with MDA to form 
a stable pink colour with maximum absorption at 532 nm. The heart, kidney and liver tissues (50 
mg) from Wistar control, untreated and OA-treated DSS rats were homogenized in 500 µL of 0.2% 
phosphoric acid. The homogenate was centrifuged at 14,000 x g at 4 °C for 10 minutes. Thereafter, 
400 L of the homogenate were supplemented with 400 L of 2% phosphoric acid followed by 
addition of 400 µL TBA/butylated hydroxytoluene (BHT) dissolved in 400 µL of 3 mM 
hydrochloric acid (HCl), and additional 200 µL of 1 M HCl added to ensure a 1.5 acidic pH. The 
solution was heated in a water bath at 100 °C for 15 min to properly dissolve TBA. After cooling, 
butanol (1.5 mL) was added and the precipitate was removed by centrifugation. Sample absorbance 
was then determined at 532 nm against a blank that contained all reagents except the homogenate 




MDA using Beer’s law. The homogenized tissue concentration of MDA was calculated using the 
equation below and expressed as units per gram protein. 
 
[𝑀𝐷𝐴] (𝑛𝑚𝑜𝑙 𝑔−1) =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒




2.7.1.2  Superoxide dismutase (SOD) 
 
Tissue SOD levels from homogenates of Wistar, SHR and DSS rat heart, kidney and liver were 
measured using a commercially available Biovision SOD Assay Kit (BioVision Research 
Products, Mountain View, California, USA). Xanthine and hypoxanthine oxidase were used to 
generate superoxide radicals, which react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-
phenyltetrazolium chloride (INT) to form a red formazan dye. SOD activity was then measured by 
the degree of inhibition of this reaction. Rat heart, kidney and liver tissues (50 mg) were 
homogenized in ice cold 0.1 M Tris /HCl (pH 7.4) containing 0.5% Triton X-100, 5 mM β-
mercaptoethanol (ME) and 0.1 mg mL-1 phenylmethane-sulphonylfluoride (PMSF). The tissue 
homogenate was centrifuged at 14,000 x g, 4 °C for 5 minutes. The supernatant obtained was added 
to each sample (20 µL) and blank 2 (20 µL) well, while blank 1 and blank 3 wells received 20 µL 
of H2O. Thereafter, 200 µL of working solution was added to each well. Dilution buffer (20 µL) 
was then added to each blank 2 and blank 3 well, while each sample and blank 1 well received 
enzyme working solution (20 µL). The solutions were mixed thoroughly with a shaker before 
reading the plate. Inhibition activity of SOD was colourimetrically measured on Anthos Venytch-
200 Spectrophotometer (Biochrom limited, Cambridge, United Kingdom) after a reaction period 
of 20 minutes at 37 °C. SOD activity was calculated as percentage inhibition using the following 
equation:  The homogenized tissue concentration of SOD was calculated using the equation below 
and expressed as units per gram protein. 
 
𝑆𝑂𝐷 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑛𝑚𝑜𝑙 𝑚𝑖𝑛−1 𝑚𝐿−1) =  
(𝐴 𝑏𝑙𝑎𝑛𝑘 1 − 𝐴 𝑏𝑙𝑎𝑛𝑘 3)  −  (𝐴 𝑠𝑎𝑚𝑝𝑙𝑒 1 −  𝐴 𝑏𝑙𝑎𝑛𝑘 2)
(𝐴 𝑏𝑙𝑎𝑛𝑘 1 − 𝐴 𝑏𝑙𝑎𝑛𝑘 3)





2.7.1.3  Glutathione peroxidase (GPx) 
 
Tissue homogenate GPx levels were measured using a commercially available Biovision GPx 
Assay Kit (BioVision Research Products, Mountain View, USA), where GPx catalyzes the 
oxidation of glutathione by cumene hydroperoxide. In the presence of glutathione reductase and 
NADPH, the oxidised glutathione is immediately converted to its reduced form with a concomitant 
oxidation of NADPH to NADP+ (Lei, Cheng and McClung, 2007). The tissues (50 mg) were 
homogenized in cold assay buffer (0.2 mL) placed in ice and centrifuged at 14, 000 x g, 4 °C for 
15 minutes. The resultant supernatant (100 µL) was loaded into a 96-well plate in duplicates. The 
NADPH standard curve was prepared by diluting the 1 mM NADPH standard through a series of 
concentrations (0, 20, 40, 60, 80, 100 nmol per well). The optical density of the standards (OD) 
was measured at 340 nm using Anthos Venytch-200 spectrophotometer (Biochrom limited, 
Cambridge, United Kingdom) and the standard curve was constructed from the values obtained. 
A reaction mix (90 µL) containing assay buffer, NADPH, glutathione reductase and GSH was 
added into each sample well, mixed thoroughly and incubated for 15 minutes at room temperature. 
The OD was measured (340 nm) (T1), cumene hydroperoxide (10 µL) was then added and the 
plate was incubated for 5 minutes in the dark (25 °C). The decrease in absorbance at 340 nm was 
expressed as units per gram protein. OD was measured (340 nm) against (T2) and GPx activity 
was calculated using following equation: 
 
  
𝐺𝑃𝑥 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑛𝑚𝑜𝑙 𝑚𝑖𝑛−1𝑚𝐿−1) =  
(𝐵 −  𝐵0)
(𝑇2 −  𝑇1)  ×  𝑉
 × 𝑠𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
 
 
Where: B - NADPH amount that was decreased between T1 and T2  
            B° - background change without cumene hydroperoxide between T1 and T2 
            T1 - time of first reading 
            T2 - time of second reading 





2.8   Ex vivo effects of OA and oleanane derivatives 
 
2.8.1   Cardiac studies 
 
The ex vivo effects of OA, Me-OA and Br-OA on cell shortening and Ca2+ currents were evaluated 




2.8.1.1  Cell isolation 
 
Cardiac ventricular myocytes isolated from Wistar and DSS rat hearts were used. The methods for 
cell dissociation and electrophysiological measurements were similar to those described in detail 
previously (Mubagwa, Stengl and Flameng, 1997; Macianskiene, Moccia, Sipido, Flameng and 
Mubagwa, 2002; Gwanyanya, Sipido, Vereecke and Mubagwa, 2006; Nevelsteen, Bito, Van der 
Mieren, Vanderper, Van den Bergh, Sipido, Mubagwa and Herijgers, 2013). Briefly, rats were 
injected with heparin (70 - 85 mg kg-1 i.p) and they were sacrificed 10 min later by injection with 
pentobarbital (150 - 300 mg kg-1 i.p). The chest was cut open and the heart was immediately 
removed and placed in a cardioplegic solution containing 27 mM KCl to arrest the contraction 
during cannulation of the aorta.  
 
The heart was then mounted in the perfusion system and was perfused with 1.8 mM Ca2+ Tyrode 
solution containing (in mM: 135 NaCl, 5.4 KCl, 0.9 MgCl2, 10 HEPES, 10 glucose, pH adjusted 
to 7.45 with NaOH) to resume contraction. The cell dissociation procedure involved retrograde 
perfusion of the aorta with a Ca2+-free solution, followed by an enzymatic tissue digestion by 
perfusion with Ca2+-free solution containing   collagenase A (0.4-0.5 mg mL-1, Roche Diagnostics, 
Mannheim, Germany) and protease (type XIV 0.08 mg mL-1, Sigma, Missouri, USA) at 37 °C. 
Thereafter, Ca2+ was gradually re-introduced up to a concentration of 0.18 mM. The ventricles 
were cut out into 0.18 mM Ca2+ solution and cells were dissociated by gentle mechanical agitation 
and filtered through a mesh (200-µm hole diameter). Cells were given time to settle down at room 




2.8.1.2  Cell shortening measurements 
 
Mechanical properties of ventricular myocytes were assessed at 35 °C using a video-based edge-
detection system (Crescent, Salt Lake City, USA). Cells were placed in a chamber mounted on the 
stage of an inverted microscope (Olympus X-70) and superfused with Tyrode solution with 1 % 
DMSO. The cells were field-stimulated at a frequency of 1 Hz, 2.5 ms in duration (Myopacer Cell 
Stimulator, IonOptix, Milton, USA). A video-based edge detector was used to capture and convert 
changes in cell length during contraction and relaxation into an analog voltage signal. Tyrode 
solution containing OA or derivatives was perfused at different time intervals during the 
experimental period. The magnitude of cell contraction was assessed by measuring the amplitude 
of cell shortening, and kinetics of contraction and relaxation were assessed using the time-to-peak 
contraction (TTP) and the time constant (tau) of relengthening as demonstrated in Figure 4 below. 
Cell contraction is expressed as percentage cell shortening based on fractional cell shortening 




Figure 4: Characteristics of contraction include a parameter such as the amplitude of cell 







2.8.1.3  Ca2+ current measurements 
 
Whole cell currents were recorded with the patch-clamp technique at room temperature to access 
the effects of OA and derivatives on L-type Ca2+ current (ICaL). Patch pipettes were pulled from 
capillary glass (GB 200-8P; Science Products, Hofheim, Germany) on a DMZ Universal Puller 
(Zeitz-Instrumente, Munich, Germany), which had a final resistance of 2 - 4 MΩ when filled with 
internal solution. For these experiments the pipette solution contained (mM): 130 CsCl, 10 
HEPES, 0.5 MgCl2, 4 MgATP (pH 7.2 with CsOH), and the external solution contained (mM): 
130 NaCl, 10 CsCl, 11.8 HEPES, 0.5 MgCl2, 1 CaCl2, 10 glucose, pH 7.4 adjusted with NaOH. 
The voltage-clamp protocol consisted of a pre-step from -70 to -50 mV to inactivate INa, followed 
by 200-ms depolarizing voltage steps to various levels between -80 mV and +70 mV. In these 
experiments, Cs+ replaced K+ to block K+ currents, and OA and derivatives were added when 
necessary to the extracellular solution.  
 
2.8.2   Vascular studies 
 
The effects of OA, Me-OA and Br-OA on vascular contraction and relaxation profiles were 
evaluated in isolated aortic rings and mesenteric arteries of male Wistar and DSS rats.  
 
2.8.2.1  Tissue isolation 
 
The methods for vascular tissue isolation, contraction and relaxation measurements were similar 
to those described in detail previously (Martinsen, Baeyens, Yerna and Morel, 2012). Briefly, male 
Wistar and DSS rats (mean body weight 250 g) were sacrificed by stunning and exsanguinations 
in accordance with institutional guidelines for the use of experimental animals. Aorta or small 
mesenteric arteries (SMA) were quickly removed and immersed in physiological saline solution 
(PSS) (composition in mM: 120 NaCl, 5.9 KCl, 25 NaHCO3, 11.5 glucose, 1.2 NaH2PO4, 1.2 
MgCl2 and 2.5 CaCl2). Arteries were cleaned of all fat and connective tissue. All dissecting 
procedures were carefully done to protect the functional endothelium from damage. Each aortic or 
mesenteric segment was cut with a sterile dissection scissor into rings of approximately 1.5 - 2 
mm width. Aortic rings with intact functional and denuded non-functional endothelium were used. 




artery with forceps tip and hair, respectively. A piece of a large diameter straight black hair was 
inserted inside the vessel and the endothelium was removed by gentle moves back and forth inside 
the vessel (Gauthier, Zhang, Cui, Nithipatikom and Campbell, 2008). Endothelium-denuded 
vessels were recognized by showing no significant response to addition of carbachol with a level 
of contraction remaining larger than 90% of the maximum contraction.   
 
2.8.2.3  Isometric tension and vasodilatory effects 
 
Aortic rings were mounted under a tension of 20 mN in a 12.5 mL organ-bath. Mesenteric arteries 
were mounted in a wire myograph (DMT, Aarhus, Denmark) under the tension determined by the 
normalization procedure in a 6 mL organ bath. The baths were perfused with PSS and gassed with 
95% O2 and 5% CO2 at 37 
°C. Artery rings were first stimulated with PSS KCl solution 
(composition in mM: 31.9 NaCl, 94 KCl, 25 NaHCO3, 11.5 glucose, 1.2 NaH2PO4, 1.2 MgCl2 and 
2.5 CaCl2) in order to assess vessel integrity. Washout and a resting period of 15 min was allowed 
before starting the experiment. 
 
Aortic rings and SMA with and without functional endothelium were pre-contracted with a single 
sub-maximal concentration of KCl (50 mM) or PHE (5 μΜ). When a sustained, stable and tonic 
contraction was observed, cumulative concentration-response effects were measured sequentially, 
to carbachol (0.01-100 μΜ) and OA or derivatives (3-30 µM) dissolved in PSS-DMSO solution.  
The presence of a functional endothelium was tested by measuring the relaxation profile of 
carbachol, a drug known to cause endothelium-dependent effects, In this regard, arterial rings were 
pre-contracted with a high-KCl solution and when maximum contraction was reached, various 
doses of carbachol were added. Each concentration of drug was left in contact with the vessels for 
2 min and the contractile tension was measured by an isometric force transducer using data 
acquisition hardware (Mac-Lab) and software (Chart v3.3; DMT, Aarhus, Denmark). Following 
each concentration-response curve the vessels were washed with PSS and rested in PSS for 15 
min. The involvement of NO in triterpene-induced effects was examined in intact aortic rings pre-
treated with appropriate antagonists [N-nitro-L-arginine methyl ester (L-NAME) (100 μM), a NOS 




the increased hypotensive action of OA in DSS rats involved the contribution of K+ channel 
opening, we pretreated the isolated vessels with Ca2+-dependent K+ channel blockers, Gli (5 mmol 
L-1) and AP (1 mmol L-1). 
 
2.9   Data management and statistical analysis 
 
Data for arterial pressure, renal function and vascular studies were analyzed using GraphPad InStat 
Software (version 5.00, GraphPad Software, San Diego, CA, USA). Statistical comparison of the 
differences between the control and experimental groups was performed with one-way analysis of 
variance (ANOVA), followed by Tukey–Kramer multiple comparison test. Data analysis for 
cardiac studies was performed using Clampfit 8.2 (Axon Instruments, Scotland) and Origin (Origin 
lab, USA). Differences between groups were analyzed for statistical significance using ANOVA 
with a Fisher post-hoc test, using Statistica 7.1 (StatSoft, USA). All data are expressed as mean ± 




















RESULTS (Phytochemical studies) 
 
3.0   General 
 
The results are divided into 3 chapters which describe the following: 
1. spectroscopic data of OA, Me-OA and Br-OA;  
2. blood pressure and renal function effects of OA in conscious male SHR and DSS rats; 
3. effects of OA and derivatives on proximal tubular Na+ handling in anaesthetised animals; 
4. OA effects on oxidative status of the heart, kidney and liver; 
5. ex vivo effects of OA and derivatives on cardiomyocyte contraction and L-type Ca2+ 
currents; 
6. effects of OA and derivatives on vascular smooth muscle contraction. 
 
 
3.1   Structure elucidation 
 
3.1.1   OA (C30H47O3) 
 
The percentage yield of OA obtained from dry plant material varied from 0.79% to 1.72%. Figure 
5 shows 13C NMR spectra. The two carbon signals at 125.6 and 122.8 ppm correspond to the 
carbon-carbon olefenic double bond at position 12 and 13 which is present in many triterpenoids. 
 
1H NMR (400 MHz, CDCl3): δ 5.30 (t, 1H, J = 3.5 Hz), 3.21 (dd, 1H, J = 11.5 and 4.4 Hz), 2.85 
(dd, 1H, J = 13.8 and 4.3 Hz), 1.21 (s, 3H), 0.99 (s, 3H), 0.92 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H), 
0.79 (s, 3H), 0.72 (s, 3H). 
 
13C NMR (400 MHz, CDCl3): δ 183.5, 143.8, 122.8, 79.2, 55.4, 47.8, 46.7, 46.1, 41.8, 41.2, 39.4, 






Infrared spectra: 3454, 2940, 2860, 1688, 1462, 1387, 1274, 1185, 1030,781, 655 cm-1. 
 
Figure 5: Syzygium aromaticum-derived OA 13C- NMR spectra. Pure OA was obtained following 
recrystallisation with methanol and the structure was elucidated using NMR spectra recorded on a 






3.1.2   Me-OA (C31H50O3) 
 
The percentage yield for the methylation step was 65%. Methylation with nitrosomethylurea 
removed the hydrogen in the carboxyl group and attached the methyl group. The product is 
indicated by the appearance of methyl peak at 3.63 ppm shown in 1H-NMR spectra (Figure 6).  
 
1H NMR (400 MHz, CDCl3): δ 5.30 (t, 1H, J = 3.5 Hz), 3.63 (s, 3H), 3.21 (dd, 1H, J = 11.5 and 
4.4 Hz), 2.85 (dd, 1H, J = 13.8 and 4.3 Hz), 0.99 (s, 3H), 0.92 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H), 
0.79 (s, 3H), 0.72 (s, 3H). 
 
13C NMR (400 MHz, CDCl3): δ 178.1, 143.9, 122.6, 79.2, 55.2, 51.5, 47.6, 46.7, 45.9, 41.7, 41.3, 
39.3, 38.7, 38.4, 37.0, 34.0, 33.1, 32.7, 32.4, 30.7, 28.1, 27.7, 27.2, 26.0, 23.6, 23.1, 18.3, 16.8, 
15.6, 15.2. 
 










Figure 6: 1H-NMR of Me-OA in comparison to OA. 1H-NMR of Me-OA shows the appearance 
of a methyl peak at 3.63 ppm upon methylation with nitrosomethylurea. The structure was 






3.1.3   Br-OA (C31H43BrO4) 
 
The percentage yield for the bromination step was 30%. 13C-NMR of the bromination product 
(Figure 7) shows that two protons at C9 and C11 were removed due to formation of a double bond 
indicated by the new peak at 124.  
 
1H NMR (400 MHz, CDCl3): δ 7.82 (s, 1H), 5.97 (s, 1H), 3.69 (s, 3H), 3.02 (d, 1H, J = 13.7 
Hz), 2.91 (d, 1H, J = 4.6 Hz), 1.44 (s, 3H), 1.29 (s, 3H), 1.23 (s, 3H), 1.17 (s, 3H), 1.00 (s, 3H), 
0.99 (s, 3H), 0.87 (s, 3H). 
 
13C NMR (400 MHz, CDCl3): δ 178.3, 170.2, 155.1, 123.7, 122.1, 67.9, 51.8, 49.6, 48.1, 47.3, 
46.1, 45.7, 44.7, 42.1, 35.8, 34.7, 34.4, 33.2, 32.7, 31.8, 31.5, 30.6, 28.0, 27.7, 27.0, 24.6, 23.1, 
22.7, 22.0, 21.6, 20.6  
 








Figure 7: 13C- NMR spectrum of Br-OA shows the appearance of a new peak at 124 indicating 
the formation of a double bond after bromination with Br2 and HBr. Structures were elucidated 









RESULTS (In vivo studies) 
 
4.1   Acute effects of OA and derivatives  
 
4.1.1                GFR and MAP measurements 
 
Following infusion of hypotonic saline to control Wistar rats, no significant variations were seen 
in the GFR and MAP throughout the 4 h post-equilibration period (Figure 8). However, 
intravenous infusion of OA or derivatives slightly increased GFR to values which did not achieve 
statistical significance. On the other hand, intravenous infusion of OA (90 µg h-1) for 1.5 h in the 
experimental group significantly (p < 0.001) reduced MAP by comparison with the control group 
(n=6). Me-OA and Br-OA decreased MAP to similar values as OA and the blood pressure did not 






















































Figure 8: Comparison of GFR (A) and MAP (B) of control rats with animals administered OA, 
Me-OA and Br-OA (90 µg h-1) during the 4 h experimental period. All drugs were administered 
for 1.5 h during the treatment period. Values are presented as means, and vertical bars indicate 
SEM (n = 6 in each group).       p < 0.001 by comparison with control animals at each corresponding 




4.1.2   Fluid and electrolyte handling 
 
In this set of our experiments, the study was restricted to a 4 h experimental period due to poor 
yields of the synthesised derivatives. The effects of intravenous infusion of OA and derivatives on 
proximal tubular function and MAP were tested in anaesthetised Wistar rats.  Figure 9A shows the 
urine flow rate of control and drug-administered animals during the 4 h experimental period. Urine 
flow rate under control conditions (i.e. in untreated animals, as well as before treatment in the 
treated group) matched the infusion rate of 9 mL h-1. OA, Me-OA and Br-OA infusion had no 
influence on urine flow rate. Figure 9B shows urinary Na+ excretion in the same animals. Urinary 
Na+ excretion of control animals was stable throughout the experiment and was comparable to the 
infusion rate of 693 µmol h-1. However, OA infusion at 90 µg h-1 for 1.5 h during the treatment 
period significantly (p < 0.05) increased urinary Na+ excretion rate by comparison with control 
animals. Similar effects to increase urinary Na+ excretion were obtained with the OA derivatives, 
but the peak excretion rate was most marked with Br-OA. This is shown in Table 3 which 
demonstrate the cumulative data for urine flow and total electrolyte excretion during the 1.5 h 
treatment period indicating the drug that was more effective among the three triterpenes studied.  
 
Figure 11 shows relationship between changes in urinary Na+ excretion and MAP at the end of the 
treatment period, as analyzed by individual values of each animal from the control and 
experimental groups. Increased urinary Na+ excretion in these acute experiments had some but 
weak correlation with decreased MAP (R = 0.67; p < 0.05). OA infusion had no influence on 
urinary K+ and Cl- outputs in comparison with control animals (Figure 10). Me-OA and Br-OA 
significantly (p < 0.05) decreased urinary K+ output and increased urinary Cl- outputs in 







































































Figure 9: Comparison of urine flow rate (A) and urinary Na+ excretion (B) of control rats with 
animals administered OA, Me-OA and Br-OA during the 4 h experimental period. Drugs were 
administered for 1.5 h during the treatment period. Values are presented as means, and vertical 
bars indicate SEM (n = 6 in each group).    p < 0.05 by comparison with control animals at each 














































































Figure 10: Comparison of urinary K+ (A) and Cl- (B) excretion rate of control rats with animals 
administered OA, Me-OA and Br-OA during the 4 h experimental period. Drugs were 
administered for 1.5 h during the treatment period. Values are presented as means, and vertical 
bars indicate SEM (n=6 in each group).     p < 0.05 by comparison with control animals at each 






Table 3: Comparison of the effects of OA and derivatives infusion on urine flow and total amount 
of electrolytes excreted during 1.5 h treatment period. Values are presented as means ± SEM (n = 
6 in each group).  
 
 Parameter 
Group Urine volume 
(mL) 
Na+ (mmol) K+ (mmol) Cl- (mmol) 
Control 14.00 ± 0.16 0.98 ± 0.02 0.24 ± 0.02 1.04 ± 0.01 
OA 14.00 ± 0.15      1.16 ± 0.01 ⃰ 0.24 ± 0.02     1.08 ± 0.04 
Me-OA 14.02 ± 0.07 1.24 ± 0.03 ⃰ 0.22 ± 0.01 1.24 ± 0.01 ⃰ 
Br-OA 13.66 ± 0.07    1.52 ± 0.04 ⃰ # 0.20 ± 0.03*     1.30 ± 0.03 ⃰ # 
 
* p < 0.05 by comparison with control animals 




























































































Figure 11: Comparison of the changes in MAP (A), urinary Na+ excretion rate (B); correlation 
between MAP and Na+ changes (C) in OA or derivative-administered animals during the 1.5 h 





4.1.3   Renal clearance measurements 
 
To determine the site that is responsible for increased Na+ output along the tubular nephron, we 
measured Li+ clearance (CLi), a marker for proximal tubular Na
+ handling (Thomsen, 1990) and 
also determined FELi. The effect of OA and derivatives on proximal tubular Na
+ clearance was 
estimated by comparing renal l Li+ clearance (FELi) between anaesthetised control and OA and 
derivative-treated rats. The Li+ doses used resulted in plasma Li+ concentrations between 0.2 and 
0.3 mmol L-1 with no difference between the groups. All measured variables during the 4-h 
experimental period were in a steady state and did not differ between the control and the 
experimental groups prior to the infusion of OA or derivatives. The infusion of OA or derivative 
for 1.5 h significantly (p < 0.05) increased FELi in the proximal and FENa in both the proximal and 













































































Figure 12: Comparison of proximal FELi (A), FENa (B) and distal FENa (C) of control rats with 
animals administered OA, Me-OA and Br-OA during the 4 h experimental period. All drugs were 
administered for 1.5 h during the treatment period. Values are presented as means, and vertical 






4.2   Sub-chronic effects of OA  
 
4.2.1   Body weight (BW), food and water intake 
 
Tables 4, 5 and 6 show the effects of various doses of OA (30, 60, 120 mg kg-1, p.o.) in Wistar, 
SHR and DSS rats, respectively, on food, water intake and BW over a 9-week period. OA 


























Table 4: Comparison of the effects of of various doses of OA (30, 60, 120 mg kg-1, p.o.) on food, 
water intake and BW change with control Wistar rats over a 9-week experimental period. Values 











 Time (weeks) 
Test Protocol 1 2 3 4 5 6 7 8 9 
Food intake  
(g 100 g-1) 
 
Control 12.8±0.8 12.4±0.4 12.0±0.4 11.6±0.4 11.2±0.8 12.0±0.4 11.6±0.8 12.8±0.4 12.8±0.8 
OA 30 11.2±0.8 10.8±0.4 11.6±0.4 12.0±0.8 12.4±0.4 11.6±0.8 12.0±0.8 12.4±0.4 12.8±0.4 
OA 60  11.6±0.4 12.4±0.8 11.6±0.4 11.2±1.2 11.2±0.8 11.2±0.4 11.6±0.4 12.0±0.8 13.2±0.4 




(mL 100 g-1)  
Control 12.4±0.8 12.8±0.4 12.4±0.4 12.0±0.8 11.2±0.8 12.0±0.4 13.2±0.4 12.4±0.4 11.6±0.4 
OA 30 12.0±0.8 12.8±0.4 12.8±0.8 12.0±0.4 11.2±0.4 12.8±0.8 12.0±0.4 12.0±0.8 12.0±0.4 
OA 60  12.8±0.4 11.6±0.8 12.0±0.4 11.6±1.2 12.8±0.8 12.8±0.4 12.8±0.4 12.8±0.8 12.4±0.4 
OA 120  12.4±0.8 11.2±0.4 11.6±0.4 12.0±0.4 11.2±0.4 13.2±0.8 12.0±0.4 12.8±0.4 12.0±0.8 
 
% BW  
change  
(g 100 g-1) 
 
Control 2.8±0.8 5.2±0.8 7.2±0.8 8.0±0.8 10.8±0.4 11.6±0.8 12.4±1.2 14.0±0.8 14.8±0.8 
OA 30 3.2±0.4 4.8±0.4 7.2±1.2 8.4±0.4 10.0±0.8 11.2±0.4 12.0±0.8 13.6±0.4 15.2±1.2 
OA 60  2.4±0.8 4.8±0.8 6.8±0.8 8.0±0.8 10.4±0.8 11.6±0.4 13.2±0.4 14.0±0.8 15.2±0.4 




Table 5: Comparison of the effects of OA administration on food, water intake and BW with 
control SHR rats over a 9-week experimental period. Values are presented as means ± SEM (n = 













 Time (weeks) 
Test Protocol 1 2 3 4 5 6 7 8 9 
Food intake 
(g 100 g-1) 
 
Control 6.0±0.4 6.4±0.8 8.0±0.4 7.2±0.4 7.6±0.4 9.2±0.4 9.2±0.4 8.0±0.4 8.4±0.8 
OA 30 5.2±0.4 7.6±0.8 8.4±0.4 7.6±0.4 8.0±0.8 7.2±0.4 8.8±0.8 7.6±0.4 7.2±0.4 
OA 60  6.4±0.8 7.2±0.4 8.0±0.4 7.6±0.8 7.6±0.4 7.2±0.8 8.8±0.4 7.6±0.8 6.8±0.4 




(mL 100 g-1)  
Control 6.0±0.4 9.2±0.4 10.0±0.8 10.8±0.8 11.6±0.8 12.0±0.4 11.6±0.4 12.0±0.8 11.6±0.4 
OA 30 7.6±0.4 10.4±0.4 12.0±0.8 11.6±0.4 12.8±0.4 13.2±0.4 13.6±0.8 13.2±0.8 12.0±0.8 
OA 60  7.2±0.8 10.4±0.4 10.8±0.8 11.2±0.4 12.8±0.4 12.8±0.4 14.4±0.4 12.4±0.4 12.8±0.4 




(g 100 g-1) 
 
Control 1.6±0.4 4.0±0.4 5.2±0.8 7.6±0.4 9.2±0.8 11.2±1.2 13.2±0.8 14.4±0.8 16.0±0.8 
OA 30 2.4 ±0.4 5.2±0.8 6.0±0.4 6.8±0.8 8.4±0.4 10.4±0.8 11.6±0.4 13.6±0.4 15.2±0.8 
OA 60  2.0±0.4 3.6±0.4 6.4±0.8 7.6±0.8 9.6±0.4 10.8±0.4 12.4±0.8 14.4±0.4 16.4±0.4 




Table 6: Comparison of the effects of OA administration on food, water intake and BW with 
control DSS rats over a 9-week experimental period. Values are presented as means ± SEM (n = 














 Time (weeks) 
Test Protocol 1 2 3 4 5 6 7 8 9 
Food intake  
(g 100 g-1) 
 
Control 6.0±0.4 8.4±0.4 10.8±0.4 10.0±0.4 11.2±0.8 10.8±0.4 10.0±0.4 9.2±0.4 8.4±0.4 
OA 30 6.0±0.8 8.8±0.4 10.4±0.4 9.2±0.4 10.8±0.4 10.8±0.4 10.4±0.4 9.2±0.4 7.2±0.4 
OA 60  6.8±0.4 8.4±0.4 10.4±0.4 9.2±0.4 9.6±0.4 10.0±0.4 9.6±0.4 9.2±0.4 8.0±0.4 
OA 120  7.2±1.2 9.2±0.4 10.0±0.4 8.4±0.4 10.0±0.4 10.0±0.4 9.2±0.4 8.4±0.4 8.0±0.4 
 
Water intake  
(mL 100 g-1)  
Control 12.0±0.4 14.0±0.4 16.8±0.8 14.4±0.4 16.0±0.4 16.0±0.8 16.8±0.4 14.0±0.4 16.0±0.4 
OA 30 12.0±0.4 14.0±0.4 16.0±0.4 14.0±0.4 15.2±0.4 15.2±0.4 15.6±0.4 13.6±0.4 15.6±0.8 
OA 60  12.8±0.4 13.2±0.4 16.8±0.8 14.4±0.4 15.6±0.4 15.2±0.4 15.2±0.4 13.2±0.8 15.2±0.8 
OA 120  12.0±0.8 14.4±0.4 17.2±0.8 13.6±0.8 14.8±0.4 14.8±0.4 15.2±0.4 14.0±0.4 14.8±0.8 
 
% BW  
change 
(g 100 g-1) 
 
Control 2.0±0.4 3.6±0.8 5.6±0.8 6.4±0.8 8.4±0.8 10.0±0.8 11.6±0.4 13.2±0.8 15.2±0.4 
OA 30 1.2±0.4 2.8±0.4 4.4±0.4 6.4±1.2 8.0±1.2 10.4±0.8 11.2±0.4 12.8±0.8 14.8±0.4 
OA 60  2.4±0.8 4.0±0.8 5.2±0.4 6.8±0.8 8.4±0.8 9.6±0.4 12.0±0.8 13.6±0.8 15.6±0.4 




4.2.2   MAP and HR measurements 
 
In the first set of our experiments, we performed a 9-week study where we tested the effects of OA 
on MAP and renal function in conscious Wistar, SHR and DSS rats. These experiments were 
restricted to OA because of the poor yield of synthetic derivatives obtained during the 
phytochemical studies. Weekly measured MAP of control Wistar animals was stable around 110 
± 2 mmHg throughout the 9-week experimental period (Figure 13). Administration of various 
doses of OA (30, 60, 120 mg kg-1 p.o.) in these Wistar rats significantly (p < 0.05) reduced MAP 
from the 3rd week until the end of the study period (Figure 13A). In contrast to control Wistar 
animals, weekly measured MAP of untreated SHR and DSS animals progressively increased to 
values ˃ 155 ± 2 mmHg by the end of the experiment (Figure 13B and C). OA administration in 
SHR and DSS rats significantly (p ˂ 0.001) reduced MAP to values that were comparable to 
normotensive rats. We did not see any dose-dependent action, it remains possible that we recruited 
maximal effects with the doses used and that more specificity could be demonstrated if sub-
maximally effective doses were administered. The HR was determined simultaneously with the 
blood pressure measurements. Figure 14 shows that OA had no significant effects on HR in both 









































































Figure 13: Comparison of the effects of the administration of various doses of OA (30, 60, 120 
mg kg-1 BW) on MAP with control animals in Wistar (A), SHR (B) and DSS (C) rats over a 9-
week experimental period. Values are presented as means, and vertical bars indicate SEM (n = 6 











































































Figure 14: Comparison of the effects of the administration of various doses of OA (30, 60, 120 
mg kg-1 BW) on the HR with control animals in Wistar (A), SHR (B) and DSS (C) rats over a 9-
week experimental period. Values are presented as means, and vertical bars indicate SEM (n = 6 




4.2.3   Renal fluid and electrolyte handling 
 
Figures 15A-C show the urine flow rate of control and OA-administered Wistar, SHR and DSS 
animals during the 9-week experimental period. OA administration had no significant influence 
on the urine flow rate in all groups of animals. Figures 15D-F show urinary Na+ excretion rate in 
the same animals. Weekly urinary Na+ excretion rate of control Wistar animals spontaneously 
increased with time without reaching statistically significant difference by the end of the 
experimental period. However, in both hypertensive models no such increase with time was 
obtained, instead, urinary Na+ excretion rate tended to decrease with time after weaning in the DSS 
model. 
 
Administration of various doses of OA (30, 60, 120 mg kg-1 p.o.) in DSS and SHR animals 
significantly (p < 0.05) increased weekly urinary Na+ excretion rate from the 3rd week to values 
that were similar to control Wistar rats by the end of the study period (Figure 15D and 15F). We 
analyzed the relationship between changes in urinary Na+ excretion rate and MAP changes in 
individual control and OA-treated animals on the last week of the study. We observed a linear 
relationship (R = 0.85, p ˂ 0.001) between an increase in urinary Na+ excretion rate and decrease 
in MAP (Figure 16C). OA administration, however, had no influence on urinary K+ and Cl- outputs 
in Wistar, SHR and DSS rats (Figure 17). In addition, there was a significant (p < 0.05) decrease 
in plasma creatinine with a concomitant increase in GFR at the end of the experiment in OA-
treated Wistar, SHR and DSS rats (Table 7). The OA-evoked increase in urinary Na+ excretion 
ratewas not reflected in the plasma collected at the end of the experiment in Wistar and SHR rats. 
OA administration had no influence on plasma urea concentrations, kidney and heart mass in all 














































































































































































Figure 15: Comparison of the effects of the administration of various doses of OA (30, 60, 120 
mg kg-1 BW) on 24 h urine flow (A, B, C) and Na+ excretion (D, E, F) rates with control Wistar 
(A, D), SHR (B, E) and DSS (C, F) animals over a 9-week experimental period. Values are 
presented as means, and vertical bars indicate SEM (n = 6 in each group).     p < 0.05 by comparison 






















































































Figure 16: Comparison of the effects of the administration of median dose of OA (60 mg kg-1) on 
changes in MAP (A) and urinary Na+ excretion rate (B) on the 9th week of the study. Correlation 
of MAP and Na+ (C) changes in conscious Wistar, SHR and DSS rats. Values are presented as 

























































































































































































Figure 17: Comparison of the effects of the administration of various doses of OA (30, 60, 120 
mg kg-1 BW) on urinary K+ (A, B, C) and CI- excretion (D, E, F) rates with control Wistar (A, D), 
SHR (B, E) and DSS (C, F) animals over a 9-week experimental period. Values are presented as 




Table 7: The effects of OA on plasma biochemical parameters in male Wistar, SHR and DSS rats 
which were administered OA twice every third day for nine weeks. Values are presented as means 
±SEM (n=6 in each group). 
  
 Experimental Protocol 
Parameter Group Control OA 30 OA 60 OA 120  
Na+ (mmol L-1) Wistar 142 ± 1 142 ± 2 141 ± 2 140 ± 1 
SHR 142 ± 2 137 ± 2 138 ± 2 140 ± 1 
DSS 157 ± 1 137 ± 1* 139 ± 2* 137 ± 3* 
 
K+ (mmol L-1) Wistar 4.3 ± 0.2 4.1 ± 0.2 4.0 ± 0.2 4.2 ± 0.2 
SHR 4.8 ± 0.1 5.1 ± 0.2 4.9 ± 0.2 5.2 ± 0.2 
DSS 5.4 ± 0.1 6.3 ± 0.1 6.2 ± 0.3 6.2 ± 0.5 
 
Cl- (mmol L-1) Wistar 105 ± 2 103 ± 2 106 ± 1 102 ± 2 
SHR 100 ± 3 109 ± 6 102 ± 3 104 ± 4 
DSS 105 ± 2 103 ± 4 102 ± 1 102 ± 5 
 
Urea (mmol L-1) Wistar 7.8 ± 0.6 8.2 ± 0.6 8.4 ± 0.5 8.5 ± 0.3 
SHR 7.0 ± 0.2 7.2 ± 0.4 7.4 ± 0.4 6.7 ± 0.4 
DSS 8.7 ± 0.4 9.1 ± 0.3 8.3 ± 0.5 7.9 ± 0.3 
 
Creatinine (µmol L-1) Wistar 28 ±2 21 ± 1* 20 ± 2* 20 ± 5* 
SHR 34 ±4 27± 5* 26 ± 2* 27 ± 4* 
DSS 33 ±1 27 ± 2* 26 ± 1* 24 ± 2* 
 
GFR (mL min-1 100 
g-1) 
Wistar 0.47 ±0.16 0.68 ±0.18* 0.76 ±0.17* 0.85 ±0.15* 
SHR 0.48 ±0.14 0.74 ±0.16* 0.86 ±0.17* 0.85 ±0.17* 
DSS 0.32 ±0.16 0.98 ±0.18* 0.98 ±0.18* 0.71 ±0.15* 
 
Kidney (g 100 g-1) 
 
Wistar 0.45 ± 0.20 0.47 ± 0.05 0.46 ± 0.07 0.47 ± 0.02 
SHR 0.62 ± 0.06 0.51 ± 0.07 0.62 ± 0.08 0.58 ± 0.05 
DSS 0.68 ± 0.02 0.48 ± 0.01 0.57 ± 0.2 0.49 ± 0.02 
 
Heart (g 100 g-1) Wistar 0.06 ± 0.04 0.05 ± 0.03 0.06 ± 0.04 0.07 ± 0.01 
SHR 0.07 ± 0.01 0.09 ± 0.02 0.09 ± 0.01 0.07 ± 0.01 
DSS 0.08 ± 0.05 0.08 ± 0.05 0.09 ± 0.07 0.09 ± 0.10 
 




4.2.4   Plasma aldosterone and AVP secretion  
 
The effects of OA on aldosterone and AVP secretion are shown in Table 8. Untreated SHR and 
DSS rats have elevated aldosterone levels compared to Wistar control animals. OA treatment 
significantly (p < 0.05) reduced aldosterone and had no influence on the secretion of arginine 



























Table 8: The effects of OA on plasma hormone measurements in acutely treated male Wistar rats, 
and terminal plasma hormone measurements in male Wistar, SHR and DSS rats which were 
administered OA twice every third day for nine weeks. Values are presented as means ±SEM (n = 
6 in each group).  
 
 Group Aldosterone (nmol L-1) AVP (pmol L-1)  
Acute study  
(Wistar rats) 
Control 1.02 ± 0.02 2.28 ± 0.04 
OA 0.94 ± 0.13 2.26 ± 0.05 
Me-OA 0.94 ± 0.22 2.12 ± 0.02 
 
Sub-chronic study Wistar control 0.77 ± 0.04 2.28 ± 0.03 
SHR control 1.30 ± 0.25* 2.78 ± 0.08* 
DSS control 1.48 ± 0.48* 2.85 ± 0.07* 
SHR OA 1.02 ± 0.02# 2.61 ± 0.05* 
DSS OA  1.01 ± 0.02# 2.74 ± 0.06* 
 
* p < 0.05 by comparison with Wistar control animals  


















4.3   Oxidative stress  
 
Tissues were harvested at the end of the 9-week study and their oxidative status assessed. There 
was no dose dependent effects observed with the three doses of OA tested in this study, hence only 
a median dose treatment was selected for this ex vivo analysis of oxidative proteins. Table 9 
compares the effects of OA treatment (60 mg kg-1, p.o.) on MDA, SOD and GPx levels in control 
and experimental SHR and DSS animals following the 9-week treatment period. The 
concentrations of MDA, SOD and GPx in Wistar control animals were used as reference levels for 
the tissues used. Significant increase of MDA and decreases of SOD and GPx were found in 
kidney, heart and liver tissues of untreated hypertensive groups as compared to control Wistar 
animals. OA administration in these hypertensive animals significantly (p < 0.05) reduced the 
levels of MDA in the kidney, heart and liver. In addition, OA administration in SHR and DSS 
animals significantly increased the production of SOD to levels that are comparable to those of 
control Wistar rats in both organs. Similar pattern was observed with GPx levels which were 


















Table 9: Comparison of MDA concentrations, and of SOD and GPx activities in the kidney, heart 
and liver harvested at the end of the study from SHR and DSS rats treated with OA twice every 
third day for 9 weeks with control Wistar rats. Values are expressed as mean ± SEM (n = 6).  
 
 Tissue 










Wistar control 2.12 ± 0.09 1.70 ± 0.05 1.52 ± 0.06 
SHR control 2.75 ± 0.01*   2.05 ± 0.02* 2.46 ± 0.04* 
DSS control 5.10 ± 0.10* 4.02 ± 0.08* 4.18 ± 0.09* 
SHR OA 1.16 ± 0.01# 1.21 ± 0.01# 1.35 ± 0.02# 
DSS OA  1.82 ± 0.20# 1.55 ± 0.10# 1.71 ± 0.30# 
 
SOD activity  
(nmol.min-1 mL-1 g 
protein) 
Wistar control 6.11 ± 0.30 10.20 ± 1.04 7.05 ± 0.13 
SHR control 2.13 ± 0.48*  3.01 ± 0.21* 3.56 ± 0.41* 
DSS control 1.25 ± 0.08*  2.29 ± 0.07* 2.12 ± 0.14* 
SHR OA 5.78 ± 0.14#  9.26 ± 0.12# 6.84 ± 0.07# 
DSS OA  4.12 ± 0.33# 11.08 ± 0.41# 8.72 ± 0.32# 
 
GPx activity 
(nmol.min-1 mL-1 g 
protein) 
Wistar control 3.82 ± 0.16 2.38 ± 0.21 0.10 ± 0.02 
SHR control 0.62 ± 0.06* 0.60 ± 0.02* Undetectable 
DSS control 0.60 ± 0.02* 0.20 ± 0.06* Undetectable 
SHR OA 3.47 ± 0.03# 3.08 ± 0.02# Undetectable 
DSS OA 4.14 ± 0.31# 3.38 ± 0.24# Undetectable 
 
Note: undetectable ≤ 0.01 nmol.min-1 mL-1 g protein 
* p < 0.05 by comparison with Wistar control animals;  












RESULTS (Ex vivo studies) 
 
 
5.1   Effects of OA and derivatives on ventricular cardiomyocytes 
 
This study was carried out in cardiomyocytes isolated from Wistar and DSS animals. SHR rats 
were excluded for this study because they were less responsive to blood pressure lowering effects 
of OA compared to the DSS animals (see Fig 13 and 16A). Therefore we speculated that 
mechanisms of blood pressure lowering effect of this triterpene and related derivatives would be 
better studied in DSS than SHR rats. 
 
 
5.1.1   Cellular shortening 
 
Figure 18 shows the effects of OA on cell shortening measured using edge detection technique. 
During the control period, the cell contraction induced by pacing the cells using a stimulator at 1 
Hz was stable before the recording was done and this control period represents 100% cell 
shortening. Upon superfusion with Tyrode solution containing OA, contraction of cells isolated 
from Wistar rats increased from 100 to 128% and went back to 120% during the wash period 
(Figure 18A). Me-OA increased the contraction of myocytes of Wistar rats (Figure 19A) from 100 
to 143%, however, the effect was not fully reversed as the contraction remained at 132% at the 
end of the wash period. Superfusion of cells from Wistar rats (Figure 20A) with Br-OA was more 
effective than OA as the contraction increased from 100 to 139% and went back to 113% during 
the wash period. In contrast to the effects in cells from Wistar rats, OA and derivatives had no 
significant effect on cell shortening in cells isolated from DSS rats (Figures 18B, 19B and 20B). 
Summary data are presented in Figure 21. We noted differences in contractile profiles of 
ventricular myocytes from Wistar and those from DSS probably caused by hypertension. Time to 
peak (TTP) and tau of relaxation were significantly (p < 0.001) increased in cells from 
hypertensive animals compared to the cells from normotensive Wistar rats (shown only for OA, 





Figure 18: Comparison of cell contraction during the control, treatment and wash periods in 
ventricular myocytes isolated from Wistar (A) and DSS (B) rats. Cells were superfused with 1.8 
mM Ca2+ Tyrode solution containing OA (160 µmol L-1) during the treatment period. Cell 








Figure 19: Comparison of cell contraction during the control, treatment and wash periods in 
ventricular myocytes isolated from Wistar (A) and DSS (B) rats. Cells were superfused with 1.8 
mM Ca2+ Tyrode solution containing Me-OA (160 µmol L-1) during the treatment period. Cell 










Figure 20: Comparison of cell contraction during the control, treatment and wash periods in 
ventricular myocytes isolated from Wistar (A) and DSS (B) rats. Cells were superfused with 1.8 
mM Ca2+ Tyrode solution containing Br-OA (160 µmol L-1) during the treatment period. Cell 



















































































Figure 21: Comparison of cell contraction during the control, treatment and wash periods in 
ventricular myocytes isolated from Wistar and DSS rats. Cell shortening (A), TTP (B) and tau (C) 
were measured at 1 Hz stimulation frequency. Cells were superfused with 1.8 mM Ca2+ Tyrode 






5.1.2                   L-type Ca2+ currents 
 
The preliminary experiments on Ca2+ currents were conducted using whole cell patch clamp 
technique with membrane potentials ranging from -80 to 70 mV. Due to time constraints, we could 
only perform the experiment on 2 animals, however, at least 3 cells were recorded for each animal 
and for each drug. These preliminary studies showed that all drugs (Figures 22, 23 and 24) have 
no significant effects on the Ca2+ current as the recordings of the control, drug and wash periods 





Figure 22: Comparison of L-type Ca2+ current density (ICaL) during the control, treatment and 
wash periods in ventricular myocytes isolated from Wistar rats. Measurements were done 
repeatedly at -40 and 20 mV. Cells were superfused with 1.8 mM Ca2+ / cesium-based Tyrode 
solution containing OA (160 µmol L-1) during the treatment period (n = 2). Patch pipettes had a 















Figure 23: Comparison of L-type Ca2+ current density (ICaL) during the control, treatment and 
wash periods in ventricular myocytes isolated from Wistar rats. Measurements were done 
repeatedly at -40 and 20 mV. Cells were superfused with 1.8 mM Ca2+ / cesium-based Tyrode 
solution containing Me-OA (160 µmol L-1) during the treatment period (n = 2). Patch pipettes had 


















Figure 24: Comparison of L-type Ca2+ current density (ICaL) during the control, treatment and 
wash periods in ventricular myocytes isolated from Wistar rats. Measurements were done 
repeatedly at -40 and 20 mV. Cells were superfused with 1.8 mM Ca2+ / cesium-based Tyrode 
solution containing Br-OA (160 µmol L-1) during the treatment period (n = 2). Patch pipettes had 






















5.2   Effects of OA on vascular smooth muscles 
 
In order to study the potential vasodilating properties of OA and derivatives, the 
contraction/relaxation pattern of vessels treated with each of the three drugs was evaluated. 
Isometric tension was measured in rat aortic rings (mounted in classical organ baths) and 2nd to 3rd 
order mesenteric arteries (mounted in wire-myographs). Experiments were performed in 
endothelium-intact and endothelium-denuded vessels to discriminate between endothelium-
dependent and independent mechanisms. Solvent controls were performed for each concentration. 
Vessels that showed a carbachol-induced endothelium-dependent relaxation amounting to at least 
30% of the maximum contraction were considered as having an intact endothelium. Endothelium-
denuded vessels had no significant response to the addition of carbachol with a level of contraction 

















































































Figure 25. Concentration-response curves for carbachol in mesenteric segments (A) and aortic 
rings (B) isolated from Wistar rats pre-contracted with sub-maximal concentration of KCl (50 
mM). Curves were obtained in arteries with denuded and intact endothelium. The values shown 









5.2.1   Comparison of the vasodilating effects of OA and derivatives 
 
Addition of OA, Me-OA or Br-OA on endothelium-intact mesenteric arteries pre-contracted with 
PHE (Figure 26A) or KCl-enriched solution (Figure 26B) evoked a significant relaxation of the 
arterial segments isolated from Wistar rats. In the mesenteric arteries, the brominated OA 
derivative showed a significantly larger maximum relaxation than OA and Me-OA (excrete, PHE 
pre-contracted rings; p < 0.01 Br-OA vs OA; KCl pre-contracted rings p < 0.001 Br-OA vs OA). 
This difference, however, was not apparent in aortic rings (Figure 26C and D). Importantly, the 
maximum relaxation evoked by Br-OA was significantly larger in the mesenteric vessels compared 
to the aorta (p < 0.001, for PHE pre-contracted vessels; p < 0.001 for KCl pre-contracted arteries). 
A similar pattern in relaxation profiles of arterial segments isolated from DSS rats was observed 






























































































Figure 26. Concentration–response curves for OA, Me-OA, and Br-OA in endothelium-intact 
mesenteric arteries [A and B] or aortic rings [C and D] isolated from Wistar rats, pre-contracted 
with sub-maximal concentration of PHE (5 μΜ) [A and C] and KCl (50 mM) [B and D]. The 



























































































Figure 27. Concentration–response curves for OA in endothelium-intact mesenteric arteries [A 
and B] or aortic rings [C and D] isolated from Wistar and DSS rats, pre-contracted with sub-
maximal concentration of PHE (5 μΜ) [A and C] and KCl (50 mM) [B and D]. The values shown 












5.2.2   Endothelium-dependent vasorelaxant effects of OA and derivatives 
 
Since there was no difference in the magnitude of relaxant effects of OA and derivatives in Wistar 
and DSS isolated vessels, further experiments to evaluate the mechanisms of vasorelaxation 
properties of OA and derivatives were conducted in arterial segments isolated from Wistar rats 
only. The relaxation evoked by OA and derivatives was only partially inhibited in the absence of 
functional endothelium as shown in endothelium-denuded vascular rings experiments (shown only 
for Br-OA, Figure 28, p < 0.05 for mesenteric vessels; p < 0.001 for aorta). This demonstrates that 
the relaxation-evoked by OA or derivatives involves both endothelium-dependent and independent 
mechanisms.  
 
In order to characterize the endothelium-dependent relaxation, endothelium-intact vessels were 
incubated in the presence of cyclooxygenase (COX) or NOS inhibitors (INDO and L-NAME, 
respectively). As shown in Figure 28, incubation with INDO blocked Br-OA-evoked relaxation to 
the same extent as removal of the endothelium p < 0.05 (mesenteric); p < 0.001 (aorta). Addition 
of L-NAME did not further inhibit the COX-resistant relaxation suggesting the involvement of 
COX and prostanoids dependent mechanisms. Qualitatively similar results were observed with 
OA and Me-OA, however, the differences between OA “INDO” vs “control” and Me-OA “intact” 
vs “denuded” did not reach statistical significance in the mesenteric arteries. Interestingly for Br-
OA, the endothelium independent portion of the relaxation is significantly larger in the mesenteric 
segments than in the aorta (p < 0.001). The absence of inhibition observed with L-NAME on the 
relaxation evoked by OA and derivatives argues in favour of a non-implication of the NOS/NO 











































































Figure 28. Concentration–response curves for Br-OA in mesenteric arteries (A) and aortic rings 
(B) isolated from Wistar rats pre-contracted with PHE (5 μΜ). Curves were obtained in 
endothelium-denuded and intact arteries. Some endothelium-intact vessels were incubated in the 
presence of INDO (10 μM) only or in combination with L-NoArg (100 μM) prior to addition of 








5.2.3.   Endothelium-independent vasorelaxant effects of Br-OA 
 
As observed in Figure 28, a significant portion of the relaxation evoked by OA and derivatives is 
resistant to removal of the endothelium suggesting a role of endothelium-independent pathways, 
such as opening of the K+ channels. To further investigate this hypothesis, denuded vessels were 
incubated in the presence of blockers of different K+ channels types (Gli for ATP-dependent K+ 
channels and AP for voltage-activated K+ channels). Either inhibitor was able to blunt part of the 
relaxation evoked by Br-OA as illustrated in Figure 29. The effects of both inhibitors were additive 
and allowed a complete blockade of the relaxation to Br-OA suggesting that ATP-dependent and 
voltage-activated K+ channels opening mediate the endothelium independent relaxation (not 
shown for OA and Me-OA). The endothelium-independent relaxation observed for Br-OA was 
also completely blunted by Gli and AP. Experiments performed with endothelium-intact vessels 
incubated with a cocktail of INDO, AP and Gli did not show any relaxation to Br-OA as shown in 




































































Figure 29. Concentration–response curves for Br-OA in denuded mesenteric arteries (A) and 
aortic rings (B) isolated from Wistar rats pre-contracted with PHE (5 μΜ). Curves in denuded 
arteries incubated in the presence of Gli (5 mM) or in combination with AP (1 mM) prior to the 















































































Figure 30. Concentration–response curves for Br-OA in intact mesenteric arteries (A) and aortic 
rings (B) isolated from Wistar rats pre-contracted with PHE (5 μΜ). Curves in intact arteries 
incubated in the presence of INDO (10 µM) and Gli (5 mM) only or in combination with AP (1 
mM) prior to the addition of the drug. Values shown are means ± SEM (n = 7).     p ˂ 0.001 vs 








The present study investigated the effects of OA and related synthetic derivatives (Me-OA and Br-
OA) on blood pressure and thereafter examined the possible underlying mechanisms. Our results 
show that 1) OA decreased MAP in both acute and sub-chronic experimental settings, and that the 
MAP lowering effect was more marked in hypertensive animals compared to normotensive rats 
(Fig 8B, 13); 2) OA or derivatives did not change urinary flow rate (Fig 9A, 15A-C); 3) OA or 
derivatives increased Na+ excretion, with a more marked effect of Br-OA compared to OA under 
acute conditions (Fig 9B, 15D-F); 4) OA decreased aldosterone secretion after chronic 
administration, but had no influence on AVP levels (Table 8); 5) OA suppressed the increased 
ROS marker production present in salt-sensitive hypertensive rats and modulated the production 
of antioxidant enzymes, SOD and GPx, which were reduced in these animals (Table 9); 6) OA and 
derivatives increased cardiomyocyte contraction in cells isolated from normotensive rats but had 
no influence on contraction of cells isolated from hypertensive animals and on L-type Ca2+ currents 
(Fig 18, 22); 7) Br-OA caused relaxation of the aorta and mesenteric arteries via endothelium-
dependent and independent mechanisms (Fig 28, 29). The results of this study are novel and 
clinically relevant because OA and related triterpene derivatives exert multiple blood pressure 
lowering mechanisms while increasing the force of cardiac contraction. 
 
The absolute stereo-structure of S. aromaticum-derived OA elucidated from the spectra using 1H- 
and 13C-NMR was comparable to previously reported data (Mahato and Kundu, 1994; Honda, 
Rounds, Bore, Finlay, Favaloro, Suh, Wang, Sporn and Gribble, 2000; Sporn, Liby, Yore, Fu, 
Lopchuk and Gribble, 2011; Fu and Gribble, 2013). In addition, OA had the same physical 
properties as the OA purchased from Sigma-Aldrich and hence isolated OA was used as a parent 
compound for the synthesis of related triterpene derivatives because it is cheaper than the 
commercially available OA. The proton and carbon peaks obtained from NMR and IR spectra 
analysis for synthetic OA derivatives (Me- and Br-OA) were comparable to previously reported 
data (Fu and Gribble, 2013). These spectra did not have any additional peaks which don’t belong 




by any traces of OA and therefore these three triterpenes were used to carry out all the experiments 
for this study.  
 
Blood pressure and renal function experimental protocols under acute and sub-chronic settings are 
well validated as they have been used extensively in our laboratory (Musabayane, Forsling and 
Balment, 1997; Musabayane, Mahlalela, Shode and Ojewole, 2005; Musabayane, Gondwe, 
Kamadyaapa, Chuturgoon and Ojewole, 2007; Gondwe, Kamadyaapa, Tufts, Chuturgoon and 
Musabayane, 2008; Kamadyaapa, Gondwe, Moodley, Ojewole and Musabayane, 2009; Mapanga, 
Tufts, Shode and Musabayane, 2009; Madlala, Masola, Singh and Musabayane, 2012; Mkhwanazi, 
Serumula, Myburg, Van Heerden and Musabayane, 2014). Renal Li+ clearance has been widely 
used in animal studies and clinical investigations as a marker for assessing proximal tubular 
function in the mammalian kidney (Thomsen, 1984; Koomans, Boer and Dorhout-Mees, 1989; 
Thomsen, 1990; Walter and Shirley, 1991; Shirley, Walter and Sampson, 1992; Shirley and 
Walter, 1993; Boer, Fransen, Shirley, Walter, Boer and Koomans, 1995; Thomsen and Shalmi, 
1997; Whiting, 1999; Madlala, Masola, Singh and Musabayane, 2012; Mkhwanazi, Serumula, 
Myburg, Van Heerden and Musabayane, 2014). SHR and DSS rats used in this study are well 
studied animal models of essential (primary) and secondary arterial hypertension because they 
share similar features with hypertension in humans and both were used together with Wistar rats 
as a control group (Okamoto, 1969; Triantafyllidi, Baldwin, Schwartz and Gavras, 2004; 
Rodriguez-Rodriguez, Perona, Herrera and Ruiz-Gutierrez, 2006; Raji, Mugabo and Obikeze, 
2012).  
 
Our data confirm that blood pressure, indeed increased progressively with time in the absence of 
drug treatment in hypertensive SHR and DSS animals, whereas it remained stable in the control 
Wistar animals (see Fig 13). OA treatment not only significantly suppressed or blunted this 
increase, but also reduced blood pressure in control animals. Our results confirm the previously 
reported antihypertensive properties of OA in experimental models of hypertension (Somova, 
Nadar, Rammanan and Shode, 2003; Madlala, Masola, Singh and Musabayane, 2012). However, 
the present study demonstrates for the first time a more marked action in SHR and DSS by 




conditions. The pathophysiological mechanisms responsible for the rise in blood pressure in 
primary hypertension remain unclear and are likely complex. Amongst the mechanisms accepted 
to play a major role for the development of hypertension is an inability of the kidney to excrete 
Na+. Indeed solute retention and the accompanying water retention result in extracellular 
(including intravascular) volume expansion (Weinberger, Miller, Luft, Grim and Fineberg, 1986; 
Somova, Channa and Khan, 1999). We were therefore interested in examining whether the marked 
hypotensive action obtained in the hypertensive models could be mediated by an effect on 
abnormal Na+ handling by the kidney. We noticed that urine Na+ excretion rate in control, 
untreated animals tended to spontaneously increase with time during the following 9 weeks post 
weaning. In both hypertensive models, no such increase with time was obtained, instead, urinary 
Na+ excretion rate tended to decrease with time after weaning in the DSS model suggesting Na+ 
retention previously reported in these animals (Somova, Channa and Khan, 1999).  
 
In support of Na+ retention in hypertension, we found increased aldosterone levels in plasma of 
non-treated hypertensive rats. Our data show that OA decreased aldosterone secretion and 
increased urine Na+ excretion rate. Significantly larger increases in Na+ output were obtained in 
the hypertensive models.  This suggests that treatment with the drugs was accompanied by 
alleviation of Na+ retention in these animals. Our data demonstrate that the natriuretic effects of 
OA and related derivatives were associated with increased Li+ clearance. This indicates that the 
increase in urinary Na+ excretion rate is, at least in part, mediated via inhibition of proximal tubular 
Na+ reabsorption. Indeed, we found a positive correlation between the increase in urinary Na+ 
excretion rate and the decrease in MAP (see Fig 11 and 16). We observed increased GFR under 
subchronic condition, however, no such increase was observed for acute studies. We speculate that 
this difference was due to time periods and dosages of the drug used for these experimental studies 
i.e 4 h in comparison to 9 weeks, 90 µg h-1 and 60 mg kg-1 BW. 
 
Despite the potent natriuretic effects of these triterpenes, the urine flow rate was not changed. 
Presence of blood pressure lowering effects in the absence of increased fluid voided in the urine 
may be explained by the effect of the drug on body fluid compartments. We speculate that OA 




low doses (Conrad, Gellai, North and Valtin, 1986; Chou, DiGiovanni, Luther, Lolait and 
Knepper, 1995). OA did not affect food intake as well as plasma Na+ concentrations in Wistar and 
SHR animals. This is again not surprising as it is in agreement with OT effects which is thought 
to produce a negative Na+ balance by stimulating Na+ excretion while inhibiting Na+ ingestion 
(Verbalis, Mangione and Stricker, 1991). 
 
The transport of Na+ from the tubular cells to the peritubular intertitium is via the Na+/K+-pump 
and Na+/Cl- cotransporter. Although OA increased Na+ excretion, this triterpene had no influence 
on urinary or plasma K+ or Cl- levels. The body has much lower extracellular fluid K+ in 
comparison to intracellular levels (Gennari, 2002). This study measured plasma K+ which is easily 
accessible compared to intracellular contents. We acknowledge that plasma K+ we measured is not 
a reflection of the whole body K+ content as most of it is found inside cells and therefore this could 
explain the reason for OA-induced natriuresis without any changes in K+ levels although these 
ions use the same pump in the kidney.  
 
Studies report that ingested K+ from diet sources stimulate insulin secretion which activates the 
Na+/K+-pump to facilitate K+ entry into cells hence preventing hyperkalemia and this could explain 
why we detected normal plasma levels of this ion (Alvestrand, Wahren, Smith and DeFronzo, 
1984). In agreement with this, various studies have shown that OA facilitates insulin secretion and 
possess insulin-like properties (Hsu, Wu, Liu and Cheng, 2006; Teodoro, Zhang, Alexander, Yue, 
Vranic and Volchuk, 2008; Musabayane, Tufts and Mapanga, 2010). In this regard, we speculate 
that OA facilitates K+ entry into cells directly or via insulin stimulation and therefore this increase 
could not be detected in the plasma. We also speculate that they maybe other mechanisms which 
cause this increase natriuresis which does not involve the Na+/Cl- cotransporter and hence we could 
not observe any changes in chloride levels. 
 
Several studies have used aortic rings and small mesenteric arteries to study smooth muscle 
vascular resistance (Leite, Estevão, Resende and Salgado, 1997; Kang, Sullivan, Sasser, Imig and 
Pollock, 2007; Rodrigues, Restini, Lunardi, Moreira, Lima, da Silva and Bendhack, 2007; Jadhav, 




these vessels to study mechanisms that mediate hypotensive effects of OA and related synthetic 
derivatives. Our experiments indicate that OA induces vasorelaxation of aortic rings and small 
mesenteric arteries in both normotensive and hypertensive animals. The relaxation evoked by Br-
OA (Figure 29) was partially inhibited in the absence of functional endothelium in endothelium-
denuded vascular rings experiments (data not shown for OA and Me-OA,). This demonstrates that 
the relaxation-evoked by OA or derivatives involves both endothelium-dependent and independent 
mechanisms.  
 
In vivo studies from previous reports suggest that OA-induced relaxation is associated with an 
endothelium-dependent increased production of NO and could be abrogated by NO synthase 
inhibitors or by NO scavengers (Rodríguez-Rodríguez, Herrera, Perona and Ruiz-Gutiérrez, 2004; 
Perona, Cabello-Moruno and Ruiz-Gutierrez, 2006; Rodriguez-Rodriguez, Perona, Herrera and 
Ruiz-Gutierrez, 2006; Dongmoa, Azebazeb, Donfackc, Dimoc, Nkeng-Efouetd, Devkotae, 
Sontiaf, Wagnerg, Sewalde and Vierling, 2011). Accordingly we acknowledge that in vivo 
treatment with OA might bring long term alterations of the pro or antioxidant balance hence 
leading to improved NO bioavailability or maybe direct expression of NOS. However, the results 
of our study suggest that OA and derivatives mediate their vasodilatory effects via additional 
mechanisms involving COX-mediated prostanoid pathway and action on K+ channels. These 
results are in agreement with previous reports that OA modulate Cox-2-dependent release of PGI2 
mediated by phosphorylation of p38 MAPK (Martínez-González, Rodríguez-Rodríguez, 
González-Díez, Rodríguez, Herrera, Ruiz-Gutierrez and Badimon, 2008).  
 
The present study tested whether two novel synthetic derivatives of OA display effects similar to 
those of the parent drug. Interestingly, the maximum relaxation evoked by the derivatives, 
particularly Br-OA, was significantly larger in the mesenteric vessels although these differences 
were not observed in the aorta. We speculate that this variation in relaxation profiles of these 
vessels was probably due to the differences in the receptors or effectors (e.g. channels) present and 





A significant portion of the relaxation evoked by OA and derivatives was resistant to removal of 
the endothelium suggesting a role of endothelium independent pathways, such as opening of the 
K+ channels. We studied this hypothesis on denuded vessels incubated in the presence of blockers 
of different K+ channels types (Gli for ATP-dependent K+ channels and AP for voltage-activated 
K+ channels). Either inhibitor blunted part of the relaxation evoked by OA and derivatives. The 
effects of both inhibitors were additive and allowed a complete blockade of the relaxation to OA, 
Br-OA and Me-OA suggesting that ATP-dependent and voltage-activated K+ channels opening 
mediate the endothelium-independent relaxation (not shown for OA and MeOA).  
 
The larger endothelium-independent relaxation observed for Br-OA was also completely blunted 
by Gli and AP. This suggests that no other mechanism is implicated and that the larger relaxation 
to Br-OA might be supported by a more effective activation of both K+ channel types. This OA or 
derivatives-induced vasodilatation resulted in decrease of total peripheral resistance which could 
be implicated in the MAP lowering effect of these triterpenes. Atrial natriuretic factor has been 
shown to reduce Na+ channel activity and intracellular Ca2+ via decreased activity of the Na+/Ca2+ 
exchange in the cardiac cells (Stone, Backx and Keurs, 1990). In this regard, we speculate that the 
improved Na+ elimination caused by these drugs could have an indirect effect on vascular function. 
Natriuresis is expected to induce a decrease in extracellular Na+ concentration (as was observed in 
DSS animals, Table 7) which can affect intracellular Na+ concentration by decreasing the 
concentration gradient for passive Na+ entry pathways (e.g. Na+ permeable channels). Decreased 
intracellular Na+ concentration may influence the activity of the Na+/Ca2+-exchanger, resulting in 
more Ca2+ efflux or less Ca2+ entry via this pathway. We speculate that the resulting decrease in 
intracellularly available Ca2+ could favour relaxation and hence contribute to other mechanisms to 
decrease vascular resistance.  
 
Vasodilation implies unhindered blood flow and this may have caused increased plasma being 
filtered in the glomerulus. In accordance with this idea, OA increased the GFR in addition to 
increased urinary Na+ output in hypertensive animals at the end of the 9-week study. GFR is an 
important marker of kidney function and a correlation between increased urinary Na+ excretion 




Steinhausen, 1986; Mapanga, Tufts, Shode and Musabayane, 2009). GFR was assessed by 
creatinine clearance (Ccr) which has been used in our laboratory and by other authors as a 
fundamental parameter of evaluating renal tubular function (Rebsomen, Pitel, Boubred, Buffat, 
Feuerstein, Raccah, Vague and Tsimaratos, 2005; Kumar, Shetty and Salimath, 2008; Mapanga, 
Tufts, Shode and Musabayane, 2009; Madlala, Masola, Singh and Musabayane, 2012; Mkhwanazi, 
Serumula, Myburg, Van Heerden and Musabayane, 2014). The increases in urinary Na+ excretion 
in conjunction with a significantly reduced plasma creatinine concentration and an elevated GFR 
over the 9-week experimental period, further suggest that these changes were, in part, mediated 
via enhanced renal blood flow. 
 
A non-renal parameter that could account for the MAP lowering action is a change in cardiac 
function, namely a decrease of the HR or of the SV. No effect on HR was obtained with the drugs 
in the present study, excluding a mechanism involving a chronotropic action. Somova also reported 
no change in HR following 6-week intraperitoneal administration of OA in DSS rats (Somova, 
Nadar, Rammanan and Shode, 2003). In another study, the same authors reported a 6% decrease 
of HR (Somova, Shode and Mipando, 2004). This bradycardiac effect was however too tiny to 
account for the marked (20-35%) decrease in MAP concurrently obtained in the same animals. In 
the absence of a change in HR, a decrease of CO and of MAP can be brought about by a change 
in SV. 
 
For cardiac function studies, we used video edge detection technique which is commonly used to 
study cell shortening in isolated cardiomyocytes (Kanai, Pearce, Clemens, Birder, VanBibber, 
Choi, de Groat and Peterson, 2001; He, Ma, Lee, Thomson and Kamp, 2003; Jiang, Xia, Xu and 
Zheng, 2004; Kang, Sohn, Lee, Lee, Han, Kim and Lee, 2004; Nevelsteen, Bito, Van der Mieren, 
Vanderper, Van den Bergh, Sipido, Mubagwa and Herijgers, 2013). In addition, we used a well 
characterised electrophysiology technique, whole-cell clamp patch, which allows a very stable 
intracellular recording (Kirichok, Navarro and Clapham, 2006) to study the effects of OA and 
derivatives on Ca2+ currents. We were not able to measure SV in the present setting. However, our 
experiments using isolated cardiomyocytes showed that OA and derivatives do not decrease but 




This suggests that a negative inotropic action, resulting in a decrease of SV, is also excluded as 
mechanism for the hypotensive action of OA and derivatives. On the other hand, increase 
cardiomyocyte contractility implies an increase in the force of cardiac tissue contraction and 
increase CO. In cells isolated from DSS rats however, OA and derivatives had no apparent effect 
on shortening. However, the time to peak and relaxation time is much more than that of cells from 
normotensive rats. A study by Gomez showed that cardiac hypertrophy and heart failure caused 
by high blood pressure reduces the ability of Ca2+ to trigger calcium release from the SR in single 
myocytes taken from hypertensive rats (Gómez, Valdivia, Cheng, Lederer, Santana, Cannell, 
McCune, Altschuld and Lederer, 1997). Based on this information, we speculate that long lasting 
time-to-peak in cardiomyocytes of hypertensive DSS rats is probably caused by hypertrophy hence 
a weaker intensity of contraction and reduction in Ca2+ release in these cells although cell size was 
not measured.  
 
Hypertension is associated with oxidative stress which causes endothelial dysfunction because of 
increased production of ROS. Increased production of ROS such as O2
− due to decreased 
antioxidant defence systems causes rapid inactivation of NO signaling and bioavailability (Panza, 
1997; Mizuno, Jacob and Mason, 2010). Based on this knowledge, this study investigated the 
oxidative status of kidney, liver and hearts harvested from untreated and OA-treated SHR and DSS 
animals at the end of the 9-week study period. Although the most direct approach for the 
assessment of lipid peroxidation is the quantification of the primary (hydroperoxides) products, 
these peroxides are labile and short-lived. Hence, detection of lipid peroxidation has relied largely 
on indirect methods, that is, analyses of secondary or end products derived from hydroperoxides 
such as malonyldialdehyde (MDA) (Kasapoglu and Özben, 2001). 
 
In this study, we therefore determined the levels of lipid peroxidation expressed as thiobarbituric 
acid reactive substances (TBARS; MDA). Thiobarbituric acid (TBA) assay is the most common 
and easiest method used to assess lipid peroxidation and free radical activity in biological samples 
(Bloomer and Goldfarb, 2004; Bouzid, Hammouda, Matran, Robin and Fabre, 2014). Different 
animal studies have shown that antioxidants protect against the oxidative damage produced by free 




Selemidis, Griendling and Sobey, 2011). Therefore we also assessed the effects of OA on oxidative 
protein damage as indicated by activities of the commonly studied antioxidant enzymes, 
superoxide dismutase (SOD) and glutathione peroxidase (GPx) (Ray, Batra, Shukla, Deo, Raina, 
Ashok and Husain, 2000; Wassmann, Laufs, Müller, Konkol, Ahlbory, Bäumer, Linz, Böhm and 
Nickenig, 2002; Herbette, Lenne, Labrouhe, Tourvieille, Drevet and Roeckel‐Drevet, 2003; Sadi 
and Güray, 2009). The results showed that tissues from untreated DSS and SHR animals had 
elevated levels of MDA by comparison with tissues from control Wistar animals. Tissues from 
OA-treated DSS animals had reduced levels of MDA by comparison with respective untreated 
hypertensive rats. Tissues isolated from untreated DSS and SHR animals had reduced activities of 
antioxidant enzymes, SOD and GPx, by comparison with tissues from control Wistar animals. 
However, tissues from OA-treated DSS and SHR animals had increased activities of these 
antioxidant enzymes by comparison with respective untreated hypertensive rats. These results are 
in agreement with those obtain by other authors although OA-evoked increase in antioxidant 
activities were analysed in different samples (Somova, Shode, Ramnanan and Nadar, 2003; Wang, 
Ye, Liu, Chen, Bai, Liang, Zhang, Wang, Li and Hai, 2010). We speculate that antioxidant 
properties of OA could play a role in hypotensive mechanisms of this triterpene. Studies indicate 
that oxidative stress is characterised by reduced production of NO (NO) which results in 
constricted vessels hence increased peripheral resistance and blood pressure. The effects of OA on 
the production of NO were not evaluated in this study, however, we speculate that OA-evoked 
decreased ROS and increased antioxidant enzymes may have enhanced the production of NO, 
thereby improving vasodilation. Preventing the imbalance of ROS and antioxidants in kidney, liver 
and the heart as shown in this study suggest that OA could have averted the progression of 
hypertension via NO-dependent vasorelaxant effects. 
 
In summary, OA and derivative-induced reduction in total peripheral resistance implies 
unhindered renal blood flow which may have caused increased plasma being filtered in the 
glomerulus as indicated by increased GFR. Increased GFR means that more Na+ content was 
filtered into the renal tubule and we further confirmed our previous observation that OA, and the 
derivatives investigated for the first time in this study, inhibit proximal tubular Na+ reabsorption 
as indicated by increased FELi. Therefore, this Na




showed that our drug lowered aldosterone hence preventing Na+ reabsorption once again in this 
part of the tubule which explains increased Na+ loss in the urine. Urinary Na+ loss may cause the 
heart to increase CO to compensate for acute intravascular compartment contraction in addition to 
redistribution of water to the interstitium in order to balance the ECF. In agreement with this 
speculation, OA and derivatives increased the force of cardiomyocyte contraction which in 
collection may enhance SV and CO although the effects of these triterpenes on whole heart 






























We provide the first report that OA and related novel synthetic derivatives, Me-OA and Br-OA 
induce similar hypotensive effects in experimental animals mediated by multiple mechanisms.  
These involve increased urinary Na+ output mediated by inhibition of proximal Na+ reabsorption 
and modulation of oxidative stress in hypertensive animals. In addition to renal mechanisms, 
vascular mechanisms are involved, since the drugs induced relaxation involving endothelium-
dependent COX/prostanoids pathway as well as endothelium-independent opening of ATP-
sensitive and voltage-activated K+ channels. These results suggest that these triterpenes influence 




7.1 Limitations and direction for future studies 
 
Due to poor yield obtained for the synthetic derivatives, we were unable to study their sub-chronic 
effects in conscious animals, therefore this should be explored in future. OA effects on renal 
function seem to mimic oxytocin-like activities i.e. increase Na+ output without changing the urine 
flow rate (Conrad, Gellai, North and Valtin, 1986), hence future studies should investigate whether 
this hormone can have synergistic effects with OA and derivatives. This study did not evaluate the 
effects of these triterpenes on NO production or expression of eNOS and phosphorylation of K+ 
channels. Further studies should also assess the plasma concentrations of OA to provide better 
understanding and direction for explaining issues such as increased natriuresis without hanging 
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